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Abstract
Alzheimer’s disease (AD), the most common type of dementia and Parkinson’s disease 
(PD), the most common movement disorder are both neurodegenerative adult-onset diseases 
characterized by progressive loss of specifi c neuronal populations and accumulation of 
intraneuronal inclusions.
The search for genetic and environmental factors that determine the fate of neurons during 
the ageing process has been a widespread approach in the battle against neurodegenerative 
disorders. Genetic studies of AD and PD have initially focused on the search for genes 
involved in the aetiological mechanisms of monogenic forms of these diseases. They later 
expanded to study hundreds of patients, affected relative-pairs and population-based studies 
sometimes performed on “special” isolated populations. A growing number of genes (and 
pathogenic mutations) is being identifi ed that cause or increase the susceptibility to AD and 
PD. This review discussed the way in which strategies of “gene hunting” have evolved during 
the last years and the signifi cance of fi nding genes such as the presenilins, α-synuclein, parkin
and DJ-1.
In addition we discuss possible links between these two neurodegenerative disorders. The 
clinical, pathological and genetic presentation of AD and PD suggests the involvement of 
few overlapping, interrelated pathways. Their imbricate features point to a spectrum of 
neurodegeneration (tauopathies, synucleinopathies, amyloidopathies) that will need further 
intense investigation to fi nd the missing links.
Introduction
In 1907, Alois Alzheimer, a German psychiatrist and pathologist, described the case of a 51-
year-old woman with presenile dementia. In addition to diffuse cortical atrophy, he reported 
“peculiar changes of the neurofi brils...which are eventually seen clustering together in thick 
bundles” and a “deposit in the cerebral cortex of a peculiar substance which can be recognized 
without staining” 1. Subsequently, these changes were recognized to be neurofi brillary tangles 
and amyloid plaques. This “new” disorder was named Alzheimer’s disease by the German 
psychiatrist Emil Kraepelin in 1910.
In 1817, James Parkinson, a British physician, fi rst described the clinical picture 
known as “shaking palsy” (paralysis agitans) based on six cases that he personally followed 
for several years. Armand Trousseau, a French internist, made two important additions 
to Parkinson’s description; he recognized both the rigidity and the occurrence of mental 
impairment in some cases 2: “The intellect...gets weakened at last; the patient loses his 
memory and his friends notice soon that his mind is not as clear” 3. Forty years later, the term 
Parkinson’s disease was fi rst used by the French neurologist Jean-Martin Charcot. Since then, 
investigators have tried to elucidate the causes of Parkinson’s and Alzheimer’s disease in order 
to understand the pathophysiology of these disorders and to design effective therapies.
These late-onset neurodegenerative disorders display remarkable clinical and 
pathological overlaps. They are characterized by progressive dysfunction and, at a later stage, 
by the loss of specifi c neuronal populations, in addition to the formation of intra and extra 
cellular protein aggregates. Here, we describe the efforts and progress made in the mapping 
of genes involved in Alzheimer’s and Parkinson’s disease. The study of the identifi ed genes, 
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proteins and pathways should help to dissect these complex disorders. In spite of the progress 
made, the chase has however just begun.
Nomenclature
Gene symbols used in this article follow the recommendations of the HUGO Gene 
Nomenclature Committee.
Alzheimer’s disease
Alzheimer’s disease (AD, OMIM 104300) is the most common type of dementia, with a 
prevalence that varies from about 3% in individuals around 65 years of age to nearly 50% 
in people aged 85 years 4. AD is characterized by progressive memory loss and deterioration 
of cognitive functions that ends with the death of the patient in a period of approximately 
10 years. However, the consequences of the disorder extend to family members and caregivers 
whose lives are also affected and to society in general. Since the prevalence of AD increases 
exponentially with advancing age 5, countries with high life expectancies are particularly 
confronted with this health problem.
Neuropathologically, the disease is characterized by extracellular amyloid plaque 
formation, the deposition of amyloid in the wall of blood vessels, the presence of intracellular 
neurofi brillary tangles and neuronal loss. Although the diagnosis of possible and probable AD 
can be made on the basis of clinical signs and symptoms, neuropathological confi rmation is 
necessary to establish a defi nite diagnosis 6.
The most common form of AD (senile dementia of the Alzheimer type) usually begins 
in the seventh to ninth decade of life. A less frequent form of the disease typically presents 
before age 65 years and segregates in families as an autosomal dominant disorder. The later 
is known as presenile dementia or early-onset AD and corresponds to Alois Alzheimer’s fi rst 
description. It should be noted that the classifi cation of AD in presenile (early-onset) and senile 
(late-onset, LOAD) dementia is not equivalent to familial (inherited) or non-familial AD.
Familial aggregation
The clustering of AD in families was recognized long ago. In 1932, presenile dementia was 
described in a four-generation family with pathological confi rmation in one case 7. Recent 
historical and genealogical research into one of Alzheimer’s fi rst cases (Johan F.) brought to 
light the occurrence of “mental illness” in several family members with transmission over 
several generations 8.
The classic “twin method” has often been applied in order to evaluate the contribution 
of genetic and environmental factors to the disease aetiology, based on the differences in 
concordance rates observed between monozygotic (MZ) and dizygotic (DZ) twins. Three 
Scandinavian twin studies, one Swedish 9, 10, one Finish 11, 12 and one Norwegian 13, found 
higher concordance rates for AD in MZ than DZ twins and concluded that AD is highly 
heritable and that genetic factors are of considerable importance for developing AD, even 
late in life. They also confi rmed the need to identify environmental triggers. In younger twin 
patients (from North America, 62–73 years old), the observed concordance rates were lower 
but still twice as high in MZ than in DZ twins 14. Furthermore, multiple-threshold models 
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have been used on AD twin studies to evaluate the genetic infl uences on age at onset (AAO). 
One study (average AAO=63.5 years) reported that additive genetic effects and a shared 
environment accounted for similar contributions to individual variation in AAO 15, whereas 
in a larger and older sample (average AAO=75 years), a considerable part of the variance was 
attributable to genetic factors 16.
Clinical and population-based studies have estimated the life-time risk of AD in fi rst-
degree relatives as being between 17% and 67% 17-20. Different methodologies and sample 
characteristics might be responsible for the wide variation in risk estimates, but they all 
indicate a role for genetic factors in the aetiology of AD.
For familial aggregation studies, population-based samples are preferred over clinic-
based samples, since the later may not represent the larger AD population (AAO, family 
history, severity of the disease) and might introduce bias in the ascertainment. Indeed, when 
comparing AD patients from tertiary centres and AD patients from geriatric nursing homes, the 
AAO in the clinical group was signifi cantly earlier; this was inversely associated with familial 
aggregation 21. The AAO of dementia among fi rst-degree relatives of early-onset AD patients 
is lower than the AAO in fi rst-degree relatives of late-onset cases. This observation had raised 
the question about the genetic control of the AAO in AD 18, even before that any gene involved 
in AD susceptibility had been identifi ed. This issue has only recently been systematically 
investigated for both AD and PD (see below).
Population-based studies have consistently shown an increased relative risk for fi rst-
degree relatives in both early- and late-onset forms of AD 22, 23. Recently, in a multi-ethnic 
population-based study comprising African-Americans, Caribbean-Hispanics and whites, 
familial aggregation of AD was found to be increased among families of patients compared 
with those of controls. Although differences between ethnic groups exist, a 50% increased risk 
for AD was found among fi rst-degree relatives of patients when compared with fi rst-degree 
relatives of cognitively normal controls 24 suggesting a genetic component for AD across 
different ethnicities.
Early segregation analysis on population- and clinic-based samples indicated that 
patterns of familial clustering observed in AD are best explained by a major autosomal 
dominant locus with reduced penetrance and a multifactorial component (in both early AD 
and LOAD), without ruling out the role of other genetic and non-genetic mechanisms 25, 26.
The boundaries between genetic and environmental factors are diffi cult to envisage. 
Despite uncertainties about the extent of the contribution of genetic factors in the aetiology 
of the common “sporadic” LOAD forms, it seems that they play an important role. Today, the 
genetic bases of the rare monogenic forms are better understood; they give insights into AD 
aetiopathology and help the mapping not only of genes, but also of biochemical pathways.
Known genes involved in familial AD aetiology
APP (AD1)
Based on the observation that middle-aged patients with Down’s syndrome (trisomy 21) 
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commonly suffer from AD, researchers suspected that a gene on chromosome 21 could be 
involved in AD aetiology. In 1987, linkage analysis in families with early-onset AD identifi ed 
a locus on chromosome 21q (AD1) close to the amyloid precursor protein gene (APP 27). The 
APP protein is the precursor for β-amyloid, which is the major component of the plaques 
observed in AD and which also accumulates in small blood vessels in the brain. Therefore,
APP was considered an obvious candidate gene for AD. In 1991, missense mutations in 
the APP gene were identifi ed 28, 29 and the fi rst gene involved in the aetiology of AD was 
recognized (Table 1).
Table 1. Loci and genes related to Alzheimer’s disease aetiology (AD autosomal dominant, AR autosomal  
    recessive AAO age at onset, FBATs family-based association tests)
Alzheimer’s 
disease locus
Chromosomal 
location
Genes and tested 
“candidates” Mapping method Molecular defects References
AD1 21q21 APP Linkage analysis (AD)
Single base substitutions 
(missense mutations, 
exon 16 and 17)
27-29
AD2 19cen-13.2 APOE Linkage analysis (AD) Susceptibility factor (APOE-İ4) 30
AD3 14q24.3 PSEN1 Linkage analysis (AD)
Single base substitutions 
(missense, splicing) 
deletions, insertions
31-33
AD4 1q31-q42 PSEN2 Linkage analysis (AD)
Single base substitutions 
(missense mutations, 
exon 4, 5, 7 and 12)
34-36
AD5 12p11.23-q13.12
Unknown, A2M,
LRP1, LBP-1c/
CP2/LSF
Linkage analysis 
(parametric and non-
parametric). FBATs
– 37-40
AD6 10q24
Unknown, PLAU,
IDE, CHAT,
VACHT, TACR2,
HK1, LIPA,
NFKB2, VR22
Linkage analysis 
(parametric, non-
parametric) and 
association analysis
– 41-44
AD7 10p13 Unknown Association and linkage disequilibrium – 45, 46
AD8 20p Unknown Covariate-based linkage method – 47
The function of APP is still largely unknown. Normal processing of APP involves cleavage by 
α-, β- and γ-secretases. The cleavage by α-secretase occurs within the Aβ domain, preventing 
the formation of β-amyloid (Aβ), whereas β- and γ-secretases are involved in the cleavage and 
production of Aβ40 and Aβ42 48, 49. Not surprisingly, all the identifi ed pathogenic mutations 
(n=16) are located within exons 16 and 17 of the gene and are clustered around the β- and 
γ-secretase sites of the APP protein. Mutations such as Lys670Asn; Met671Leu 50, which is 
located upstream of the β-cleavage site, and Val717Ile 29 and Val717Phe 51, which are situated 
close to the γ-site, result in an increase in the formation of Aβ40 and/or Aβ42 29, 52, 53.
The identifi cation of APP as the fi rst gene shown to be involved in AD led to the 
generation of transgenic animal models over-expressing normal or mutated human AD genes. 
As in human disease, Aβ over-expression and deposition greatly increases with age and occurs 
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selectively in those brain regions most heavily affected in AD (hippocampus and cortex). 
Interestingly, most of the mouse models successfully mimic important features of the human 
disease, such as the presence of amyloid plaques, gliosis and neurodegeneration with age-
related cognitive impairment, but neurofi brillary tangles are absent 54.
PSEN1 (AD3)
It soon became evident that APP was not the only gene involved in AD aetiology and several 
groups continued their searches. Earlier evidence suggesting genetic linkage 55 and the 
genomic location on chromosome 14 of a putative candidate gene, the serine protease inhibitor
α1-antichymotrypsin (AACT), turned the attention of researchers to this chromosome and, in 
1992, a new AD locus was identifi ed by linkage analysis in families with presenile AD (AD3) 
31-33. However, the physical localization of the AACT gene in a different chromosomal region 
(14q32.1) and the existence of several recombinants quickly ruled out the “candidature” of 
this gene. Interestingly, signifi cant linkage to chromosome 14q was also observed in families 
previously reported to be linked to the AD1 locus (APP). None of these pedigrees had 
individually shown signifi cant evidence of linkage to chromosome 21 27 and no mutations in 
the APP gene had been identifi ed 56. After the exclusion of several candidate genes and the 
refi nement of the chromosome 14 region, the presenilin 1 (PSEN1) gene was identifi ed as the 
responsible gene 57, only 3 years after the linkage fi ndings.
Approximately 268 families have been reported with PSEN1 mutations worldwide (AD 
mutation database, http://molgen-www.uia.ac.be/admutations/). Most of them display 
early-onset AD but some also show atypical features, such as parkinsonism, frontotemporal 
dementia, epilepsy, myoclonus 58-60, cerebral amyloid angiopathy 61, 62 and spastic paraparesesis. 
The last mentioned has been associated with the deletion of exon 9 (Delta9) and unusual large 
“cotton wool” plaques 63.
PSEN2 (AD4)
In 1995, evidence for a locus on chromosome 1 (AD4 35) was reported in several kindreds 
known as the Volga-German families, a group of related kindreds of German-Russian origin 
with multiple cases of early-onset AD. Subsequently, the presenilin 2 gene (PSEN2) on 
chromosome 1 34, 36 was quickly identifi ed because of its high homology with PSEN1 and 
its localization within the genomic region previously identifi ed on chromosome 1 by linkage 
analysis.
Unlike PSEN1 mutations that usually lead to an early disease onset, great disparity 
in AAO has been observed in carriers of PSEN2 mutations 64-66. Available neuropathological 
studies report moderate cortical atrophy and abundant neurofi brillary tangles with senile 
plaques throughout the cerebral cortex 65.
During the last decade, an increasing number of mutations in APP, PSEN1 and PSEN2
causing AD have been reported. Around 158 mutations have been identifi ed in these three 
genes, most of them (n=133, 84.2%) in PSEN1, followed by the APP gene, which accounts 
for 10.1% of the mutations. Mutations in PSEN2 represent only a small percentage (5.7%) 
of all the mutations; a mere nine mutations in 15 families have been described (AD mutation 
database, http://molgen-www.uia.ac.be/admutations/ and http://www.alzforum.org/).
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In an effort to estimate the genetic contribution of the PSEN1 and PSEN2 genes 
in a Dutch population-based study of presenile AD, mutation frequencies of 6% and 1%, 
respectively, were found after mutational screening of 101 unrelated familial (48%) and 
sporadic patients. When family history was taken into account, mutation frequencies for
PSEN1 were 9% in familial cases and 18% in autosomal dominant cases 67.
Furthermore, 56% of the early-onset French families assessed for mutations in the
PSEN1, PSEN2 and APP genes were found to be positive for PSEN1 mutations and 15% for
APP mutations 68. When four genes were investigated (PSEN1, PSEN2, APP and the prion 
protein gene, PRNP) in a heterogeneous group of European patients with presenile dementia,
PSEN1 accounted for 8% of the mutations, whereas frequencies of 5%, 8% and 11% were 
found for the other genes, respectively. A lower frequency of PSEN1 mutations (5.2%) was 
found in a clinic-based sample of 76 unrelated Colombian patients (30% with familial AD) 
with early (34%) and LOAD. When considering the autosomal dominant cases only, PSEN1
mutations were recognized in 27.2% of the patients. No PSEN2 or APP mutations were 
identifi ed 69.
True differences between populations and the different ascertainment and inclusion 
criteria applied across the studies might explain the wide differences observed. Similarly, fi nal 
estimates of prevalence are diffi cult to make. However, the studies have found evidence for 
a signifi cant contribution of these genes to the aetiology of presenile AD, especially when 
a positive family history is present. Today, in addition to pathological confi rmation of the 
disease, the fi nding of pathogenic PSEN1, PSEN2 and APP mutations is used to confi rm the 
diagnosis of AD. Importantly, the majority of familial AD patients do not have mutations in the 
three known genes suggesting the involvement of other genes not yet identifi ed.
Although the factors involved in the cause and progression of AD are not yet well 
known, the discovery of PSEN1, PSEN2 and APP mutations involved in the monogenic forms 
of AD has made a huge contribution to the fi eld of neuroscience.
Presenilin activity is essential for the normal processing of APP 70, 71 and is also 
required for the cleavage of Notch1 at the plasma membrane and the release of its intracellular 
domain 72, 73. Transgenic mice over-expressing human wild-type or mutant PSEN1 have 
consistently shown elevated amounts of Aβ, especially Aβ42, disturbing the ratio Aβ40/Aβ42
70, 74 and double mutants (APP/PSEN1) produce more Aβ than either transgene alone 48, 74, 75.
Moreover, the double transgenic mouse, PSEN2/APP, develops age-related cognitive decline 
associated with severe amyloidosis and infl ammation in discrete brain regions 76.
Mutations in the presenilins alter the γ-secretase cleavage of APP resulting in over-
production of the amyloidogenic Aβ42 peptides 70, 74, 77. Indeed, it has been suggested that the 
presenilin1 protein could itself be a γ-secretase 78.
Recent studies indicate that presenilin proteins interact with other proteins, such 
as niscatrin 79 (also implicated in Notch signalling), APH-1 and PEN-2 to form a complex 
responsible for γ-secretase activity 80-82. Determination of the roles of each component of the 
complex may provide means of intercession to arrest or prevent the pathogenic processes 
leading to AD.
The “amyloid cascade hypothesis” emerged more than 10 years ago 83, 84 and placed 
APP and specially its Aβ40–42 residue as the central protein in the mechanisms leading to 
AD. Considered together, the available data is consistent with the notion that presenilins and
APP mutations affect the normal processing of APP by the β- and γ-secretases favouring the 
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production of the Aβ residue, especially of the toxic Aβ42 fraction. The imbalance between 
Aβ production and clearance leads to its cerebral deposition and consequent plaque formation. 
The occurrence of neuritic dystrophy, microglial activation and astrocytosis within amyloid 
plaques supports the hypothesis that these mature fi brillar lesions can induce injury 85.
Furthermore, the tau pathology observed in AD is likely to be a consequence of the Aβ
imbalance 85, 86. Mutations in the microtubule-associated protein tau gene do not cause AD but 
rather a rare form of dementia known as frontotemporal dementia (FTD) that usually occurs 
with parkinsonism (linked to chromosome 17, FTDP-17). The identifi cation of mutations 
in the tau gene in patients with familial FTD 87 has strengthened the link of the tau gene 
to neurodegeneration and has contributed to the recognition of a group of related disorders 
known as the tauopathies. Intriguingly, coexistent tau and amyloid pathology (diffused and 
cored plaques plus amyloid angiopathy) in FTD patients with tau mutations has been reported 
88 suggesting an interaction between the two pathologies.
Loci implicated in the common form of AD
APOE (AD2)
Pathogenic mutations are generally causal for certain phenotypes or diseases, with some 
exceptions (i.e. reduced penetrance). In contrast, susceptibility factors are neither necessary 
nor suffi cient to cause a disease but they increase the probability or risk of having the 
associated phenotype or disorder.
A major susceptibility factor for AD, the apolipoprotein gene (APOE), was initially 
discovered by linkage analysis. In 1991, evidence supporting linkage to this region on 
chromosome 19 (AD2) was found in a set of families with LOAD 30. Subsequent association 
studies have confi rmed an increased risk in carriers of the ε4 isoform (APOE allele ε4) for late 
and early-onset forms of AD 89-91. Others have shown the protective effect of the ε2 allele 92
and have estimated that the APOE genotype (ε4/ε4 and ε2/ε3) can make a difference of around 
17 years in the AAO of AD 93. Furthermore, a contribution of 7%–9% of APOE to the total 
variance in AAO of familial AD has been reported 93. The presence of the APOE-4 allele is 
also associated with an earlier expression of clinical symptoms in carriers of specifi c APP 94 or
PSEN1 mutations 95 suggesting epistasis between the genes.
The mechanisms by which APOE-4 increases the occurrence of AD and lowers 
the AAO are not clearly understood. However, studies on transgenic animals have shown 
that APOE infl uences Aβ metabolism early in the amyloidogenic process and that APOE 
facilitates, in an isoform-dependent way, fi bril and plaque formation 96, 97. Recently, APOE 
has been described to undergo proteolytic cleavage resulting in the accumulation of carboxyl-
terminal-truncated fragments of APOE, which are neurotoxic. Moreover, the cleavage of 
APOE-4 occurs in a more effi cient way than that of APOE-3. APOE-4 C-terminal-truncated 
fragments are present in AD brains and are suffi cient to provoke AD-like neurodegeneration 
and behavioural defi cits in transgenic mice 98, 99.
Not surprisingly, the association with APOE is one of the few that has been 
consistently replicated and, so far, is the risk factor with the highest effect on AD. At least four 
more genes are thought to contribute to AAO variation of AD, with an effect as large as or 
larger than that of APOE 93.
Regardless of the progress made in the mapping of genes for Mendelian forms of 
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AD, efforts aimed at identifying genes implicated in the common late-onset form (other 
than APOE) have not been extremely successful. The genetic basis of this form is largely 
unknown. To address this problem, two main types of genetic studies have been performed: 
(1) linkage-based studies that mostly involve a collection of small families with two or more 
patients, viz. affected sib-pairs (ASP) and affected relative pairs (ARP) or multiplex families; 
(2) association-based studies that attempt a candidate gene approach in samples of patients 
and controls.
The principle underlying association studies is straightforward involving the search 
for signifi cant differences in alleles at a specifi c locus between a well-selected group of patients 
and controls. However, the performance of these studies and the interpretation of their fi ndings 
remain a major challenge, as corroborated by the observation that the consistent replication of 
association studies has, in most instances, been diffi cult to achieve. A recent review has found 
that only six out of the 166 positive associations that has been studied three or more times 
have been consistently replicated 100. Some of the possible reasons for inconsistent results are 
false-positive results attributable to Type I error, false-negative results attributable to lack or 
insuffi cient power to detect the association in potential replication studies, the presence of 
population stratifi cation and true differences between studied populations 101.
A combination of strategies such as family-based association tests have been used by 
others 37, 102. As a result, several groups have identifi ed a number of loci across the genome (i.e. 
chromosomes 12, 10, 9, 20) and an association with approximately 40 genes has been reported 
103, although none has as yet been defi nitely established as an AD-susceptibility factor locus.
Chromosome 12 (AD5)
In 1997, a genome-wide screen and multi-analytical procedure that employed both parametric 
and non-parametric analyses identifi ed a region on chromosome 12 (D12S373-D12S390) in 
which a gene related to AD could be located 39. Subsequently, the region (12p11.23-q13.12) was 
called AD5. Strikingly, no confi rmation was reached during a second (fi ne mapping) study in the 
same sample set. Two peaks (~20 cM in between) were generated depending on the way in which 
data stratifi cation was performed, i.e. by APOE genotype, diagnosis of Lewy-body dementia at 
autopsy or family size. The largest contribution to the peak at D12S1042 came from a group 
of families in which at least one patient had the neuropathological diagnosis of Lewy-body 
dementia and that were lacking the APOE-4 allele 104.
Following this initial report, several groups carried out replication studies on the 
chromosome 12 locus in different sample sets but with similar methodologies 40, 105 106. Evidence 
for linkage to a larger chromosomal interval that included AD5 (67 cM, D12S358–D12S96) 
in the presence of genetic heterogeneity was found in a group of 53 families. The level of 
signifi cance was still reached after applying the Bonferroni correction for multiple testing 40.
However, in an independent and larger set of patients (ASP from 230 families with LOAD), the 
previous fi ndings could not be replicated and a different region on chromosome 12p (12p13.3-
p12.3) showed suggestive evidence of linkage, close to the alpha-2macroglobulin gene (A2M).
Most of the evidence came from affected pairs where both members were APOE-4-negative 106.
Although several groups have attempted to confi rm and refi ne the genetic location 
of the putative AD locus on chromosome 12, the results have been inconsistent. This 
inconsistency may arise because of several reasons: genetic heterogeneity, diffi culties 
inherent in the diagnosis of dementia, lack of good “biological markers” for the disease 
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and sample admixture. Similarly, methodological problems such as multiple testing and 
improper corrections for this may obscure the actual signifi cance of the fi ndings. Furthermore, 
preliminary power calculations and the proper determination of signifi cance levels are lacking 
in most of the studies.
The selection of the most appropriate method of analysis is also a complex issue and 
depends on several factors: the disease under study, the type and size of the available sample 
and the density and type of the genetic markers. It is alarming to observe the amount of positive 
linkage reports obtained after multiple analyses of the genetic data without the appropriate 
correction or defi nition of stringent signifi cance levels having been made. Although it is valid 
to perform exploratory analyses to assess the best genetic model or a better method of study, 
the results emerging from such analyses should not be interpreted as true linkage fi ndings.
In order to avoid some of these problems, several groups have chosen the 
“candidate gene approach” as an alternative strategy to identify the AD5 gene(s). The alpha-
2macroglobulin (A2M), its receptor the low density lipoprotein receptor-related protein1
(LRP1) and the transcription factor LBP-1c/CP2/LSF genes have been intensively studied as 
candidates infl uencing the susceptibility to AD because of their chromosomal location within 
the critical regions and their role in β-amyloid metabolism 39, 107. Initial positive reports of 
association 37, 38, 108-110, have been followed by negative fi ndings and the absence of confi rmation 
by independent groups studying different populations 110-122. Furthermore, little evidence of the 
functionality of the polymorphisms has been presented.
In conclusion, although the identifi ed regions on chromosome 12 bear tentative 
candidate genes and the positional candidate gene approach seems to be a good strategy, the 
various studies have yielded inconsistent and controversial results.
Chromosome 10 (AD6)
A two-staged genome screening was performed in ASP with LOAD from the National Institute 
of Mental Health (NIMH) AD Genetics Initiative; the sample was stratifi ed on the basis of 
whether both or neither of the ASP members possessed at least one APOE-4 allele. The fi rst 
stage involved genotyping 292 ASP by using a 20-cM marker interval 123, 124. During the second 
stage, 451 ASP were genotyped with an additional 91 markers, located within the 16 regions 
in which the multipoint LOD score was greater than 1 in stage I 124. Signifi cance levels were 
estimated by simulation calculations. The best results in both stages corresponded to a region 
on chromosome 10q for which the initially obtained maxLOD score of 2.3 increased to 3.9 in 
stage II. The region on chromosome 10 was refi ned to approximately 44 cM spanning from 
D10S1426 to D10S2327 44, 124.
Subsequently, Myers et al. 124 attempted to track the region by examining linkage 
disequilibrium in the area but they could not fi nd a positive association when independent 
groups of discordant sib-pairs and a case-control sample were assessed. The same genomic 
region has been found by another group 125 but, because of overlap in the sample set, these 
studies cannot be considered completely independent 124.
Evidence pointing to the same region on chromosome 10q was found in a sample of 
late-onset extended pedigrees that were selected based on probands with extremely high plasma 
values of Aβ42. The investigated region gave a maximum multipoint LOD score of 3.93 at 
81 cM, when high plasma values of Aβ42 were considered as a surrogate trait in a quantitative 
trait analysis 42. Abnormal levels of tau protein and Aβ42 in cerebrospinal fl uid have been used 
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as potential biological and diagnostic markers of AD, although other neurological disorders 
may also cause anomalous protein levels 126. Conversely, results of plasma levels of Aβ40 and 
Aβ42 in relation to AD have been contradictory. Whereas the plasma level of Aβ42 has been 
found to be elevated in familial forms of AD with PSEN1, PSEN2 and APP mutations 127, 128
others have found no such relationship with “sporadic” AD 129, 130.
Several candidate genes located on chromosome 10q have been tested for association 
with LOAD in different sample sets by using single nucleotide polymorphisms (SNPs) within 
and around the candidate genes and by searching for association between the independent 
SNPs and/or SNPs haplotypes and the disease (Table 1). Most of these studies have produced 
negative results 131-135 however, some groups have reported a positive association for PLAU 133,
136 and IDE 137. Moreover, hippocampal IDE protein levels are reduced by more than 50% in 
ε4-positive LOAD patients compared with ε4-negative patients and controls, suggesting that 
IDE may interact with APOE status to affect Aβ metabolism 138.
Recently, signifi cant association has been found with two SNPs located within 
intron 10 of the VR22 gene in the same set of families for which linkage to high plasma levels 
of Aβ42 was initially described (10q, 81 cM) 42, 43. VR22 encodes a novel α-catenin (α-T 
catenin), which interacts with β-catenin in a functionally effective fashion 139; β-catenin also 
interacts with presenilin 1 140. Biological evidence is now needed to explore the way in which
VR22 variants are associated with high plasma levels of Aβ42 and whether these variants 
modify the risk for LOAD.
On the other hand, there is a growing interest in the identifi cation of not only “risk 
genes”, but also “AAO genes” that may be involved in controlling the AAO of some genetic 
disorders. Using an interesting approach that merged a sample of 449 AD families and 174 
PD families, a putative locus controlling AAO of these two neurodegenerative disorders was 
identifi ed on chromosome 10q (133–135 cM) 141. Recent data suggest that the glutathion 
S-transferase omega-1 (GSTO1) gene, a positional candidate, is down-regulated in the 
hippocampus of AD cases and act as a modifi er for the AAO in both AD and PD cases 142.
AD7
The AD7 locus has been assigned to chromosome 10 close to marker D10S1423 (10p13). After 
a genome screen, allelic association with AD was observed for six genetic markers (D1S518, 
D1S547, D10S1423, D12S1045, D19S178, DX1047) 46. Independent replication came from 
a German sample of 80 AD patients and approximately 300 controls 143 and a prospective 
longitudinal study (11.5 years follow-up) of 325 asymptomatic fi rst-degree relatives who 
carried the 234-bp allele (D10S1423), the APOE-4 allele or both. Individuals carrying both 
risk alleles had the greatest age-specifi c risk of developing AD 144.
 The same region (AD7, 10p13), 5 cM away from D10S1423, was found in a genome-
wide linkage-disequilibrium mapping investigation in Finland. The study was performed in 
a sample of patients and controls chosen from a geographically restricted area in eastern 
Finland in which the population has descended from a small group of founders who migrated 
to the region in the late 16th and early 17th centuries. Another six chromosomal regions were 
identifi ed that contained more than one marker associated with AD: 1p36.12, 2p22.2, 3q28, 
4p13, 18q12.1 and 19p13.3 45.
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AD8
In addition to the linkage signal repeatedly observed in the APP region (chromosome 21), a 
joint effect with chromosome 20p was reported in 272 ASP with AD by Olson et al. 47. The 
authors revised the data that had previously been collected and genotyped as part of the NIMH 
AD Genetics Initiative 123, 124. Using an interesting approach that incorporated covariates to 
the linkage analysis and that allowed for detection of genetic linkage in the presence of locus 
heterogeneity, this group was able to identify a region on chromosome 20p (AD8, 21 cM) 
when the current age of patients was taken into the analysis. The incorporation of the presence 
of the APOE-2 allele as a covariate yielded a higher LOD score (4.09). Moreover, a two-
locus model provided evidence of strong epistasis between chromosome 20p and the APP
region on chromosome 21, especially in those patients who were of an older age and lacked 
APOE-4. The authors suggested that the development and/or rate of progression of AD in such 
families is infl uenced by the presence of high risk alleles at both loci, which probably interact 
biologically to increase disease risk 47, 145.
During this last analysis, the regions previously reported as being positive in the 
same dataset were not detected, probably because of the different analysis methods applied. 
Incorporation of covariates and allowance for locus heterogeneity increases the probability of 
Type I errors attributable to multiple analyses of the same genetic data. The authors therefore 
recommended careful selection of covariates and cautious interpretation of the results 47.
A recent reanalysis of the genotypic data of 437 families from the NIMH Genetic 
Initiative, with a similar method that ordered subset of families by using covariates (in this 
case, AAO), detected regions on chromosome 2q34 (210 cM) in a subset of families with 
early-onset AD, 9p22 (42 cM) in families with LOAD and 15q22 (60–62 cM) in families with 
AD of very late onset (≥79 years) 146. In spite of the overlapping of the sample sets, only the 9p 
region has been reported before. On the other hand, a region 12 cM away from AD8 was also 
identifi ed when the specifi c set of families were reanalysed with the ordered subset method 146.
Other loci
Recently, a genetic isolate community (Israeli-Arab) with a high degree of inbreeding and 
unusual high prevalence of “dementia of the Alzheimer type” was described. The diagnosis 
of the patients was mainly clinical and only a few cases underwent neuroimaging studies; 
neuropathology was unavailable. Multiple loci were found after performing a genome 
scan and association analysis; all of the loci overlapped with loci reported previously. The 
chromosome 9 (32–45 cM) and chromosome 12 (~83 cM) regions were highly signifi cant, 
whereas the chromosome 10 region (~105–115 cM) and the chromosome 2 region (~41 cM), 
which lies 6–10 cM away from a region previously detected by linkage-disequilibrium 
mapping in Finland 45, showed suggestive linkage 147. Other studies also found several regions 
on chromosome 9: 9q22 123, 124, 148 9p22.1 and 9q34.2 125.
Another recent genome scan carried out in the full NIMH Genetic Initiative sample 
(437 AD families, most of them with only one ARP) identifi ed regions that overlapped with 
previous reports. For chromosome 1 (1q23 123, 148), a region close to the gene encoding niscatrin 
(NCSTN), which binds presenilin and is required for γ-secretase activity and Aβ generation 
was found 149. The 6p21 39, 123, 141, 148, 6q26 39, 145, 6q27 148 and 19q13 (close to APOE) 39, 123, 
148 regions have been frequently reported. Patients sharing alleles at the 19q13 region had 
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signifi cantly more APOE-4 alleles than those who did not share alleles at the chromosome 19 
marker, suggesting that the linkage signal on this region corresponds to the APOE gene 124.
Because of the overlap of the sample sets used in the different studies, similar 
results are expected. Thus, the use of largely overlapping sample sets limits the ability of 
independently replication of the positive results. Moreover, the use of different statistics in the 
same sample sets has also resulted in the identifi cation of diverse genomic regions.
We believe that the presence of genetic heterogeneity, the lack of comprehension of 
the actual genetic model in complex disorders and methodological problems are having an 
effect on the successful mapping of susceptibly genes involved in AD aetiology. Only our 
ability to overcome these diffi culties will lead to the detection of predisposing genes that have 
modest effects and whose interaction ends in neurodegeneration and disease.
Parkinson’s disease
Parkinson’s disease (PD, OMIM 168600) is the second most common neurodegenerative 
disorder in humans. Similarly to AD, the prevalence of PD increases with age, age being one 
of the most important risk factors. PD prevalence has been estimated to be around 2% among 
people over the age of 65 years 150.
PD is a progressive disorder that is characterized by severe motor symptoms, including tremor, 
slowness of movement, muscular rigidity and postural imbalance. The main pathological 
hallmarks of this disorder are a pronounced loss of dopamine-producing neurons in the 
substantia nigra pars compacta 151 with Lewy bodies, cytoplasmic inclusions consisting of 
insoluble protein aggregates, in surviving group of neurons 152.
Clinically defi ned PD represents a heterogeneous disorder that encompasses a 
spectrum of a small proportion of individuals with disease inherited in a Mendelian fashion, 
families with more than one patient but unidentifi able pattern of inheritance and a larger 
population of patients with isolated (idiopathic) disease. Families with autosomal dominant 
and autosomal recessive inheritance can often be distinguished from idiopathic PD; they 
usually have an earlier AAO, especially in autosomal recessive juvenile parkinsonism 
(AAO<21 years) and early-onset Parkinson’s disease (EOP, AAO<45 years).
The contribution of genetic factors to PD has been, for many years, the object of 
controversy. Early contentious fi ndings in MZ and DZ twin studies, the role of environmental 
factors such as MTPT in the aetiology of PD-like phenotypes and that PD seems to be a 
syndrome rather than a single entity have challenged our understanding of the contribution of 
genetics to the aetiology of typical PD.
Familial aggregation
In the early 1980s, several twin studies reported low concordance rates for MZ and DZ 
twins with PD 153, 154, however, others subsequently noticed methodological pitfalls and 
recommended caution when interpreting those premature fi ndings 155. AAO 156 and the long 
latency (preclinical) period of the disease were also identifi ed as potential pitfalls. In 1999, a 
large cross-sectional twin study (white males in United States) identifi ed a high concordance 
rate for MZ over DZ twins that was only present when the disease started at or before the age 
of 50 years 156. Concordance for subclinical striatal dopaminergic dysfunction was also found 
to be signifi cantly higher in MZ than in DZ twins in a 7-year positron-emission-tomography 
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longitudinal study 157 suggesting that the low rates of concordance in previous studies could 
have arisen because of the inability to detect presymptomatic disease and the absence of 
follow-up.
In addition to the known monogenic forms, familial aggregation has been found 
for typical late-onset PD (>50 years of age) 158, 159. First-degree relatives of PD cases are 2–7 
times more likely to develop PD than the fi rst-degree relatives of controls in community-based 
studies 159-161. In a comparative clinic-based case-control study of early-onset and late-onset PD 
cases, the age-specifi c risk of PD increased 7.76-fold in the relatives of early-onset cases and 
2.95-fold in relatives of those with late-onset disease 162. A stronger association for younger 
than for older PD patients was also observed in an large community-based study in Europe, 
whereas the analysis showed a signifi cant trend of increasing risk with increasing number of 
affected relatives 163.
Furthermore, segregation analysis by using information on families of PD patients 
ascertained randomly from a movement disorder clinic suggested that familial clustering in 
PD was best explained by a rare “familial factor” transmitted in a non-Mendelian way and 
infl uenced the AAO of the disease 164. Complex segregation analysis performed in a Finnish 
population considered to be genetically homogeneous because it evolved from a small group 
of founders suggested that the role of a major gene in early-onset cases is greater than in 
late-onset PD. Moreover, in families with several affected members, the best fi tting genetic 
hypothesis was a major locus infl uencing the susceptibility to PD, although the exact model 
(dominant or recessive) could not be defi ned 165. Early- and late-onset patients were also 
ascertained in the Icelandic population and linked to the information from a population-based 
genealogical database. Calculation of kinship coeffi cients (a measure of genetic relationship 
between two persons) showed that PD patients were signifi cantly more related than the 
control group, the clustering of PD extending beyond the nuclear family. Accordingly, all risk 
ratios for fi rst- and second-degree relatives were high, for the complete sample (6.6–2.4, 772 
patients) and for the late-onset group (6.7–2.7, n=560). The risk ratios for siblings were higher 
than those for offspring, suggesting a role for some environmental factors shared early in life, 
whereas the spouses of PD patients were not at an increased risk for the disease 159.
Recent segregation analysis performed on 948 nuclear families with 4351 persons 
being included in the study have found evidence for both a major dominant gene infl uencing the 
AAO and a major additive gene infl uencing the susceptibility to PD 166. Finally, recent genome 
scans have presented evidence suggesting the localization of putative genes infl uencing the 
AAO 141, 167 and a locus infl uencing the susceptibility to late-onset PD 168.
Known genes involved in Mendelian forms of PD
Alpha-synuclein (PARK1)
The fi rst gene for familial PD (α-synuclein, PARK1) was mapped in 1996 in a large kindred of 
Italian origin, known as the Contursi kindred, with an autosomal dominant form of the disease 
169. The Contursi kindred is a large family originating from a town with this name in Italy. Many 
of the family members immigrated to New Jersey where they were recognized as part of this 
multiplex kindred the founders of which can be traced back to the 18th century 170. The illness 
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in this family is comparable to PD but the AAO is on average 15 years younger (46±13.6) and 
there is a rapid disease progression. Moreover, some degree of cognitive impairment occurs in 
some patients 170. Autopsy of two affected individuals showed Lewy bodies and other changes 
typical of PD 171.
A genome scan performed in this large family lead to the identifi cation of a 
chromosomal interval that yielded a signifi cant LOD score (maxLOD=6.04) 169. Soon after, a 
mutation in the α-synuclein gene, Ala53Thr, located in the former identifi ed 6 cM candidate 
region was found in the large Italian family and three families of Greek origin 172. Several 
Greek families with a similar clinical picture and the Ala53Thr mutation were reported; the 
presence of unaffected carriers older than the expected AAO suggested incomplete penetrance 
of the mutation 173. Further genetic studies in these Greek families found evidence for a 
common founder haplotype in the α-synuclein region and the origin of these families was 
traced to an area in the northern Peloponnese in Greece. The same haplotype was found in the 
kindred from Contursi, a region geographically and historically linked to Greece, suggesting 
that patients from these families may all be descendants of a single founder 174. Re-examination 
of one of the original brains from the Contursi kindred, with new immunohistochemical tools, 
showed a dense burden of α-synuclein pathology, “rare Lewy bodies” and tau inclusions. 
Therefore, the neurodegenerative process caused by the Ala53Thr mutation is not identical to 
that seen in idiopathic PD 175.
A second mutation resulting in a substitution of alanine with proline at position 30 
(Ala30Pro) has been described in a German family 176. However, mutations in the α-synuclein
gene are a rare cause of PD; no mutations were found after screening large numbers of 
PD patients with familial, sporadic, late- or early-onset forms of the disease 177-180. Genetic 
heterogeneity became evident for the familial forms of parkinsonism (Table 2). 
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Table 2. Loci and genes related to Parkinson’s disease aetiology (AD autosomal dominant, AR autosomal  
 recessive, AAO age at onset, FBATs family-based association tests, QTL quantitative trait loci)
PD locus Chromosomal 
location
Genes Mapping method Molecular defects References
PARK1 4q21 Alpha-Synuclein Linkage analysis (AD)
Missense mutations: A53T 
(G209A, exon 4), A30P (G88C, 
exon 3)
169, 172 
PARK2 6q25.2–27 Parkin Linkage analysis (AR)
Single base substitutions 
(missense, nonsense, frameshift, 
splicing) deletions, duplications
181, 182
PARK3 2p13 Unknown
Linkage analysis (AD, reduced 
penetrance). For AAO: linkage 
and association (FBATs)
- 167, 183 
PARK4 
(actually
PARK1)
4p15 (actually 
4q21)
Alpha-
Synuclein
Linkage and haplotype analysis 
(AD) Gene triplication 184, 185
PARK5 4p14 UCHL-1 Mutation analysis (AD, reduced penetrance) I93M (exon 4) 186
PARK6 1p35–36 Unknown Linkage analysis (AR) - 187 
PARK7 1p36 DJ-1 Linkage, homozygosity mapping (AR)
Single base substitutions 
(missense, nonsense, splicing), 
deletions
188, 189
PARK8 12p11.2-q13.1 Unknown Linkage analysis (AD) - 190
PARK9 1p36 Unknown Linkage analysis (AR) - 191
PARK10 1p32 Unknown
Linkage analysis (population 
design, model-free). For AAO: 
QTL analysis
- 141, 168
PARK11 2q36–37 Unknown
Linkage analysis (model-free 
and AD model with reduced 
penetrance)
- 192, 193
Alpha-synuclein mutations provided one of the fi rst clues for understanding the pathways 
leading to PD. The role of α-synuclein in PD was confi rmed by the fi nding of this protein 
as the major component of the Lewy bodies 194. This observation also revealed the role of 
abnormal protein folding and aggregation in PD and, indeed, early in vitro experiments 
showed accelerated mutation-induced (A53T) protein aggregation and fi bril formation 195.
Animal models of neurodegenerative disorders have been crucial in the understanding 
of the pathogenesis of these diseases. Transgenic mice over-expressing the wild-type human α-
synuclein gene 196 or with the A53T mutation develop adult-onset motoric dysfunction leading 
to death and α-synuclein pathology 197-199. Results from experiments in knockout α-synuclein
mice support the hypothesis that α-synuclein is an essential presynaptic activity-dependent 
negative regulator of dopamine neurotransmission 200. A transgenic fl y model (wild-type or 
mutant α-synuclein) of PD displays adult-onset loss of dopaminergic neurons, fi lamentous 
intraneuronal inclusions containing α-synuclein and locomotor alterations compatible with the 
clinical picture observed in humans 201.
Both α-synuclein mutations (see above) have subsequently been shown to accelerate 
the formation of prefi brillar oligomers (protofi brils) in vitro 202. Biophysical studies and animal 
modelling aimed at elucidating the mechanism of fi bril formation support the emerging notion 
that toxic protofi brils may be responsible for cell death and that the fi brillar formations are 
observed later 203, 204.
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The over-expression of α-synuclein is believed to be a risk factor for PD. Some 
studies have shown associations with polymorphisms (e.g. Rep-1; 205, 206) located within the 
promotor region of α-synuclein and related to variations in the gene expression 207-209.
Recently, in a large family with parkinsonism (originally PARK4, see below), 
Singleton et al. 185 have found evidence consistent with triplication of the α-synuclein gene. 
The authors suggest that the increased dosage of α-synuclein is the cause of PD in this family 
and that a “dosis effect” (complete gene triplication) can be considered as the third mutation 
in this gene.
Parkin (PARK2)
In 1997, the PARK2 locus was mapped to a 17-cM region in chromosome 6q by linkage 
analysis in Japanese patients with EOP and autosomal recessive inheritance 182. Clinically, 
the classic signs of bradykinesia, rigidity, tremor and early dystonia characterize this form of 
juvenile parkinsonism, plus slow progression, sleep benefi t and good response to levodopa 
treatment. Pathologically, neuronal loss, gliosis (substantia nigra and locus ceruleus) and 
absence of Lewy bodies have usually been reported 210-212.
The second gene involved in the pathogenesis of parkinsonism was identifi ed, in 1998, 
by positional cloning; the gene was named parkin 181. Since then, a wide variety of mutations 
have been described in this gene ranging from point mutations to complex rearrangements, 
including deletions and/or multiplications of complete exons in the homozygous or 
heterozygous state 213-217. In a large European study, parkin mutations were found in almost 
50% of the families with EOP 216. Among sporadic patients with disease onset below 45 years,
parkin mutations were detected in 15% of the cases showing that mutations in this gene are a 
major cause of EOP 216, 218.
The contribution of parkin mutations or polymorphisms to typical late-onset PD 
has been the subject of intense research. A recent study involved mutation analysis in a large 
number of ASP (early- and late-onset). Mutations were identifi ed in 103 (18.4%) of these 
familial PD cases; among these, 60% had a single mutation. Thirty-fi ve (35/103) had an AAO 
of more than 60 years 219 suggesting that parkin mutations should be considered when late-
onset PD patients are evaluated, especially when they have a positive family history.
The clinical consequence of carrying only one parkin mutation has been an issue of 
debate. Several studies have hypothesized that haploinsuffi ciency attributable to the partial 
loss of parkin expression may be a risk factor for dopaminergic cell death 220 and may confer 
risk for late-onset PD 219, 221. Others have suggested that this simply refl ects the inability to 
fi nd a second DNA change located in regulatory regions, promoters or introns. Whether 
one heterozygous parkin mutation is suffi cient to confer susceptibly to PD or whether this 
happens through a combination with other changes within this or another genes remains 
unclear. Recently, a genome scan performed in families with only one parkin mutation also 
found suggestive evidence of linkage to chromosome 10q24 suggesting a potential epistatic 
or additive interaction between the parkin gene and a chromosome 10 susceptibility locus 222.
Interestingly, the same region has been linked to AD.
Although Lewy bodies are a remarkable pathological feature of PD, the underlying 
mechanisms leading to the formation and their signifi cance are poorly understood. The absence 
of Lewy bodies in the majority of patients with parkin mutations suggests that parkin might 
be required for the formation of Lewy bodies 223. The available reports on the pathological 
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aspects of “parkin disease” are based on cases with homozygous exon deletions 210, 211, 224 and 
compound heterozygous exon deletions and point mutations 212, 225. Lewy bodies have been 
documented in one patient with EOP belonging to the last group (compound heterozygous: 
deletion of 40 bp in exon 3 plus Arg275Trp, R275W); positive ubiquitin and α-synuclein
inclusions were also found in this patient.
Recent experiments in cellular models have shown that the R275W mutation, located 
within the RING fi nger 1 domain, leads to an unusual cellular distribution of the protein, 
with large cytoplasmic and nuclear inclusions 226. Cookson et al. 226 suggest that some parkin
mutations may confer a dominant gain of function depending on the protein domain affected. 
Simultaneously, a case-control study found a similar R275W frequency in cases and controls 
(unaffected at age ≥75 years) 227 suggesting that the R275W allele and possibly other point 
mutations that do not cause a complete loss of function may predispose to PD in compound 
heterozygotes.
Although the mechanisms leading to neurodegeneration, cell death and disease are 
not well understood, parkin is known to be involved in protein degradation as an ubiquitin 
ligase, collaborating with the ubiquitin-conjugating (E2) enzyme UbcH7 or UbcH8. Parkin 
itself is a RING-type ubiquitin (E3) ligase involved in the ubiquitination of targeted proteins. 
Loss of the parkin ubiquitin-protein ligase function leads to the accumulation of proteins 
such as the synaptic vesicle-associated protein, CDCrel1 228, Paelr 229 and neural cell death 230,
231. Parkin interacts also with synaptotagmin XI, an interaction resulting in its ubiquitination 
and degradation. The interaction with a member of the synaptotagmin family suggests an 
involvement of parkin in neurotransmitter traffi cking, in the regulation of the synaptic vesicle 
pool and in vesicle release 232.
Several fi ndings indicate that the relationship between “parkin disease” and PD 
extends beyond a simple clinical overlap. Loss of parkin function is expected to cause the 
pathological accumulation of a form of glycosilated α-synuclein (αSp22) because of its 
inability to polyubiquitinate αSp22 233. In addition, over-expression of parkin can mitigate 
α-synuclein-induced pathology and suppress its toxicity 234. Parkin over-expression in cellular 
models with impairment of proteasomal activity also leads to the formation of aggresome-
like inclusions; these are eosinophilic inclusions (resembling Lewy bodies) with a core and 
halo. Furthermore, wild-type parkin has a tendency to aggregate and form inclusions that 
may have implications for the pathogenesis of sporadic PD 235. Parkin also interacts with 
and ubiquitinates the α-synuclein-interacting protein, synphilin-1 236, which is enriched in 
Lewy bodies, specifi cally in their central core 237. These fi ndings potentially link two familial 
associated PD genes, viz. parkin and α-synuclein, through synphilin-1. Parkin ubiquitinates the 
Lewy-body-like inclusions that are formed when α-synuclein is co-expressed with synphilin-
1; this ubiquitination is impaired by familial-associated parkin mutants 236. These results aid 
our understanding of the molecular mechanisms underlying “parkin disease” and typical PD 
and the plausible interaction of two PD-related gene products in a common pathway: the 
ubiquitin-proteasome system.
Ubiquitin C-terminal hydrolase (PARK5)
A mutation (Ile93Met) in the ubiquitin C-terminal hydrolase gene (UCHL-1, PARK5) 186 was 
identifi ed in a German family with autosomal dominant PD. The missense mutation was found 
in two siblings and seemed to have incomplete penetrance in the family, since the phenotype 
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was lacking in the father who was presumed to be a carrier. Partial loss of the catalytic activity 
in the mutant protein was found in vitro 186.
In the search for UCHL-1 mutations, several polymorphisms have been described 
in this gene, S18Y (serine to tyrosine) situated in exon 3 has been associated with a low risk 
for PD 238, 239, suggesting a protective effect of this variant, but not all studies have found this 
association 240. Recently, an interaction with AAO has also been suggested, since carriers of the 
Y allele were found to have a decreased risk of developing PD at a younger age 241.
The UCHL-1 protein is present in large amounts in brain 242; it has been found in 
Lewy bodies of patients with PD 243 and its role in recycling free monomeric ubiquitin units 
is thought to stimulate protein degradation. An in-frame deletion including exon 7–8 of the
UCHL-1 gene in gracile axonal dystrophy mice (gad mice) leads to the altered function 
of the ubiquitin system by disturbing the re-utilization of free ubiquitin, which results in 
the accumulation of target proteins and neurodegeneration. Nevertheless, the clinical and 
pathological features of the gad mouse are not consistent with those of PD 244.
Although sporadic and familial PD cases have been assessed for mutations in the
UCHL-1 gene during the last few years, none has been found 238, 239, 245, 246 indicating that, if this 
is truly a PD gene, mutations in the coding region of UCHL-1 are a rare cause of PD.
DJ-1 (PARK7)
The PARK7 locus was found by homozygosity mapping in a family with several consanguinity 
loops and autosomal recessive EOP; the family comes from an isolated community in the 
south-western part of the Netherlands 189. The initial genomic region (1p36) spanned 16 cM 
and was separated from the nearby PARK6 locus by ~25 cM. Confi rmation of this fi nding 
came from one additional family of Italian origin with early-onset autosomal recessive 
parkinsonism 247. The identifi cation of a homozygous point mutation, resulting in a leucine 
to proline substitution (Leu166Pro, Italian), and a 14-kb deletion (Dutch) in the DJ-1 gene 
located in the PARK7 region provided the evidence for the fourth gene involved in PD 188.
To date, several mutations have been found in the gene including base changes, 
deletions and splicing mutations 248, 249. Some of them are probably pathogenic: the homozygous 
(Met26Ile) mutation affecting a highly conserved amino acid has not been found in ethnically 
matched controls; a heterozygous single-base deletion and a base change in exon 2 (c.56delC, 
c.57GoA) are predicted to cause a truncated protein and, fi nally, the base change IVS6–1Go
C is expected to lead to an aberrant DJ-1 RNA because of defective splicing. Less clear is the 
case of one EOP patient with a heterozygous (Asp149Ala) mutation (not present in controls) 
but in whom a second mutation was not found. It is should be noted that the studies published 
to date only involve sequence analysis; gene dosage studies are still lacking. Furthermore, the 
fi nding of heterozygous sequence changes and other variants has raised the hypothesis (as for 
the parkin gene) as to whether these changes confer susceptibility to the disease, alone or in 
combination with other unknown factors. The contribution of DJ-1 mutations to the aetiology 
of EOP seems to be rare; however, their prevalence needs to be established. Further studies 
involving mutational analysis, including exon dosage, and other studies to determine the 
functional implications of these mutations are required.
The DJ-1 gene encodes a multifunctional protein that is ubiquitously expressed in 
body tissues and brain areas. Evidence has been obtained regarding its involvement in the 
oxidative stress response 250, 251.The fi nding of the DJ-1 mutations and the putative role of the 
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DJ-1 protein in oxidative stress provide a link between this pathway and the pathogenesis 
of parkinsonism 188. Recent studies on the crystal structure of the DJ-1 protein have shown 
that the protein may function only as dimers 252-254; the Leu166Pro mutation abolishes the 
dimerization of DJ-1 253, 255-257 possibly affecting its function. Moreover, a chaperone activity 
(which suppresses the aggregation of unfolding intermediates) has also been reported 256.The
fi nding that DJ-1 is sumoylated, an ubiquitin-like protein modifi cation, suggests that it might be 
a target for parkin, thus connecting it to the ubiquitin-proteasome pathway 258. Indeed, mutant 
DJ-1L166P is less stable than the wild-type protein 257 and its degradation might be promoted via 
the ubiquitin-proteasome pathway 259. The identifi cation of DJ-1 interacting proteins and DJ-1
variants and their possible relationships with those from other PD-related genes would be an 
interesting approach to elucidate the mechanisms causing parkinsonism.
Nuclear receptor related-1
Two heterozygous mutations have been identifi ed in exon 1 (–291delT and –245T to G) of the
nuclear receptor related-1 gene (NR4A2, formerly known as Nurr1) in 10 out of 107 cases 
with PD and a positive family history. The clinical picture is similar to those of individuals 
with typical PD, with a mean AAO of 54±7 years. The mutations have been found to co-
segregate with the disease in all (n=10) investigated families, whereas none of the mutations 
has been observed in cases with “sporadic” PD. Haplotype analysis has also shown a common 
haplotype in three different families of German origin suggesting a founder effect of the 
mutations 260. Therefore, the frequency of the mutations in the general population is likely to 
be rare. The mutations result in a marked decrease in NR4A2 mRNA levels in transfected cell 
lines and in lymphocytes of affected individuals.
NR4A2 is a transcription factor that has a role in the differentiation of midbrain 
precursors into dopamine neurons and their maintenance 261. Mice lacking NR4A2 fail to 
generate midbrain dopaminergic neurons, are hypoactive and die soon after birth. The brains 
of heterozygous animals, which are otherwise apparently healthy, contain reduced dopamine 
levels 262. Despite the evidence that makes the NR4A2 gene an attractive candidate gene for 
PD, the search for mutations has so far been fruitless 263-265 indicating that the contribution of
NR4A2 mutations to the aetiology of PD, if any, is very low.
Known loci implicated in PD aetiology
PARK3
This susceptibility locus for late-onset PD was mapped in German/Danish families to 
chromosome 2p13. The clinical characteristics of the ascertained families resembled those of 
typical PD. Signifi cant evidence for linkage was found in four out of six families in the study 
by using parametric affected-only analysis 183.
Strikingly, the PARK3 locus has also been implicated as an AAO locus for PD. The 
positive association with allele 174 (bp) of marker D2S1394, which is also present in the 
common haplotype in two PARK3 families (German-Danish), suggests that this allele is in 
linkage disequilibrium with a susceptibility PD gene or a gene infl uencing the AAO of PD 
167.
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PARK4, PARK6, PARK8 and PARK9
A number of loci for familial parkinsonism have been found in various families around the 
world. The PARK4 locus was reported in a large family with early-onset levodopa-responsive 
parkinsonism (Iowa kindred, 4p15)184. The obtained LOD scores were not signifi cant but were 
suggestive and the fi ndings were not replicated. Four years later, re-evaluation of the genetic 
data (an unaffected individual who did not share the 4p15 haplotype became ill), showed a 
multipoint LOD score of 3.5 at the α-synuclein locus. No mutations were found by direct 
sequencing of the gene, but real-time polymerase chain reaction analysis yielded results 
consistent with a whole gene triplication co-segregating with parkinsonism. Carriers of the α-
synuclein triplication are predicted to have four functional copies of the gene, suggesting that 
this increased dosage of α-synuclein is the cause of the disease in this family 185.
The PARK6 locus (1p35–36) was identifi ed in an Italian family with autosomal 
recessive EOP, from Sicily 187. Subsequently, suggestive evidence of linkage was found in 
other families from Europe 266, 267.
The PARK8 locus (12p11.2-q13.1) was found in a large Japanese family with a 
genome-wide signifi cance level. Interestingly, neuropathological examination of two cases 
showed pure nigral degeneration without Lewy bodies 190. Recent replication has come from 
two families (family A, German-Canadian; family D, western Nebraska) with genetic linkage 
to the same region. Remarkably, pathological data has shown a variable spectrum within one 
family with several individuals with and without Lewy-body pathology 268.
Kufor-Rakeb syndrome was described in the offspring of a consanguineous 
Jordanian couple. The disorder is an autosomal recessive nigro-striatal-pallidal-pyramidal 
neurodegeneration, with juvenile onset 269. Linkage to chromosome 1p36 was reported 
(maxLOD=3.6)191 and the PARK9 locus was assigned; however, this parkinsonian syndrome 
has apparently little in common with PD.
PARK10
This was the fi rst susceptibility locus for PD mapped by using a “population-wide” design. 
The study included 51 extended families with 117 patients connected at or within six meiotic 
events and 168 of their unaffected relatives from Iceland 168. Hick et al. 168 used a dense map 
of 781 markers and model-independent, affected-only and allele-sharing methods for the 
analysis. They specifi cally searched for genomic regions that were shared by affected relatives 
more often than expected under the assumption of no linkage. A maxLOD of 3.9 was obtained. 
After fi ne mapping, this value increased to 4.9 and the detected region spanned ~7.6 cM on 
1p32 168.
Signifi cant evidence of linkage was found on chromosome 1p (D1S2134, 78 cM) 141 at the 
same location of PARK10, by using a different approach that considered AAO as a quantitative 
trait in a sample of 174 families with PD from the US and Australia. Remarkably, two loci 
(PARK3 and PARK10) were found to contribute to both disease susceptibility and the AAO 
of the disease. It will be interesting to decipher whether the same gene(s) are involved in 
mechanisms that increase disease susceptibility and lower the AAO.
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PARK11
Recent non-parametric analysis of a sample consisting mainly of ASP (see below) found 
suggestive LOD scores for regions on chromosomes X and 2 192. Follow-up of the 2q36–37 
region in a larger sample set provided additional evidence of linkage to this region. A LOD 
score of 2.47 was obtained in the expanded sample containing ASP and multiplex families 
(n=150 families) but augmented to 3.51 with the inclusion of 25 families with one or two
parkin mutations. This suggests a potential epistatic or additive interaction between parkin
and the PARK11 locus 193.
Other loci
Several genome searches aimed at the identifi cation of new PD susceptibility genes have 
found other chromosomal regions that might bear genes conferring risk for PD. Two main 
strategies have been applied: (1) the family-based approach, which uses large pedigrees 
with an identifi able Mendelian pattern and parametric analysis, and (2) the sib-pair approach 
involving the use of large collections of ASP or ARP from smaller families and mainly non-
parametric analyses that do not require specifi cation of the genetic model.
As discussed above, application of the family-based approach has led to the 
identifi cation of several genes/loci for AD and PD. Recently, we have also found suggestive 
evidence for a novel PD locus on chromosome 19p13.3-q12 in an extended Cuban family with 
PD (mean AAO of 61.2 years) and autosomal dominant inheritance 270.
Other studies have applied the sib-pair approach. The fi rst study was performed 
in a sample of 113 ASPs. Parametric and non-parametric analyses yielded slightly positive 
LOD scores on chromosomes 1, 9, 10 and 16. A maxLOD of 1.3 was found for the region 
on chromosome 9 271. During a second analysis of the data by using AAO as the phenotypic 
outcome, suggestive evidence for linkage was obtained for the same region on chromosome 9 
and for chromosome 2 (PARK3) 167, they both overlap with regions previously implicated in 
studies that had examined affection status.
The second study used a group of 174 multiplex families (with two or more PD 
patients, 260 ARP); the sample was stratifi ed according to AAO and the response to levodopa. 
This investigation identifi ed regions on chromosomes 5q, 6q, 8p, 9q and 17q 272. The linkage 
observed on chromosome 17 (close to tau) was mainly supported for the group of families 
with levodopa non-responsive parkinsonism. It is tempting to speculate that this may represent 
a subgroup of patients for whom variations within the tau gene act as risk factors. The highest 
LOD score (MLOD=5.07) came from a sample of 18 families from whom at least one patient 
had an AAO≤40 years and was obtained for marker D6S306 located in intron 7 of the parkin
gene. Nevertheless, mutations in the parkin gene were not identifi ed in 10 of these families 272
suggesting the existence of unidentifi ed parkin mutations or the involvement of other genes 
in EOP.
The third genome scan was performed in families with at least one pair of affected 
living siblings, the sample was stratifi ed according to the diagnosis “stringency”: model I 
comprised 96 sibling pairs with more stringent diagnosis criteria, whereas model II included 
all affected individuals (170 ASP). Linkage and sequence analyses allowed the identifi cation 
of  “parkin families” (n=22), reducing the genetic heterogeneity in the sample set. Pankratz et 
al. 192 found evidence for linkage on chromosomes 2 (236 cM) and X (105–122 cM), both under 
the more restrictive (model I) and broader model (model II) and by non-parametric analysis. The 
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linkage to chromosome X was supported mainly by the brother-brother pairs 192. Follow-up of 
the chromosome 2q36–37 region resulted in the identifi cation of the PARK11 locus 193.
The next study conducted by this group in a expanded sample set comprising 425 
ASP from 362 multiplex families 222 confi rmed the previous regions and identifi ed others. A 
new interval on chromosome 14 was identifi ed (besides PARK11) yielding a LOD of 2.4 in 
85 families with strong family history of PD. The analysis of the remaining 277 families again 
revealed the chromosome X region and new regions on chromosomes 10q24, 1 and 18 222. The 
10q24 region has been previously linked to both PD and AD 141 in an analysis that considered 
AAO as a quantitative trait.
Considerations of genome-wide scans in PD
In PD, as in other complex disorders, the success of gene mapping attempts based on genome-
wide scans depends on several factors. They can be summarized as follows. First, a precise 
defi nition of the phenotype is essential for reliability of results. Even with an excellent clinical 
evaluation and phenotype delineation, the presence of clinical variability, phenocopies and 
age-dependent penetrance will complicate the selection of a homogeneous sample set. 
Consequently, without proper sample stratifi cation, the effect of the potential loci is expected 
to be “diluted”. The appropriate selection of both the choice of sample to collect (extended 
pedigrees, ASP, ARP) and the method of analysis is also a crucial step. In addition, the number 
of subjects included in the study and the origin of those individuals (population isolate, 
admixed population, ethnic group) are essential factors. Small or modest samples sizes tend 
to limit the power of the study 273 and increase the probability of Type I error 274. The study 
of patients coming from special isolated populations or large extended families is a known 
strategy for reducing genetic heterogeneity in the sample set, with the inconvenience that they 
are not always available. Finally, the genotyping approach, type, heterozygocity and spacing 
of the markers used in the study are important issues to consider.
A recent review of 101 genome-wide scans on 31 complex disorders found that the 
majority (66.3%) of the them did not show signifi cant linkage when the Lander and Kruglyak 
criteria 275 were used and the results of studies of the same disease were often inconsistent. 
Two factors were closely related to the success of studies: increased sample size and ethnic 
homogeneity of the samples 273.
If we look at data available from the genome searches performed on PD, limitations 
related to sample size and heterogeneity seem to be evident, limiting the power to detect 
linkage. Several regions have been reported with suggestive or signifi cant LOD scores 
(PARK10, PARK11) but replication studies in independent datasets are lacking. Some regions 
have shown overlapping among the screenings, for both affected status and AAO (PARK3, 
PARK10, chromosomes 9 and 10). The distinction between a real but weak effect and a false-
positive result remains problematic.
Searching for genes conferring risk to non-mendelian disorders have been more 
diffi cult that originally thought. However, they hold promise in the elucidation of the causes 
and pathophysiology of genetically complex disorders.
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Final remarks of a gene-hunting story
Genetic studies of common neurodegenerative disorders such as AD and PD initially focused 
on the search for genes involved in the aetiological mechanisms of the monogenic forms. 
This search has been particularly diffi cult considering the complexity of such disorders and 
the number of factors involved: genetic heterogeneity, variable AAO, variable expression and 
reduced penetrance, among others.
During the last two decades of the 20th century, enormous progress was made in 
the fi eld of molecular genetics and genetic epidemiology. Many tools and strategies were 
developed: dense marker maps, high-throughput genotyping and sequencing facilities, together 
with statistical methodologies and sophisticated programs for the analysis and interpretation 
of the genetic data. However, the elucidation of the genetic bases of oligogenic, polygenic and 
multifactorial disorders still remains a challenge.
What lessons can be learned from the existing data? First, we lack adequate tools (such 
as biological markers) that allow the unambiguous identifi cation of the disease of interest and 
that permit the distinction of clinical sub-phenotypes. Second, the methods successfully applied 
to the analysis of monogenic Mendelian disorders have shown limited value in identifying the 
multiple genes with small effects that lie behind complex polygenic and oligogenic disorders. 
Third, “alternative routes” can be applied, by combining positional mapping and functional 
evidence obtained, for instance, from gene expression profi les (microarrays) or proteomics, 
although the latter may have limited value in neurodegenerative disorders.
The search for disease genes, which fi rst focused on single family studies, has 
evolved to the analysis of larger samples with hundreds of patients, ASP and population-based 
studies that can sometimes be performed on “special” isolated populations. The fascinating 
gene-hunting story in AD and PD is an outstanding example of the way in which identifi ed 
genes can contribute to clarifying the pathogenic mechanisms leading to these devastating 
disorders. As initial results, several genes have been successfully identifi ed as contributing to 
the risk of both diseases. Further studies of the effects of abnormal gene products on cellular 
and animal models should help to elucidate the pathogenesis of AD and PD. Hopefully, they 
will lead to the discovery of effective therapies and eventual prevention.
Missing links in neurodegenerative disorders
AD and PD are neurodegenerative adult-onset disorders that characterized by the progressive 
loss of specifi c neuronal populations and the accumulation of extra- and intra-neuronal 
inclusions. They both display substantial clinical overlap: around one-third of AD patients 
show clinical evidence of parkinsonism and close to 33% of PD patients develop dementia 
during the course of the disease 276-278.
Increased genetic risk for AD and PD has been found for relatives of patients with 
either of the disorders 279, 280. Recently, a locus that might act as a common modulator of the 
AAO in both disorders has been localized on chromosome 10q 141 and a positive association 
with the gene GSTO1 has been found for both disorders 1412.
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There are also overlaps between the pathologies of these disorders. Neurofi brillary tangles and 
amyloid plaques, cardinal features of AD, are also found in PD brains with a frequency six times 
higher than in age-matched controls. About half of the patients with pathologically confi rmed 
PD have clinical features of dementia and an AD pathology at post-mortem examination 281.
Lewy bodies, the pathological hallmark of PD, also occur in up to 61% of the patients with 
“sporadic” AD 282, 283. Indeed, the density of Lewy bodies is thought to correlate positively with 
the severity of dementia 284, 285. Furthermore, Lewy bodies also occur in familial AD caused by 
mutations in the APP, PSEN1 and PSEN2 genes and their presence is not associated with any 
particular mutation, suggesting that the effects of these mutations converge into a fi nal common 
pathway 286-288. In addition, neurodegenerative changes in the substantia nigra consistent with the 
diagnosis of PD are found in autopsy-confi rmed AD cases 289.
The genes and subsequent abnormal products found so far for the monogenic forms 
of AD and PD point to pathological protein processing and aggregate formation. Cerebral 
accumulation of β-amyloid, α-synuclein and tau has been found in patients with the genetic 
and “sporadic” forms of the disorders and in transgenic mouse models. Double-transgenic mice 
(β-amyloid/α-synuclein) display an intermediate phenotype that resembles human Lewy-body 
dementia, a disorder displaying both dementia and parkinsonism. Further, β-amyloid peptides 
may promote the aggregation of α-synuclein, exacerbate its intraneuronal accumulation in 
vivo and accelerate the development of motor defi cits in transgenic mice; specifi cally, the 
overproduction of Aβ1–42 induces intracellular accumulation of α-synuclein in vitro 290.
Tauopathies are a group of heterogeneous disorders usually displaying primary 
or secondary tau pathology, such as FTD, corticobasal degeneration (CBD; a rare and 
rapid progressive movement disorder) and progressive supranuclear palsy (PSP; a disorder 
characterized by parkinsonism, early postural instability and vertical supranuclear palsy). 
The positive association found with a tau haplotype (H1) for PSP, CBD and PD 291-294 and 
the occurrence of tau pathology in AD and PD patients suggest a role for tau as a common 
denominator in neurodegenerative diseases. Although tau mutations are mainly found in 
patients with FTD, the fi nding of tau mutations in some patients with PSP and CBD 295-297
strengthens this view.
A pathogenic interaction between α-synuclein and tau is suggested by the co-
occurrence α-synuclein and tau fi lamentous inclusions in humans, by transgenic mice 
expressing mutant α-synuclein, and by mice that express wild-type human α-synuclein plus 
mutant tau. Co-incubation of tau and α-synuclein synergistically promotes fi brillization of 
both proteins (induced by α-synuclein). Furthermore, tau inclusions have been found in 
PD patients carrying the Ala53Thr α-synuclein mutation 175. This suggests that interactions 
between α-synuclein and tau can promote their fi brillization and drive the formation of 
pathological inclusions in human neurodegenerative diseases 298.
Double-mutant transgenic mice (tau/APP) exhibit enhanced neurofi brillary tangle 
pathology indicating a possible APP or Aβ1–42 infl uence in the formation of neurofi brillary 
tangles in vivo 299. The fi nding that amyloid pathology precedes tangle formation in AD 
predicts that Aβ could trigger tau pathology 86, 300.
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Unexpectedly, DJ-1 antibodies do not label Lewy bodies in brains of PD or 
Lewy-body dementia patients. However, co-localization of tau and DJ-1 in Pick bodies 
(characteristic inclusions containing tau and ubiquitin often observed in FTD) and DJ-1 
immunoreactivity observed in neurofi brillary tangles and neuropil threads in patients with AD 
and Lewy-body dementia constitute further evidence towards common mechanistic pathways 
in neurodegenerative disorders 301.
The clinical, pathological and genetic presentation of AD and PD suggests the 
involvement of a few overlapping interrelated pathways. It is still uncertain whether the 
affected proteins converge in a common underlying pathway or whether they represent the 
end stage of parallel neurodegenerative processes. Their imbricate features point to a spectrum 
of neurodegeneration (tauopathies, synucleinopathies, amyloidopathies) that needs further 
intense investigation to fi nd the missing links.
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Abstract
We studied a Cuban family with presenile dementia (autosomal dominant) consisting of 281 
members within six generations, the proband descended from a Spanish founder. Mean age 
at onset was 59 years of age. Memory impairment was the main symptom in all patients, 
additionally; ischemic episodes were described in 4 (n=18) patients. Neuropathological 
examination of brain material (1 patient) revealed neuronal loss, amyloid plaques and 
neurofi brillary tangles.
Thirty DNA samples were genotyped (regions on chromosome 1, 3, 10, 12, 14, 17, 19, 20 and 
21). A maximum Lod score of 3.79 at θ = 0 was obtained for marker D14S43, located in a 9 
cM interval in which all patients shared the same haplotype. Sequencing of the PSEN1 gene 
revealed a heterozygous base substitution, C520A (exon 6), which is predicted to cause an 
aminoacid change from leucine to methionine in the TMIII of the presenilin 1 protein. The 
mutation was found to co-segregate with the disease phenotype and the associated disease 
haplotype. The C→A change was not observed in 80 control chromosomes from the Cuban 
population. Leucine at position 174 is highly conserved among species and is identical in 
presenilin 1 and presenilin 2 proteins. We propose the L174M mutation might lead to an 
abnormal N-terminal and probably C-terminal fragments and malfunction of the protein 
complex.
In conclusion, we found a novel PSEN1 mutation in a large family with clinical and 
pathological diagnosis of early-onset familial Alzheimer’s disease, which may be relevant for 
other Hispanic populations. 
Introduction
Alzheimer disease (AD, MIM 104300) is the most common type of dementia, characterised 
by progressive memory loss and deterioration of cognitive functions resulting in a state of 
complete dependency, with severe implications for patients, relatives and caregivers. 
The complex aetiology of AD comprises both genetic and environmental factors; 
sporadic and familial (FAD) forms of the disease have been described. The high similarity 
in clinical and neuropathological features between the early-onset familial and “sporadic” 
late-onset AD suggests that similar pathophysiological factors are involved. Studies focusing 
on large families with the rare, early-onset, autosomal dominant form of the disease led to 
the discovery that mutations in the amyloid precursor protein (APP)1, Presenilin 1 (PSEN1)2,
and Presenilin 2 (PSEN2)3, 4 genes cause AD. Although these autosomal dominant families 
represent only a small percentage of the total AD cases, functional studies of the effects of 
the identifi ed mutations have become an important way to dissect the causes and underlying 
disease mechanisms leading to AD.
Mutations in PSEN1 are responsible for 6%-18% of the AD cases with early-onset 5.
To date the majority of the described PSEN1 mutations are missense mutations giving rise to 
the substitution of a single aminoacid (www.alzforum.org/members/resources/pres_mutations/ 
and molgen-www.uia.ac.be/admutations/). It has been speculated that most AD related 
mutations result in a gain of function. Mutations in PSEN1 alter the processing of βAPP by 
favouring the production of potentially toxic long tailed β-amyloid (Aβ) peptides ending at 
residue 42 or 43 6. Presenilin 1 activity is also required for the cleavage of Notch1 at the plasma 
membrane and the release of the Notch1 intracellular domain 7. Mutations in genes involved in 
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Notch signalling also lead to late-onset neurological diseases such as CADASIL 8.
Although the provisional diagnosis of AD may be made on the basis of clinical 
symptoms, neuropathological confi rmation is necessary to establish a defi nite diagnosis. AD 
neuropathology includes the presence in the extracellular space of amyloid plaques composed 
mainly of Aβ, deposition of amyloid in the wall of blood vessels and the presence of 
intraneuronal neurofi brillary tangles (NFT), consisting of hyperphosphorylated microtubule-
associated protein tau. 
Only a few PSEN1 mutations have been described in Latin-American 9-11 and 
Caribbean populations 12. In Cuba, a prevalence for AD of 5.13% has been reported for the 
population over 60 years 13 but to date genetic studies for AD had not been performed. Here we 
describe a large Cuban family with clinical and neuropathological diagnosis of AD carrying a 
novel PSEN1 mutation, the fi rst to be reported in the Cuban population.
Patients and methods
Family description
A large Cuban family with presenile dementia was ascertained through Patient IV-26 (Fig. 1A) 
descending from a founder (I-1) of Spanish origin (Canary Islands) who settled in Cuba in the 
early nineteenth century. We interviewed 50 people to complete family history, genealogy, and 
clinical data. The pedigree consists of 281 family members within six generations, 22 patients 
were reported, and a disease description was obtained for 18 patients of whom 6 were alive 
and 4 were available for clinical examination. No pathological studies had been performed. 
Medical records were available from patient IV-26 and III-26. Segregation of the disease in the 
family was consistent with an autosomal dominant mode of inheritance with high penetrance 
(Fig. 1A). Informed consent was obtained for both clinical examination and venous puncture 
for blood collection. The research project was approved by the Ethics Committee at the Higher 
Institute of Medical Sciences in Havana, Cuba.
Clinical studies
Two independent neurologists examined 4 patients and 6 at risk family members, some of 
them with memory complaints, 9 were admitted to hospital for a complete examination. Blood 
and cerebrospinal fl uid tests, electroencephalography (EEG), brain computed tomographic 
(CT) scan and neurophysiological tests were performed. Neuropsychological studies, which 
consisted of a battery of several tests: Mini-Mental State examination 14, Wechsler Memory 
Scale, Word List Memory test and Wechsler Adult Intelligence Scale (WAIS) 15 were applied. 
Follow-up of some patients was necessary and a second evaluation was performed after 1 year. 
The NINCDS-ADRDA criteria 16 were used to establish the clinical diagnosis. 
Pathology
Patient (III-26) died at age of 73 years during the course of this research. Neuropathological 
studies such as classical hematoxylin/eosin staining, Bielschowsky silver impregnation, Luxol 
fast Blue, Congo red, and trychromic Masson techniques were carried out on brain tissue 
(temporo-occipital region fi xed in paraformaldehyde). In addition immunohistochemical 
studies using antibodies against  Presenilin 1 N-terminal (dilution 1:50, from Chemicon 
International), presenilin 1 C-terminal (1:100, from Santa Cruz Biotechnology), Aβ (1:100) 
and Ubiquitin (1:500, DAKO), AT8 (1:40, Innogenetics, SA), PHF (a gift from P. Davies), α-
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synuclein (1:1000) and Prion protein (1:100, Chemicon) were performed. Working conditions 
were implemented as recommended by the manufacturers. Diagnosis based on pathology 
fi ndings was done according to CERAD criteria 17.
DNA studies
Blood samples were collected from 76 family members. DNA was isolated following standard 
procedures 18. Thirty samples were tested with fl uorescently labelled markers (short tandem 
repeat polymorphisms) from the CHLC Human screening set/Weber version 6, covering AD 
candidate regions on chromosomes 1, 10, 12, 14, 19 and 21 1, 3, 19-22. Additional regions where 
other dementia-related loci had been localised on chromosome 3 23, 17 24 and 20 25 were also 
tested. Genomic DNA (20 ng) was amplifi ed in 7.5 μl PCR reaction, using 1x GeneAmp PCR 
Gold buffer, 1.5 mM MgCl2, 10 pmol of each primer (forward primer labelled with FAM, 
TET or HEX), 250 μM dNTPs and 0.4 units of AmpliTaq Gold DNA polymerase (Applied 
Biosystems).  PCR products were pooled and loaded on an ABI 377 automatic DNA sequencer 
(6.25% denaturing FMC Long Ranger acrylamide gel, fi lterset C and GS-500XL Tamra as size 
standard). Data were analysed using Genescan 3.1 and Genotyper 2.5 (updated) software from 
Applied Biosystems. 
Haplotypes for every region were constructed based on the minimal number of 
recombinations. Additional markers from the Genethon linkage map 26 were tested for the 
chromosome 14q24.3 region. 
Genotypes for APOE were also determined following the one-stage PCR method 
described elsewhere 27. PCR products were digested with HhaI (10U/μl, Life Technologies), 
fragments were separated on Excell Gels (Pharmacia) using the Multiphor electrophoresis 
system (Pharmacia) and visualised by silver staining. Gels were scored by two independent 
observers.
Linkage analysis
Simulation calculations using the SLINK and MSIM programs 28 showed an average Lod 
score of 2.17 and a maximum of 5.55 at θ = 0 demonstrating the family had enough statistical 
power to detect genetic linkage.  In our linkage analysis, AD was assumed to be an autosomal 
dominant disease with a gene frequency of 0.001. Mutation rate was set equal to 0 and equal 
recombination rates were assumed for males and females. Age-dependent penetrance was 
defi ned by fi ve liability classes based on the ages at onset observed in this family: unaffected 
at risk (< 40 years old): 0, 0, 0; 40-55 years old: 0.001, 0.5, 0.5; 56-70 years old: 0.01, 0.7, 0.7; 
71-85 years old: 0.01, 0.8, 0.8; married in and affected: 0, 0.9, 0.9. Equal allele frequencies for 
markers were assumed since there were no data available from the Cuban population. Two-
point linkage analysis was performed using the MLINK program from the LINKAGE package 
version 5.1. Marker order and genetic distances were used according to the Marshfi eld 
integrated linkage maps (www.marshfi eldclinic.org/research/genetics/).
Sequence analysis.
All 12 exons from the PSEN1 gene were sequenced by the use of intronic fl anking primers as 
described previously 5. For exon 2 (forward primer: 5’-TCGTGACAAATTAATACATTCC-
3’) and exon 6 (forward 5’-CAGTCTGGGCGACAAAGTG-3’ and reverse 5’-
TTAAATGATAGCTACACAGCA-3’) we designed new primers, further away from the 
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exon-intron boundary (Genbank Accession No. AH004968).  We also sequenced part of the 
regulatory region, 2 kb upstream exon 1 (primer sequences published elsewhere 29). Genomic 
DNA (50 ng) from two patients and two healthy Cuban controls were used as template for 
PCR reactions. Specifi c conditions were 1x PCR buffer GibcoBRL, 1.5 mM MgCl2, 200 μM
dNTPs, Taq DNA Polymerase 2 U/reaction and 25 pmol of each forward and reverse primer in 
50 μl of reaction volume. PCR product (5 μl) was checked on 1.5% agarose gel, the rest was 
purifi ed (Qiagen kit) and used for a second reaction using the BigDye terminator kit (Applied 
Biosystems). Products were loaded on an ABI 377 Automatic DNA sequencer and analysed 
with Factura and Sequence Navigator program (Applied Biosystems). Once a heterozygous 
base change or another variation was found in the index case, all patients and 4 healthy 
controls were sequenced.
Allele Specifi c Oligonucleotide hybridisation.
Sixty family members and 40 unrelated Cuban controls were tested for the C→A change 
detected in exon 6 of the PSEN1 gene. Allele specifi c oligonucleotides 30 were designed for 
the normal 5’- ATTGTTGCTGTTCTT-3’ and mutated allele 5’-ATTGTTGATGTTCTT-3’ 
and radioactive labelled with α-dATP32. PCR products from exon 6 were fi xed on two nylon 
membranes and hybridised with the normal and mutated oligonucleotide respectively, under 
specifi c conditions (35°C 1 hour). Filters were washed until a fi nal stringency of 0.3x SSC and 
0.1% SDS (35°C) was reached. Membranes were exposed to X-ray fi lms.
Results
Clinical studies
Clinical characteristics of 14 patients are shown in Table 1. Memory impairment was the main 
symptom shared by all patients. Mean age at onset was 59 years of age, with a mean disease 
duration of 9 years. Patient III-17 showed late-onset dementia (76-83), but with similar clinical 
characteristics to the other patients. No cases of presenile dementia have been reported among 
his descendants.
The propositus, IV-26, started having problems at age 48 years when she suffered a 
cerebral ischemic episode. After recovering from unconsciousness (a few minutes), she had 
right hemiparesia in the face and body. The presence of any symptom before this episode could 
not be confi rmed. Thereafter, she complained of memory loss, lack of interest, she started 
making mistakes at work, and due to progressive worsening of symptoms, she was admitted 
to hospital. The neuropsychological studies were altered, the EEG showed slow base activity 
and bifrontal irritative areas and head CT scan displayed cerebral and cerebellar atrophy and 
a hypodense lesion in left parieto-temporal area. At age 53 years she was unable to recognise 
even her closer relatives, she was completely dependent on caregivers and was bedridden until 
she died 6 years later.
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Table 1.     Clinical description of patients
Patients
Clinical characteristics II-2a II-4a III-1a III-3a III-8a III-14a III-17a III-23a III-25a III-26 IV-20a IV-24 IV-26 IV-28
Age at onset/death 65–80 61–68 55–72 63–68 51–56 59–67 76–83 58–69 63–72 67–73 53–62 51–(56) 48–59 50–(54)
(current)
Memory loss
Impairment of daily + + + + + + + + + + + + + +
activities
Altered behavior – – + + + – – + – – + + + +
Depression – – + – + + – – + – + – + –
Anxiety – – + – – – – – – – – – – +
Aggression – – + + + – – – – – – – – –
Aphasia + + – + + + + + + + + – + –
Apraxia – – – + – + + + – + + – + +
Agnosia + + – – + + + + + + + – + –
Dementia + + + + + + + + + + + DCF + DCF
Ischemic episodes – – – – – – – + – + + – + –
Gait disorder + + – + + – + – + – – – – +
Seizures – – – – – – – – – – + – + –
+ + + + + + + + + + + + + +
Signs and symptoms
a Based on family history   + Feature present   - Feature absent   DCF= Deterioration of cognitive function
In addition to the propositus, 5 relatives were reported as patients; 3 of them were 
available for clinical examination (III-26, IV-24 and IV-28). Patient III-26 had a well-
established dementia with fi ve years of disease evolution and was bedridden. Generalised 
cortical atrophy, ventricular enlargement, and hypodense regions suggestive of vascular 
lesions were observed on brain CT scan. The patient died one year later at age 73 years. 
Patient IV-24 was seen for the fi rst time after 1 year of disease evolution. 
Neuropsychological tests were clearly altered. Patient IV-28 had a subtle alteration in 
neuropsychological studies a few months after the onset of symptoms. Follow-up of patients 
IV-24 and IV-28 confi rmed a progressive deterioration of cognitive functions with impairment 
of daily activities. The patients had concentration and calculation defi cits, diffi culties in 
immediate and delayed recall of recently presented material, decreased emotional response, 
impairment of spatial skills, delay of  speech and anosoagnosia. CT scans from patients IV-
24 and IV-28 were normal at fi rst-time examination. A second CT scan performed two years 
later (patient IV-28) showed signs of diffuse cortical atrophy. Other causes of dementia were 
excluded and the diagnosis of presenile dementia, probable AD was established.
Neuropathological studies
Microscopical examination of brain material (patient III-26) revealed neuronal loss and 
both diffuse and core neuritic plaques. The presence of amyloid plaques was confi rmed 
by immunostaining with a Aβ antibody (Fig. 2A and B). Cerebral amyloid angiopathy 
was also observed (Fig. 2B). The existence of abundant amyloid plaques was the most 
prominent feature. Tau immunohistochemistry (AT8 and PHF antibodies) revealed numerous 
neurofi brillary tangles (Fig. 2C and D, respectively). Immunohistochemistry using antibodies 
against prion protein did not show any difference between normal controls and our patient. 
No inclusions were detected with the α-synuclein antibody. Pathological fi ndings provided 
suffi cient evidence to confi rm the diagnosis of AD.
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Novel PSEN1 mutation in a large Cuban family with AD
Figure 1B. Direct sequencing revealed an 
heterozygous base change C→A in exon 6 of the 
PSEN1 gene.
DNA studies
APOE genotypes
Forty-seven DNA samples were tested, 32 were homozygous ε3, 13 had the ε3/ε4 genotype 
and 2 were homozygous ε4. Allele ε4 was only present in the second branch of the pedigree. 
Of 4 tested patients, 3 had the ε3/ε4 genotype. 
Other genotypes
Genotypes for markers situated on chromosomal regions 1q31-42 (PSEN2), 10q24 (AD6),
12p11.23-q13.12 (AD5), 14q24.3 (PSEN1), 19cen-q13.2 (AD2), and 21q21 (APP) were 
determined for 30 family members. In addition, other dementia-related regions 3p11.1-q11.2 
(DMT1), 17q21.1 (MAPT), and 20pter-p12 (PRNP) were tested. Haplotype and linkage 
analyses allowed us to exclude the presence of the gene responsible for most of them. 
Evidence supporting genetic linkage was only found for the chromosome 14q24.3 
region, two-point linkage analysis revealed positive LOD scores for several adjacent markers, 
and a maximum LOD score of 3.79 was obtained for marker D14S43 at θ = 0. 
We then saturated the region with additional markers from D14S52 to D14S617 
covering 50 cM. Haplotypes from 45 family members are shown in Fig. 1A. The 4 patients 
shared a common region spanning 9 cM from marker D14S588 to D14S43. Patient IV-24 
showed recombination events in both telomeric and centromeric parts of the haplotype, 
allowing us to determine the upper and lower limit of the region shared by all 4 patients. 
Several demented patients were reported to have psychiatric symptoms (aggression, 
restlessness, anxiety, depression), but did have haplotypes identical to the other patients.  
Sequencing of PSEN1
According to several genetic maps, the PSEN1 gene is located close to markers D14S1002 
and D14S77 in the middle of our critical region. Since mutations in the presenilin genes are 
the most common cause of the presenile dementias with autosomal dominant inheritance, we 
performed direct sequencing of 12 exons of PSEN1 and part of its regulatory region for both 
sense and antisense strands.
A heterozygous base substitution at position +520 from the ATG starting site, resulting in a C to 
A transversion was found in exon 6 (Fig. 1B) which is predicted to cause an aminoacid change 
from leucine to methionine in the transmembrane domain III of the presenilin 1 protein. We 
then included additional samples; all available DNAs from the family (60 individuals) and 40 
unrelated Cuban controls were tested with allele-specifi c oligonucleotides. The mutation was 
found to co-segregate with the disease phenotype and the associated disease haplotype and 
was present in 8 at risk subjects (5 are shown in Fig. 1A) but not in other healthy individuals 
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and spouses (96 chromosomes). The C→A change was not observed in any of the 80 control 
chromosomes from the general Cuban population.
Figure 2. Sections of temporal cortex of patient III-26, stained with β-amyloid antibody (A and B), showing numerous 
extracellular plaques and amyloid deposition in the wall of a blood vessel (B), magnifi cation 200x.
C and D: immunostaining with AT8 and PHF antibodies shows several neurofi brillary tangles, magnifi cation 400x.
Discussion
The clinical picture was compatible with AD except for the fact that 4 out of 18 patients had 
vascular episodes such as transient ischemic crises. 
Cerebral amyloid angiopathy (CAA) is best known as a leading cause of lobar 
haemorrhages in the elderly and as a common fi nding in AD. It has also been implicated in 
the production of other cerebrovascular lesions 31. The presence of CAA might explain the 
vascular episodes described in patients III-23, III-26, IV-20, and IV-26. Hypodense zones 
suggestive of vascular lesions were observed on CT-scans from patients III-26 and IV-26; 
in addition, amyloid deposits were present in the wall of brain blood vessels (patient III-26), 
confi rming the presence of CAA.
Factors such as the vasoactive character of β-amyloid which can produce vasospasm 
in vitro at low concentrations 32, the secretion of Aβ by activated human platelets 33 and the 
hyaline necrosis surrounding the amyloid deposit in the vessel wall 34 have been postulated as 
possible mechanisms by which amyloid in the vessels can lead to vascular lesions.
Furthermore, a relationship between APOE ε4 allele and the presence of CAA and 
cerebrovascular pathology in AD has been suggested, since the APOE ε4 allele is a risk factor 
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for the development of CAA in AD 35. In this family, available patients with ischemic episodes 
carry also the APOE ε4 allele (patients III-26 and IV-26). 
We found signifi cant evidence for genetic linkage to chromosome 14q24.3. We were 
able to reconstruct haplotypes for 11 deceased patients using fi rst degree relatives; all of them 
had the same “disease haplotype”, except one patient (III-17) in which the reconstructed 
haplotype was different. This patient showed a much later disease onset  (76 years old) while 
the observed range in the other patients was 48-67 years old. Unfortunately, only family 
history but no medical records were available. It might be that this patient had dementia due 
to other causes and therefore could be a phenocopy. Coexistence of both early-onset (with an 
associated PSEN1 mutation) and late-onset forms of AD in the same family has been reported 
before 36.
Several heterozygous base changes were detected during PSEN1 sequencing but 
none of the sequence alterations were found to co-segregate with the disease except the C520A 
change. Several facts indicate the pathogenicity of this novel PSEN1 mutation. The C520A 
change was present in all examined patients and in all relatives carrying the disease haplotype, 
although they were still below the age at onset of AD in the family. The C→A change is 
unlikely to be a common polymorphism, we did not fi nd it in 80 control chromosomes (from 
the same population) or in unaffected relatives (96 chromosomes) that did not carry the disease 
haplotype.
L174M is a conservative amino acid substitution seeing that leucine and methionine 
are both nonpolar amino acids. Nevertheless, close to half of the PSEN1 and PSEN2 reported
mutations also lead to the same type of aminoacid change. The leucine at position 174 of 
the presenilin 1 protein is highly conserved among different species (Fig. 3) and between 
homologous proteins like presenilin 2 and sel-12, indicating that this position (TMIII) is 
important for protein function. Adjacent amino acid positions at 163, 165, 166, 169, 171, 173 
and 184, where other mutations have been found, are also evolutionary conserved.
Presenilin 1 (Homo sapiens) 151 V V L Y K Y R C Y K V I H A W L I I S S L L L L F F F S F I Y L G E V F K T Y N V A V D Y I
Presenilin 1 (Bos taurus) 152 V V L Y K Y R C Y K V I H A W L I V S S L L L L F F F S F I Y L G E V F K T Y N V A M D Y I
Presenilin 1 (Rattus norvegicus) 151 V V L Y K Y R C Y K V I H A W L I V S S L L L L F F F S F I Y L G E V F K T Y N V A V D Y I
Presenilin-alpha (Xenopus laevis) 117 V V L Y K Y R C Y K V I H G W L I I S S L L L L F F F S Y I Y L G E V F K T Y N V A V D Y I
Presenilin 1 (Danio rerio) 140 V V L Y K Y R C Y K V I Q A W L F F S N L L L L F F F S L I Y L G E V F K T Y N V A M D Y F
Presenilin 1 (Microcebus murinus) 151 V V L Y K Y R C Y K V I H A W L I I S S L L L L F F F S F I Y L G E V F K T Y N V A V D Y I
Presenilin 1 (Mus musculus) 151 V V L Y K Y R C Y K V I H A W L I I S S L L L L F F F S F I Y L G E V F K T Y N V A V D Y V
Presenilin (Drosophila melanogaster) 173 I V L Y K K R C Y R I I H G W L I L S S F M L L F I F T Y L Y L E E L L R A Y N I P M D Y P
Presenilin 1protein (Cyprinus carpio) 70 V V L Y K Y R C Y K V I Q G W L F F S N L L L L F F F S F I Y L G E V F K T Y N V A M D Y F
Presenilin 2 (Homo sapiens) 157 V V L Y K Y R C Y K F I H G W L I M S S L M L L F L F T Y I Y L G E V L K T Y N V A M D Y P
Presenilin 2 (Bos taurus) 158 V V L Y K Y R C Y K F I H G W L I M S S L M L L F L F T Y I Y L G E V L K T Y N V A M D Y P
Presenilin 2 (Rattus norvegicus) 157 V V L Y K Y R C Y K F I H G W L I M S S L M L L F L F T Y I Y L G E V F K T Y N V A M D Y P
Presenilin-beta (Xenopus laevis) 160 V L L Y K Y R C Y K F I H G W L I L S S L M L L F M F T Y I Y L S E V F K T Y N I A M D Y P
Presenilin 2 (Danio rerio) 156 V L L Y K Y R C Y K F I H G W L I L S S L M L L F W F S F M Y L G E V F K T Y N V A M D Y P
Presenilin 2 (Microcebus murinus) 157 V V L Y K Y R C Y K F I H G W L I M S S L M L L F L F T Y I Y L G E V L K T Y N V A M D Y P
Presenilin 2 (Mus musculus) 157 V V L Y K Y R C Y K F I H G W L I M S S L M L L F L F T Y I Y L G E V L K T Y N V A M D Y P
Sel-12 protein (Caernorhabditis elegans) 120 I V F Y K Y K F Y K L I H G W L I V S S F L L L F L F T T I Y V Q E V L K S F D V S P S A L
* * * * * * *


L174M
aa# Protein sequenceOrganism
Figure 3. Alignment of human presenilin 1, presenilin 2, and orthologous protein fragments. Highly conserved amino 
acids are shown in boxes. Leucine at position 174 is substantially conserved across several species. Asterisks indicate 
where other PSEN1 mutations are located.
Under normal conditions Presenilin 1 holoprotein is rapidly converted into two fragments, 
an amino terminal fragment (NTF) and a carboxy terminal fragment (CTF) 37. Presenilin 1 
fragments can associate into tightly bound complexes that may represent the principal form 
in which presenilin functions in cells 38. Formation of these high molecular weight complexes 
60
Chapter 2
composed of both presenilin 1 fragments may also explain why FAD-associated mutations 
within the N-terminal region of presenilin 1 (like L174M) result in the hyperaccumulation not 
only of the NTF but also of the CTF. It has been proposed that the observed elevation in the 
accumulated amounts of mutant presenilin 1 NTFs and CTFs must be the result of enhanced 
endoproteolitic processing of mutant presenilin 1 protein and/or greater stability of mutant 
presenilin 1-derived fragments 39, which appears to be associated with enhanced production of 
Aβ42 and early-onset FAD. 
Another possible mode of action of the L174M mutation might be that of an alternative 
translation start site. From the 82 mutations described in PSEN1 only V94M in exon 4 9 and the 
current mutation (exon 6) introduce a new methionine in the protein sequence. 
Functional assays will be required to determine whether the L174M mutation affects 
presenilin 1 protein activity for the cleavage of Notch1 at the plasma membrane and the release 
of the Notch1 intracellular domain. 
 In conclusion, we found a novel PSEN1 mutation in a large family with clinical and 
pathological diagnosis of early-onset FAD. This is the fi rst genetic study on AD that identifi es 
the involvement of the PSEN1 gene in Cuba. 
L174M is the seventh mutation described in Latin-American and Caribbean 
populations; for some of them (Colombia and Dominican Republic) a founder effect has been 
described. We are currently in the process of collecting new familial and sporadic cases with 
early-onset AD. It will be of interest to see the contribution of this mutation to other early-onset 
cases with AD of the Cuban population or in others of Hispanic origin. 
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Abstract
The study was conducted in a large Cuban family with early-onset familial Alzheimer’s disease 
(AD). Fifty-six fi rst-degree relatives of familial cases with AD were interviewed concerning 
their clinical and genetic knowledge about AD and their attitudes toward the possible use of 
presymptomatic genetic testing of AD. The individuals had only limited knowledge about their 
personal risk of developing AD. All 56 family members would use presymptomatic testing to 
know their own risk of AD. Confronted with a hypothetical reproductive choice, 50% would 
choose not to have children if they themselves had the mutation. A positive prenatal test would 
lead 48.2% of the participants to have an abortion, and 19.7% would continue the pregnancy 
regardless of the positive test result.
Introduction
Advances in molecular genetics have led to the development of tests that can determine the 
specifi c individual risk of having inherited the disease genes for several adult-onset diseases. 
The implications of widespread testing for such diseases have to be considered at the societal 
level, but the decision to be tested is an individual one. It is therefore important to investigate 
the attitudes toward genetic testing and the knowledge about the possible consequences of 
testing among individuals at high risk.
Alzheimer’s disease (AD) is a progressive and degenerative disorder that attacks the 
brain, fi rst described by Alois Alzheimer 1. The main symptoms are memory loss, cognitive 
impairment, deterioration of motor skills, and withdrawal from social contact. The clinical 
diagnosis can be diffi cult to establish and is only confi rmed by post-mortem microscopic 
examination of the brain. The disease has severe emotional and fi nancial consequences for 
individuals, families, and society. 
AD can be familial or sporadic. Around 5% of all AD cases have an early onset, i.e.
before age 65 2, 3. A few autosomal dominantly inherited genes causing a small percentage 
of all cases with AD have been identifi ed. These include the amyloid precursor protein
(APP) gene on chromosome 21, the presenilin-1 gene (PSEN1) on chromosome 14, and the 
presenilin-2 gene (PSEN2) on chromosome 1. Mutations in these genes usually lead to early-
onset AD. It is possible to test for mutations in these genes among cases with familial AD and 
some commercial tests are now available 4. The tests can be used presymptomatically or to 
confi rm a clinical diagnosis.
In general, genetic testing for AD, diagnosis or disease prediction is a controversial point and 
is presently recommended in rare, early-onset familial cases with presumable autosomal dominant 
inheritance only 5. Among genetic and environmental risk factors for AD the most established 
involve the APOE gene polymorphisms, but genetic testing of the APOE gene polymorphisms in 
AD is not recommended (Nuffi eld Council on Bioethics, http://www.nuffi eldfoundation.org).
Many relatives whose family members suffer from the disease, wonder about their 
personal risk of developing AD, but as with Huntington’s disease, no prevention or effi cient 
cures are available for AD. Thus, predictive testing for AD can become a profound dilemma 
for the individuals at high risk for the disorder. The consequences of providing potentially 
devastating information to the individual and the family should be weighed against the 
principles of autonomy and self-determination of the family members.
Very few studies have examined the wishes of, and knowledge among, family 
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members at high risk of AD concerning genetic testing 6. The present study was conducted in a 
large Cuban family that originated in the middle of the 19th century when immigrants coming 
from the Canary Islands settled in the western part of Cuba. Nineteen family members from 
this seven-generation family have suffered from an early-onset form of AD caused by a newly 
described mutation in the presenilin-1 gene 7. In this large family, fi rst-degree relatives of 
patients with AD, for whom the questions of testing are particularly relevant because of their 
personal experiences 8, 9, were asked about their clinical and genetic knowledge and attitudes 
concerning the possibilities of presymptomatic testing for early-onset familial AD.
Method
A total of 56 fi rst-degree relatives participated in the survey, of which 37 (66.1%) were female. 
The age range of the participants was from 20 to 69 years, most of them living in smaller cities 
with a level of education between middle school and high school; all 56 family members were 
of European Caucasian descent. Most of the subjects have been personally involved in care 
giving for relatives with AD; 64.3% were children of an affected parent and the female children 
of the Alzheimer patients in this family had a larger burden of care than the male children.
Further description of the sample appears in Table 1. The mean age of onset of AD 
in this family is 62 years and the mean duration of AD around 9 years.  The family members 
were informed that they might be at risk for early-onset familial AD, but not about their carrier 
status. The aims of the survey were explained and following informed consent, questionnaires 
were distributed to 56 people. No family members refused to participate. 
The survey was composed of questions concerning the level of information about 
their individual risk for AD, their attitude toward possible presymptomatic testing in the future, 
and their main reasons for this attitude. The impact of a hypothetical positive test result on 
reproductive decisions and attitudes toward possible prenatal diagnosis was also determined.
Table 1.              Description of the sample set
Socio-demographic characteristics n %
Gender
Male 19 33.9
Female 37 66.1
Age
20-29 8 14.3
30-49 29 51.8
50-69 19 33.9
Marital status
Married 33 58.9
Divorced 14 25
Single 9 16.1
Living with family 53 94.6
Living alone 3 5.4
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Results
The survey was conducted from May 1996, to January 1997. Thirty-one individuals (55.3%) 
showed some knowledge concerning their individual risk. These family members had obtained 
their primary information from either another member of the family (51.6%), their general 
practitioners (38.7%), or from newspapers and journals (9.7%). 
All 56 participants were interested in presymptomatic testing, with their main reasons 
being to know their own disease risk (Table 2). Only 9 of the 56 individuals were tested for the 
mutation and no one was informed about their true carrier status.
Concerning a hypothetical reproductive choice, 28 participants (50%; 9 males and 19 
females) of the 56 persons would choose not to have children to avoid passing on the disease if 
they personally had a dominant disease mutation for presenile Alzheimer. The remaining 50% 
(10 males and 18 females) would choose to have children regardless of their mutation status.
Thirty-three individuals (58.9%; 7 males and 26 females) were interested in prenatal 
diagnosis if it becomes available, whereas 19 (33.9%; 9 males and 10 females) answered that 
they would like more information concerning the magnitude of risk before making a decision. 
Four participants (7.2%; 3 males and 1 female) would not use the test to obtain a prenatal 
diagnosis.
The hypothetical scenario of a positive prenatal diagnosis was presented to explore 
the possible behaviour of the participants in such a case. Twenty-seven participants (48.2%; 9 
males and 18 females) would like to have an abortion; 18 participants (32.1%; 6 males and 12 
females) would like more information about a possible future treatment or cure for the disease 
before making a decision; and 11 individuals (19.7%; 4 males and 7 females) would continue 
the pregnancy.
Table 2.              Reasons for choosing presymptomatic testing
Reasons n %
To be prepared for the disease 37 66.1
Curiosity 34 60.7
To modify choices of health behavior 24 42.8
To plan career and retirement from work 24 42.8
To plan marital and reproductive choices 24 42.8
To diminish anxiety 22 39.2
Discussion
This is the fi rst reported study concerning attitudes regarding genetic counselling and predictive 
testing in early-onset familial AD from a Latin American country. It offers information about 
the expectations and attitudes of family members at high risk for the disease. 
It is an important fi nding of the study that there were no differences in attitudes 
between the two sexes to any of the questions. Around 55% of family members were aware 
that they were at risk for developing AD. All participating family members at high risk for 
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early-onset familial AD were interested in presymptomatic counselling and testing given that 
a dominant mutation could be identifi ed.
Concerning reproductive choice, 50% would choose not to have children if they 
themselves had the dominant mutation. Concerning possible prenatal testing, around 60% 
were interested in this option. Only 7.2% were not interested at all in prenatal testing. 
This is in contrast with previous results from other studies of early-onset familial AD and 
Huntington’s disease, where the uptake of prenatal testing was low among counselled couples 
and participation in reproductive testing even lower overall (Nuffi eld Council on Bioethics).
Many factors affect the uptake of prenatal testing for single gene conditions, such as 
age of onset and severity of the disease, the certainty of the test, and especially the possibility 
of treatment. Almost 50% of the relatives would choose abortions as a possibility, if the test 
result was positive for the mutation. In Cuba, abortion is a legally and socially accepted 
intervention and such a decision would be met without any prejudice. 
The decision to undergo genetic testing for diseases such as early-onset familial AD 
where no cure or adequate treatment are available is very complex and personal. The present 
study suggests a clear need for education and genetic counselling of family members at high 
risk, especially for those individuals at risk who are about to make reproductive decisions.
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Abstract
The identifi cation of disease genes using family-based approaches has provided important 
insights into the pathogenesis of Parkinson’s disease (PD) demonstrating the importance of 
genetic studies on monogenic forms of the disease. We studied a large Cuban family with 
typical, late-onset PD and probable autosomal dominant inheritance. Mean age at onset 
was 61.2 years (±12.53, 45-76). Other phenotypes such as essential tremor and atypical 
parkinsonism were observed in this family. 
We carried out a genome-wide scan and linkage analyses. The genetic data were analyzed 
using a conservative model in which only patients with clinically defi nite or likely PD were 
considered affected, other phenotypes were regarded as “unknown”. Multipoint analyses 
yielded a maximum LOD of 2.26 between markers D19S221 and D19S840. Haplotype analysis 
showed a region on chromosome 19 shared by six of seven PD patients. The essential tremor 
phenotype and the atypical parkinsonism do not segregate with this haplotype, suggesting a 
different etiology. 
Our fi ndings suggest the presence of a novel locus for PD on chromosome 19p13.3-q12. We 
propose that an oligogenic model with moderate contribution of two or three genes rather than 
a “pure” monogenic model might explain better the wide range in age at onset, the reduced 
penetrance and the phenotypical variability observed in PD families. 
Introduction
Parkinson’s disease (PD, MIM168600) is the second most common neurodegenerative 
disorder after Alzheimer’s disease, with a prevalence of around 2% among people over the age 
of 65 years.1, 2 The cardinal clinical features of PD, bradykinesia, rigidity, resting tremor, and 
postural instability are associated with neuropathological fi ndings such as loss of neurons in 
the substantia nigra and the presence of Lewy bodies.3 The etiology of PD is largely unknown, 
but there is evidence that genetic factors play a role.4, 5 Familial aggregation has been found 
for typical, late-onset PD (> 50 years of age)6, 7. First-degree relatives of PD cases are 1.5 to 
9.5 times more likely to develop PD than fi rst-degree relatives of controls4, 8, 9 and segregation 
analysis supports a major gene infl uencing the susceptibility to late-onset PD10, 11, 12. Moreover, 
a susceptibility locus for late-onset idiopathic PD has been mapped to chromosome 1p32 
(PARK10)13 and mutations in the nuclear receptor related-1 gene (Nurr1 or NR4A2) have
been found associated with familial PD.14
Until now, eight different forms of monogenic PD have been identifi ed. Autosomal 
dominant forms are associated with mutations in the D-synuclein gene (PARK1 locus, 
chromosome 4q22)15, ubiquitin C-terminal hydrolase-L1 (PARK5, 4p14)16, and three 
unidentifi ed genes on chromosomes 2p13 (PARK3)17, 4p14-16.3 (PARK4)18 and 12p11.2-
q13.1 (PARK8).19 The parkin gene (PARK2, 6q25.2-q27)20, the recently discovered DJ-1
gene21 (PARK7, 1p36)22 and the PARK6 locus (1p35-36)23 are associated with autosomal 
recessive forms of early-onset. In addition, several genome screens have been carried out 
recently on large groups of smaller PD families, revealing new regions on chromosomes 5q, 
8p, 9q, 17q24, 1, 9, 10, 1625; X and 226 (PARK11)27 where further susceptibility genes for PD 
might be located. 
The study of genes and their products identifi ed using family-based approaches 
has provided substantial insights into PD pathogenesis and has implicated oxidative stress, 
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abnormal protein folding and protein degradation through the ubiquitin-proteasome system.28-30
The fact that several large families segregating PD have been found negative for the 
genes and loci known until now,31-34 suggests the existence of other genes (perhaps pathways) 
involved in PD etiology. Large families suitable for linkage mapping, however, are rare and 
diffi cult to fi nd. The study of an extended Cuban family with late-onset typical PD gave us 
the opportunity to localize the genetic defect for a late-onset form of Parkinson’s disease. We 
carried out a genome-wide screen and linkage analyses and found suggestive evidence for 
genetic linkage and a haplotype segregating with typical PD on chromosome 19p13.3-q12.
Patients and methods
Family description
A large Cuban family with Parkinson’s disease was studied (Fig. 1). The oldest known affected 
member, of Spanish descent was born in 1891 in the western part of Cuba and settled in Havana 
in 1898. Data was collected from 213 family members within fi ve generations by review of 
baptism, marriage, death certifi cate and medical records when available, or by direct interview 
of family members. Informed consent was obtained for clinical examination, venous puncture 
for blood collection and genetic research. The Ethical Committee at the Higher Institute of 
Medical Sciences in Havana approved the research project. 
Clinical studies
Two neurologists (J.L.G.B. and E.A.G.) independently examined 58 family members plus 11 
affected individuals. Videotapes of most patients were reviewed by a third neurologist (V.B.). 
For all patients and 14 at risk relatives a second and third evaluation was done within an 
interval of 1-year follow-up.
The diagnosis of clinically defi nite PD was based on the presence of at least two of 
three cardinal signs (bradykinesia, resting tremor, rigidity), improvement with levodopa (L-
dopa) treatment, asymmetric onset, no atypical features, and no other identifi able causes of 
parkinsonism. Together, these items refl ect the widely accepted criteria for PD diagnosis35,
and they also include some supporting features that confer more than 90% accuracy in the 
identifi cation of genuine Lewy body PD.36, 37 In addition, the following diagnoses were made:
Clinically likely PD: when the clinical picture was otherwise typical, but information on L-
dopa response was not available or unclear;
Clinically possible PD: only one cardinal sign and no atypical features were present;
Atypical parkinsonsism: two or more cardinal signs were present in the context of additional 
neurological signs (early cognitive defi cit, ophthalmoplegia, pyramidal signs, cerebellar signs, 
peripheral neuropathy);
Essential tremor: when postural or action tremor were the only signs, and they had been present 
for at least fi ve years without other neurological signs nor identifi able causes of tremor.38
The Unifi ed PD Rating Scale (UPDRS)39 and the Hoehn Yahr40 scales were used for 
clinical evaluation in “on” (with medication) and “off” (without medication) states. 
Blood biochemistry, EEG, neuroconduction studies, head CT scan or MRI (1.5 T) were 
carried out in all affected individuals. Mini-Mental state examination (MMSE)41 was carried 
out in all patients and three at risk relatives. The Weschler Memory Scale and Weschler Adult 
Intelligence Scale (WAIS)42 was carried out on patient IV-14.
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Molecular analysis
Blood samples were collected from 46 family members. DNA was isolated after standard 
procedures.43 A genome-wide screen was carried out with 382 fl uorescently labeled markers 
from the ABI PRISMTM MD-10 Linkage mapping set v.2 (Applied Biosystems) covering all 
autosomes with an average spacing of 10 cM. Additional markers from the CHLC Human 
screening set v.6 and the Marshfi eld integrated genetic map (available online at http:
www.marshfi eldclinic.org/research/genetics/) were typed for fi ne mapping of some regions. 
Genomic DNA (20 ng) was amplifi ed in 7.5 Pl PCR reactions, following the 
manufacturer’s recommendations (Applied Biosystems). PCR products were pooled and loaded 
on an ABI 3100 automatic DNA sequencer, data were analyzed using GeneMapper v.2 (Applied 
Biosystems). Haplotypes were constructed based on the minimal number of recombinations 
and using the Cyrillic v2.1 program (available on line at http:cyrillicsoftware.com). 
Statistical analysis
We used the SPSS v.10.0 program (SPSS, Chicago, IL) to tabulate some patient characteristics. 
Simulation studies (500 replicates) carried out using the SLINK and MSIM programs44, yielded 
an average maximum LOD score (LODmaxav) of 1.47 (SD ± 0.93) and a maximum LOD of 3.61. 
In addition, 31.6% of the replicates yielded a LOD above 2.0 and 3.2% above 3.0 respectively 
(T=0). The family had suffi cient statistical power to detect genetic linkage.  
PD was assumed as an autosomal dominant disease with a gene frequency of 0.001. 
Age-dependent penetrance was defi ned by 4 liability classes based on the ages at onset 
observed in this family: unaffected at risk d45 years old: penetrance of 50%; 46 to 65 years 
old: 65%; t66 years old: 80%; married-in and affected: 95%. A phenocopy rate of 0.3% and 
3% was defi ned for the group of 46 to 65 and t66 years, respectively.  
Patients with defi nite and likely PD were considered as “affected”. Individuals with: 
(1) normal neurological examination; or (2) those who could be retrospectively defi ned free 
of parkinsonian symptoms were considered “unaffected”. Patients with other phenotypes 
including possible PD, atypical parkinsonism or essential tremor were assigned the “unknown” 
status.
One PD patient (IV-30) was referred to us later during the course of this research. For 
our linkage analyses (Model 1), the status of this patient was considered as “unknown” due to 
uncertainty of the diagnosis at the start of this study. After 1 year of follow-up, the diagnosis 
of defi nite PD was made and we carried out a second and exploratory analysis considering this 
patient as affected (Model 2).  
Two-point linkage analyses were carried out using the MLINK program from the 
LINKAGE package (v5.1).45 Equal allele frequencies were assumed, because no data on allelic 
frequency distribution from the Cuban population are available. For fi ne mapping, population 
specifi c allele frequencies were calculated based on 47 unrelated Cuban controls. Marker order 
and genetic distances were according to the Marshfi eld integrated linkage map. For some 
markers with unresolved order the Icelandic (deCODE) genetic map46 was used. Parametric 
multipoint analyses (Model 1) were carried out using subsequent four point analyses for the 
complete chromosome 19 (Linkmap program v.5.1). 
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Results
Clinical features
Fourteen family members, nine of whom were living, were reported affected by PD (Fig. 1). 
Eight of these patients were examined, whereas one patient was not available for examination. 
Another three asymptomatic relatives (IV-1, IV-5 and V-4) showed mild parkinsonian signs 
during our examination.
After our clinical evaluation, the following diagnoses were established (Table 1 
and Fig. 2): 5 cases of defi nite PD (III-4, III-6, IV-12, IV-25 and IV-30), 2 cases of atypical 
parkinsonism (IV-14, IV-19), 2 cases of possible PD (IV-1, IV-5) and 2 cases of essential 
tremor (IV-23, V-4). Another 5 cases (defi nite and likely PD) were ascertained among 
deceased or unavailable individuals based on their medical history. No pathological studies 
have been carried out. 
 Mean age at onset for PD (defi nite and likely PD, n=10) was 61.2 years (±12.53, 
45-76). Asymmetrical onset, good response to l L-dopa therapy, no atypical features and a 
rather benign course were observed in fi ve personally examined defi nite PD cases. CT scan 
or MRI from these patients showed mild, diffuse brain atrophy. In patient IV-25, CT evidence 
of a more pronounced fronto-temporal atrophy was not associated with overt cognitive or 
behavioral disorders.
I
II
III
IV
V
Figure 1.  Extended pedigree of the Cuban family. Filled symbols represent individuals that were described initially 
as affected by Parkinson’s disease. Gender is not specifi ed for confi dentiality reasons.
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Clinically possible PD cases: When fi rst examined at age 59 years, patient IV-1 
showed clear hypomimia with slight global bradykinesia. Signs have shown no progression, 
and no new signs have appeared during 3 years of follow-up. In 1997, patient IV-5 was 
treated with neuroleptics (trifl uoperazine 3 mg/day) for a few months, due to severe agitation 
resulting from stress. At fi rst examination in 1998, she had been free from neuroleptics for 2-3 
weeks, and bradykinesia and rigidity in her right arm were found. At last examination in 2002, 
there was almost no progression of the described signs but tremor of the inferior lip was also 
observed.
Atypical parkinsonism: Patient IV-14 (aged 59) has been a heavy alcohol and tobacco 
consumer for 40 years. He fi rst experienced behavioral changes and memory defi cit at age 
49. Five years later, he noticed tremor in the right hand, slowness, and gait diffi culties. Our 
examination showed a coarse resting tremor, postural and action tremor in the right upper limb, 
hypokinesia, pyramidal and cerebellar signs, and sensory polyneuropathy. Neuropsychology 
studies revealed defi cit in short-term memory and attention, slowness of thought, dyscalculia, 
bradylalia, with diffi culty to initiate, execute and control complex motor programs, and severe 
depression. Brain CT scan showed multiple hypodense areas suggestive of vascular damage 
(subcortical, right putamen, left caudate nucleus) and cerebellar atrophy. We consider that 
this individual has parkinsonism in the context of a diffuse encephalo-neuropathy of likely 
alcoholic etiology.
His brother (IV-19) was 67 years old at fi rst examination with the onset of neurological 
symptoms 7 years before, when he noticed bilateral hand tremors, diffi culties in walking 
and postural imbalance. The clinical course was described as progressive, but at least three 
episodes of acute, transient neurological defi cit have since then occurred. Our examination 
showed masked face, Meyerson’s sign, dysarthria, dysphagia, mild left side hemiparesis, 
rigidity (mainly left-sided), mild but typical resting tremor, trunk dyskinesias and weak tendon 
refl exes in lower limbs. Posture, balance and gait were relatively preserved. Levodopa therapy 
has been irregular, and the response to this drug was unclear. Results of neuroimaging studies 
were unavailable. We consider this patient has parkinsonism in the context of a cerebral 
vasculopathy.
Molecular analysis
Linkage and haplotype analyses excluded all known loci for dominant PD (PARK1 D4S414 
LOD= -3.25, PARK3 D2S2368= -2.36, PARK4 D4S391= -4.49, PARK5 D4S405= -4.16, 
and PARK8 D12S345= -3.62). Autosomal recessive PD loci (PARK2, PARK6 and PARK7) 
were excluded mainly by haplotype analysis. Other phenotypes associated with parkinsonism 
such as frontotemporal dementia-parkinsonism linked to chromosome 17 (FTDP-17), 
spinocerebellar ataxia type 2 (SCA2) on 12q and SCA3 on 14q were excluded by haplotype 
and linkage analyses (data not shown). 
After performing two-point linkage analyses (Model 1), 60.3% of the markers from 
the genome screen gave a LOD score < -2.0, the accepted criterion for exclusion of linkage, 
37.9% were between LOD=-2.0 and 0.99. We found positive (t1.0) LOD scores for 1.8% of 
the markers (Table 2). The chromosomal regions surrounding these markers were subsequently 
excluded by haplotype analysis. 
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Table 2.            Regions with markers from the genome screen generating a LOD score t 1
Chromosome
Two-Point LOD scores (Model 1)
Marker Location (cM) LOD Score at   0
Chr. 6 D6S264 179.1 0.37
D6S446 189.0 1.12
D6S281 190.1 0.88
Chr. 9 Telomere
D9S288 9.8 1.36
D9S286 18.1 0.31
Chr. 11 D11S1320 141.9 0.66
D11S968 147.8 1.34
Telomere
Chr. 13 D13S170 63.9 4.02
D13S265 68.7 1.51
D13S159 79.5 
Chr. 15 D15S117 51.2 0.54
D15S153 62.4 1.09
D15S131 71.3 3.62
Chr. 19 D19S884 26.4 1.25
D19S221 36.2 1.84
D19S226 42.3 0.53
D19S414 54.0 0.08
D19S220 62.0 1.94
D19S420 66.3 2.46
Only for chromosome 19, adjacent markers gave LOD scores higher than 1.0 and exceeded the 
average LOD score reached by our simulation studies (LODmaxav=1.47). The CAG expansion 
of the alpha 1A-voltage dependent calcium channel gene (SCA6), which maps to chromosome 
19 was assessed in three defi nite PD patients from the family, they all carried normal alleles 
of 10-12 CAG repeats (data not shown). Therefore, the chromosomal region was investigated 
more closely by typing additional markers between D19S209 to D19S210. 
Results from the two-point linkage analyses are shown in Table 3. The maximum 
LOD score was 2.01 for marker D19S410 (45.48 cM). We used 24 markers from chromosome 
19 for multipoint analyses, which provided better evidence for genetic linkage, with a 
maximum LOD score of 2.26 between markers D19S221 and D19S840 (fi g.3).
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Table 3.  Results from the two-point linkage analysis (Model 1) for chromosome 19 fi ne mapping
Marker name Location in cMa
0.00 0.01 0.05 0.10 0.20 0.30 0.40
D19S209 10.97 -0.08 -0.06 0.01 0.04 0.05 0.03 0.01 
D19S894 15.55 -4.66 -1.07 -0.44 -0.23 -0.11 -0.1 -0.07 
D19S216 20.01 -0.19 -0.18 -0.15 -0.12 -0.1 -0.1 -0.07 
D19S1034 20.75 0.91 0.89 0.81 0.69 0.45 0.22 0.06 
D19S884 26.37 1.25 1.24 1.17 1.06 0.78 0.43 0.11 
D19S865 32.39 1.03 1.02 0.98 0.90 0.67 0.38 0.11 
D19S586 32.94 1.22 1.21 1.17 1.10 0.86 0.54 0.19 
D19S221 36.22 1.84 1.82 1.72 1.58 1.22 0.79 0.32 
D19S840 37.94 1.41 1.38 1.27 1.12 0.78 0.41 0.11 
D19S714 42.28b 0.42 0.42 0.42 0.40 0.28 0.15 0.04 
D19S226 42.28b 0.83 0.81 0.75 0.66 0.45 0.24 0.07 
D19S410 45.48 2.01 1.98 1.85 1.67 1.24 0.72 0.20 
D19S566 47.31 -0.25 -0.23 -0.18 -0.15 -0.12 -0.10 -0.05 
D19S932 50.81 1.32 1.29 1.15 0.98 0.63 0.28 0.04 
D19S433 51.88 -3.01 -0.21 0.38 0.53 0.48 0.29 0.08 
D19S414 54.01 -0.08 -0.07 -0.06 -0.05 -0.03 -0.02 -0.01 
D19S587 59.36b 1.70 1.67 1.56 1.41 1.04 0.60 0.18 
D19S425 59.36b -1.60 0.64 1.15 1.21 0.99 0.60 0.19 
D19S220 62.03 1.96 1.91 1.73 1.49 0.98 0.48 0.12 
D19S420 66.30 -2.48 -0.2 0.43 0.62 0.63 0.43 0.16 
D19S902 72.72 0.16 0.2 0.28 0.32 0.28 0.17 0.06 
D19S418 92.56 -4.30 -1.78 -1.02 -0.65 -0.28 -0.09 -0.01 
D19S210 100.01 -0.47 -0.44 -0.35 -0.25 -0.10 -0.01 0.00 
      a Map location according the Marshfield genetic map.  
b Marker orders according to the Icelandic genetic map. 
θ
Two-point linkage analyses under Model 2 yielded positive LODs higher than 1 for seven 
markers on different chromosomes (LODs between 1 and 1.51). Haplotype analyses showed 
in most of them the presence of common alleles shared for many individuals. In the case of 
chromosome 11q, marker D11S1320 and D11S968 gave positive LOD scores (1.15 and 1.34) 
with Model 2 and 1, respectively. We determined the actual allele frequencies using a group of 
47 independent individuals (from the Cuban population) and recalculated the LOD scores that 
dropped to -0.61 and 0.97 (Model 1) and  -0.15 and -1.5 (Model 2), indicating that the original 
results were likely false positive fi ndings because of alleles inherited identical by state (IBS) 
rather than identical by descent (IBD).  Linkage analysis with Model 2 resulted in a highest 
LOD score of 2.43 for marker D19S221 (T=0). Therefore for both models chromosome 
19 generated the highest LOD scores. Subsequent haplotype analysis showed a common 
chromosomal region shared by four defi nite PD patients. The same “disease haplotype” could 
be reconstructed in two deceased PD patients (III-8 and III-16). Patient IV-30 in Branch II 
(Fig. 2), however, has a different chromosome 19 haplotype. 
For marker D19S221, all PD patients, including IV-30, shared allele 10. Estimation 
of true allele frequencies in 94 Cuban chromosomes showed that this is not a common allele 
(2.1%). Recalculation of LOD scores for D19S221 using the obtained allele frequencies 
resulted in LOD scores of 1.57 for Model 1 and 2.63 under Model 2.  Haplotype analyses 
showed that for fl anking markers no other allele was shared by this patient. This suggests that 
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allele 10 of D19S221 was probably shared IBS in patient IV-30 rather than IBD, although 
the possibility that this patient carried a very small “disease haplotype” due to a double 
recombination events cannot be ruled out completely.  
Although the age at onset is similar to patients of Branch I, this patient exhibited a 
slightly different clinical picture. Even though resting tremor is the more prominent feature 
in PD patients from Branch I, patient IV-30 has a severe akinetic form and almost no tremor. 
The parents of this patient (Branch II, Fig. 2) died free of parkinsonian symptoms at 79 
and 80 years of age, in contrast to Branch I where every patient had an affected parent and 
unaffected parents have healthy offspring. If this patient has PD due to the same genetic cause 
of patients from Branch I, we have to consider the existence of non-penetrant individuals in 
two consecutive generations. Based on these fi ndings it is conceivable that patient IV-30 is a 
phenocopy. 
A recombination event between the telomeric marker D19S894 and D19S216 (patient 
III-4) delimited the upper border of the haplotype. In the centromeric side, we observed 
a recombination between markers D19S932 and D19S433 (patient IV-25). The minimal 
candidate region is spanning 35 cM from D19S216 to D19S932 (Fig. 2). 
The whole disease-linked haplotype was present in 4 at risk individuals (ages between 
59 and 65 years old); two of them (IV-1 and IV-5) have parkinsonian signs of hypomimia, 
bradykinesia, or rigidity that might suggest a prodromal clinical phase. Clinical examination 
of IV-6 and IV-21 who shared part of the haplotype was completely normal. Moreover, the 
disease-linked haplotype was not found in old, unaffected individuals (III-10, healthy, 76 years 
old), III-19 (unaffected, died at age 73 years of age), and III-12 (unaffected, died at age 85 
years of age).
See next page:
Figure 2. Condensed pedigree of the family showing individuals included in the genome screen and linkage analyses. 
In the fi gure, Generation IV has been divided into two levels in order to gain space. Filled symbols correspond 
to defi nite and likely PD patients, vertical and horizontal half-fi lled symbols show essential tremor and atypical 
parkinsonism phenotypes, respectively. Quarter-fi lled symbols indicate possible PD cases, ‘N’ inside a symbol means 
Normal neurological examination. Haplotypes of the chromosome 19 are shown; black bars correspond to the disease 
haplotype. Genotypes between brackets are inferred.  
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Figure 3. Multipoint LOD score graph for markers (fi ne mapping) from chromosome 19. Triangle-shaped labels 
correspond to markers D19S586, D19S221 and D19S840.
Discussion
The presence of asymmetry of symptoms at onset and at examination in combination with 
typical resting tremor, bradykinesia, rigidity and good response to L-dopa, is consistent with 
the diagnosis of typical PD. None of these cases (defi nite and likely PD patients) presented 
any atypical features. Age at onset and disease duration are similar to those of typical, sporadic 
PD and to other PD families that had been reported17, 32, 33. They differ however, from several 
autosomal dominant families displaying a younger disease onset or more aggressive course 
(PARK1, PARK4, PARK8). 
Segregation of PD in Branch I of the family (defi nite and likely cases) is consistent 
with an autosomal mode of inheritance with high penetrance (Fig. 2); a “vertical” segregation 
pattern, no generation gaps and male-to-male transmission were observed.  In Branch II, only 
one patient was found, with no close relative being affected. Since PD in the rest of the family 
seems to be highly penetrant, this case might be a phenocopy. 
Besides typical PD, we observed three cases with action, postural tremor compatible 
with essential tremor (ET) and apparently autosomal dominant transmission through three 
generations. Intrafamilial association of PD and an essential tremor-like phenotype has been 
reported 32, 33, 47, 48, supporting a relationship between PD and ET. In most cases, however, the 
nature of the relationship is unknown. 
We also observed two cases with atypical parkinsonism. Personal history of cerebral 
vascular episodes or cognitive decline was reported and physical examination or neuroimaging 
revealed a vascular component in the clinical picture. It is remarkable that two siblings have 
the diagnosis of atypical parkinsonism. Considering that they have been living in different 
environments for more than 40 years, we think there could be predisposing genetic factors 
that may interact (or relate to vascular factors) resulting in a similar phenotype. In the case of 
patient IV-14, a toxic exposure such as heavy alcohol consumption could act as a modifi er and 
is probably responsible for the “coarse” neurological picture.
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Considering the presence of other phenotypes in our family and the uncertainties 
whether these phenotypes represent variations of the “PD gene”, we have analyzed the genetic 
data using a conservative clinical model, in which only patients with clinically defi nite or likely 
PD were considered “affected” and atypical cases were regarded as diagnosis “unknown”. 
Using this approach, the statistical power to detect linkage is less because the number of 
patients is lower, but it increases the probability of fi nding the true genomic location.     
In general, the positive LOD scores obtained for the chromosome 19 region were 
close to the average value (1.47) but well below the maximum value (3.61) obtained with 
simulation analysis: low marker informativeness (marker heterozygozity) seems to be the most 
likely explanation. The multipoint analyses helped to overcome this problem partly, as more 
information was extracted when markers were analyzed together. Although no signifi cant 
LOD score was obtained, the fact that 6 PD patients in two generations share a large haplotype 
for this region and not anywhere else in the genome indicates a true IBD allele sharing. Our 
results suggest that the region on chromosome 19 bears a gene responsible for this PD form. 
Both the ET phenotype and the atypical parkinsonism in this family do not segregate 
with the chromosome 19 haplotype, suggesting a different etiology. 
Several interesting genes are located in our candidate region (19p13.3-q12). The 
genes coding neurturin (NTN) and persephin (PSPN), two neurotrophic factors, are located 
on the 19p13.3 at the telomeric part of our region. PSPN is an attractive candidate gene for 
PD. The encoded protein is thought to function as a survival factor for midbrain dopaminergic 
and spinal neurons in vivo.49 Other genes as homer-3 and telencephalin could be considered 
as candidate genes. The homer protein family has been implicated in synaptogenesis, signal 
transduction, receptor traffi cking and axon pathfi nding.50 Because we are considering a 
large chromosomal region, many other genes with known function can be considered as 
“candidates”; confi rmation of our results in additional families are needed to reduce our 
candidate region and start the search for the responsible mutation.
In complex diseases such as PD, one of the advantages of studying large families 
is to avoid the heterogeneity problem. Many studies, however, have also encountered 
an intrafamiliar spectrum of parkinsonian phenotypes that required a precise phenotype 
refi nement. For modeling the disease, we assumed an autosomal dominant inheritance. 
Although Mendelian models are useful for identifying the primary genetic cause of familiar 
disorders, they might be incomplete models for the true physiological and cellular nature of 
the defect.51
An oligogenic model with moderate contribution of two or three genes rather than 
a “pure” monogenic model might better explain the wide range in age at onset, the variable 
penetrance and the phenotypical variability observed in this and other PD families. 
The study of additional extended families with the same ethnic origin will allow us 
to use different approaches such as a two-locus analysis. Using traditional linkage approaches 
will lead to the initial discovery of loci with major effects that follow Mendelian patterns 
of segregation, such as the chromosome 19 locus. Other methods, however, will then be 
necessary to detect “modifying” loci with a minor contribution or those who have a synergetic 
effect. A combination of methods can help us to understand the true genetic model for PD and 
can advance our efforts to dissect the genetic and molecular bases of the disease.
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Abstract
The study of genetically isolated populations, which are thought to be more genetically 
homogeneous than the general population, has proved to be a successful strategy for disease 
gene mapping, including the monogenic variants of complex disorders such as Parkinson’s 
disease (PD). 
In order to identify genomic regions containing genes that infl uence the susceptibility to PD, 
we studied 44 patients with idiopathic PD, 87 unaffected fi rst-degree relatives and 25 spouses 
of patients who served as controls. The genealogic study showed that 40 of the patients could 
be connected to a common ancestor from an isolated community in the Netherlands. We 
performed a genome wide scan (STRPs, marker grid ~ 10 cM) and single-marker association 
analysis using the DISLAMB and CLUMP program.
With the DISLAMB analysis, four markers showed evidence of association at a nominal p-
value of 0.01: D2S2333, D4S405, D9S158, D13S153. Furthermore for D9S158 (p=0.006) a 
neighbouring marker, D9S290, was also found to be associated (p=0.006) using the CLUMP 
analysis. Moreover, a common haplotype was observed in this 9q region for 10 patients (23%), 
and only one control individual (4%). This region overlaps with a previously identifi ed interval 
(9q) that showed evidence of linkage with PD. In addition, marker D2S2333 (p=0.009) maps to 
the same location of a PD locus, PARK3, implicated in disease susceptibility and age at onset. 
The results of the study of this genetic isolate are consistent with previous studies suggesting 
the presence of genes contributing to Parkinson’s disease susceptibility on chromosomes 
2p and 9q. Further investigation of the identifi ed regions will allow the confi rmation and 
refi nement of these candidate PD loci.
Introduction
Parkinson’s disease (PD, OMIM 168600) is a late-onset neurodegenerative disorder 
characterized by bradykinesia, resting tremor and rigidity. The cerebral pathology includes loss 
of dopaminergic neurons, particularly in the substantia nigra, and cytoplasmatic eosinophilic 
inclusions called Lewy bodies. In the majority of patients the cause of PD is unknown, and 
currently available therapy neither halts nor cures the disease. 
The role of genetic factors in the origin of PD with Mendelian inheritance is being 
rapidly elucidated, now that nine recessive and dominant forms have been identifi ed 1-9. The 
genetic basis of the late-onset form of PD that has a complex inheritance pattern, however, 
is less evident. Although twin studies showed the genetic component of late-onset PD to 
be smaller than that of early-onset PD 10, the risk in fi rst-degree relatives of PD patients to 
develop the disorder is still 2-14 times the risk in fi rst-degree relatives of unaffected family 
members, arguing in favour of a genetic component 11. Familial aggregation of the disorder 
was demonstrated by a genealogical search in Icelandic PD patients, leading to the mapping of 
a new locus for late-onset PD, PARK10, on chromosome 1p32 12, 13.
Linkage disequilibrium (LD) mapping of disease loci is based on the identifi cation 
of marker alleles or haplotypes, which are more frequent in patients than in controls. Outbred 
populations are assumed to be genetically heterogeneous, therefore,  genome-wide association 
studies using LD mapping would require very large case-control series and dense maps of 
polymorphic markers or Single Nucleotide Polymorphisms (SNPs).
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In contrast, genetically isolated populations are more homogeneous due to the small 
number of founders and limited inward migration. Furthermore, LD might be maintained over 
sizeable regions around disease genes in recently isolated populations. Coarser marker maps 
should therefore be suffi cient to successfully map disease genes in isolated populations 14. The 
recent discovery of the PARK10 locus 13 illustrates the potential of such approach. 
 We performed a genome scan in a group of 44 patients with typical PD from a 
genetically isolated population in The Netherlands. The aim of this study was to map gene(s) 
involved in PD susceptibility. 
Methods
Patients
This study is part of a research program named Genetic Research in Isolated Populations 
(GRIP) 6, 15. The scientifi c protocol of GRIP has been approved by the Medical Ethics 
Committee of the Erasmus MC. The GRIP population is a genetically isolated community in 
the Southwest of The Netherlands. Around 1750, this population counted approximately 150 
individuals. Since that time there has been a considerable population growth and until recently, 
a minimal inward migration 16. An estimated 20,000 descendants of this population are now 
scattered over eight adjacent villages. Church and municipal registers are readily available and 
date back to the 1800s. Genealogical history up to the 15th century has been computerised to a 
large extent, holding information on more than 60,000 individuals. 
Patients with parkinsonism were traced through local general practitioners, 
neurologists and nursing-home physicians. All patients provided informed consent to participate 
in the study. Parkinsonism was diagnosed when at least two out of three cardinal symptoms 
(bradykinesia; rigidity; resting tremor), as well as clinical improvement on dopaminergic 
therapy were present. The diagnosis of idiopathic PD was established after exclusion of 
other possible causes of parkinsonism and was verifi ed by two independent neurologists 
according to the EUROPARKINSON criteria 17. Data on the presence of PD, essential tremor 
and dementia in fi rst, second and third-degree relatives were collected by means of a family-
history questionnaire. In order to detect any subclinical or untreated parkinsonism, fi rst-degree 
relatives of patients also underwent neurological examination. 
Finally, genealogical information obtained from the participants and from local 
municipal, church and computerised registers was extended up to 16 generations 18. A total of 
109 patients with parkinsonism were initially ascertained, of these, 57 could be connected to a 
common ancestor. A detailed clinical characterization of the patients is reported elsewhere 18.
Forty-four patients with the diagnosis of idiopathic PD were included in the genome 
wide scan. From these patients, 38 presented with late-onset PD (mean age at onset of 65.7 r
10.8 years). Only 6 patients had a disease onset below 50 years (43.3 r 3.2 years). 
DNA analyses
The fi rst genomic screen  (stage I) comprised series of 23 PD patients, 48 fi rst-degree relatives 
and 16 controls (spouses). We increased the sample size for further analysis, and the initial 
group was extended. In the second genome screen 21 PD patients and 39 fi rst-degree relatives 
were included plus 9 controls (stage II). The inclusion of fi rst-degree relatives in the study 
allowed for segregation checks and for the construction of haplotypes. The spouses of the 
patients served as controls in the analysis. They also originated from the same population. Our 
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total sample set comprised 156 individuals from whom 44 were PD patients, 87 fi rst-degree 
relatives and 25 were controls. For fi ne typing of the regions identifi ed during the genome 
screen, the group of controls was extended to 88 control individuals, all from the GRIP 
population.
Genomic DNA was isolated from peripheral blood as described elsewhere 19. For the 
systematic genome scan we used short tandem repeat polymorphisms (STRPs) from the ABI 
PRISM® Linkage Mapping Set MD-10 (Applied Biosystems). Additional markers for fi ne 
mapping were obtained from the Genethon and Marshfi eld genetic maps. Information about 
marker order and distances were obtained from the NCBI physical map, Marshfi eld integrated 
genetic map and Celera human genome database. 
Genomic DNA (20 ng) was amplifi ed in 7.5 Pl PCR reactions prepared using a 
Beckman Biomek 2000 robot system and performed in 384-well plates. PCR products 
were pooled and loaded on an ABI377 (fi lterset D; 6.25% denaturing FMC LongRanger 
acrylamide gel) for stage I, or ABI3100 automated sequencer for stage II. Data were analysed 
using ABI GeneScan 3.1 and ABI Genotyper 2.5 or Genemapper 2.1 software from Applied 
Biosystems.
All patients in this study tested negative for the deletion extending from exon 1 to 
5 of the DJ-1 gene, which was identifi ed in a family with early-onset autosomal recessive 
parkinsonism from the same community 6, 18. As previously reported, 3 early-onset, and 18 
late-onset PD patients (from stage I) were studied for genetic markers fl anking known PD 
genes and loci (4q22, 6q25.2-q27, 2p13, 4p14-16.3, 1p35-36, 1p36, 12p11.2-q13.1 and 1p32) 
but showed no association 18.
Statistical analysis
After completion of the genotyping phase, a single analysis of the complete data was 
performed.  Because the genome scans had been performed with different equipments: gel 
electrophoresis for the fi rst 87 samples (stage I) and capillary electrophoresis for the last 69 
individuals (stage II), differences of 1 to 6 base-pairs were observed between alleles coming 
from the different stages. To merge the genetic data, a program was developed “in house”, 
“pooling” the data based on the allele lengths and frequencies observed in each group. The 
program uses a maximum likelihood approach to obtain the best correspondence between 
alleles. Simulation studies showed that with sample sizes of about 100 individuals, 70% 
of the allele correspondences were achieved with an error rate less than 1% (manuscript in 
preparation, Y. S. Aulchenko et al.). 
Genotypic data were analysed using a likelihood-based disequilibrium analysis 
program to investigate for single locus association (DISLAMB program version 2.1) 20,
under the assumption that one marker allele will be over-represented on chromosomes that 
carry the disease mutation. The program estimates allele frequencies for cases and controls 
and performs a likelihood ratio test (LRT), the corresponding chi-square and p-value are 
obtained. The proportion of patients in whom the disease is associated to an ancestral allele is 
represented by the parameter lambda (O).
To assess association, we also used the CLUMP software, which allows for allelic 
heterogeneity. The method clumps alleles together into a 2-by-2 table in such a way that the highest 
chi-square statistic is obtained 21. Its corresponding p-value is obtained empirically by Monte-Carlo 
simulations. A total of 10, 000 simulations were performed each time. By using this program, it is 
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feasible to test the possibility that more than one ancestral allele is associated with PD. 
A nominal value of p 0.01 corresponding to a LOD score of 1.18 was used to decide 
whether a region was interesting for further study 20, 22. For these regions, we determined 
haplotypes with the MERLIN program, using data from the fi rst-degree relatives. 
For the saturation-mapping analysis (chromosome 10), haplotype construction 
was not possible due to ambiguous order of markers on the physical map (NCBI, build 34, 
version 3). We performed single-point analysis of each marker separately using the CLUMP 
program.
Results
Forty of 44 patients with idiopathic PD could be connected to a common ancestor within 
16 generations. The average kinship coeffi cient for patients was 7.2 x 10-4. There were no 
affected fi rst-degree relatives included in the analysis, 3 pairs of patients were related in 3-4 
meiosis, and for the rest the genetic relationship extended beyond 5-6 meiosis. For the control 
group only 13 out of 25 individuals could be found in the genealogical database, their average 
kinship coeffi cient was lower than the patients (1.15 x 10-5).
Table 1 shows all 14 markers with p-value  0.01 corresponding to a LOD  1.18, 
with either DISLAMB (n=4) or CLUMP (n=11). For the DISLAMB analysis only 4 markers 
had a p-value  0.01 with lambdas of 0.21 (2 markers), 0.29 and 0.37. Furthermore, three of 
these four markers (D4S405, D9S158, D13S153) also yielded low p-values  (Table 1) with the 
CLUMP analysis. 
In addition, the associated allele detected with the DISLAMB analysis was also 
identifi ed with the CLUMP analysis; for D4S405 allele 6 and alleles 6 and 7 were detected 
with each analysis; for D9S158, allele 3 and alleles 3, 5, 6; for D13S153 allele 2 and alleles 2,
3, 5, showing consistency between results coming from both analyses. 
Only one marker, D9S158, showed evidence for association with PD for both 
analyses (DISLAMB, p=0.006 and CLUMP, p=0.009). Furthermore, this was the only region 
where close markers showed association. D9S158 and D9S290 are both located at the 9q34 
region, 21 cM apart according to the Marshfi eld sex-averaged genetic map. We constructed 
haplotypes in all individuals for the complete chromosome 9. A common haplotype was 
observed extending from D9S1776-D9S1682-D9S290-D9S1826-D9S158 (Fig. 1). The marker 
D9S164 was initially positioned between D9S290 and D9S1826 but its precise location is not 
certain yet; data from the draft sequences (NCBI physical map, build 34, version 3) positioned 
this marker on two different chromosomal regions on 9q34. Therefore D9S164 was excluded 
from the haplotype analysis. Ten out of 44 patients (23%) and only 1 out of 25 controls (4%) 
carried a common haplotype extending 3 or more markers. Patients carrying the common 
chromosome 9 haplotype were also more closely related (average kinship coeffi cient of 1.31 
x 10-3) than the complete group of 40 patients; most of them could be connected to a common 
ancestor within 10 generations (Fig. 2). For the remaining markers none of the haplotypes 
were associated with PD. 
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Marker D2S2333, which showed evidence of association during this study 
(DISLAMB p=0.009, O=0.29), is at the same location as the PARK3 locus. Markers on 
chromosome 4, D4S1534 at 136 cM (p=0.015, O=0.31), and on chromosome 17, D17S949 
at 102.3 cM  (p=0.021, O=0.17) were also interesting despite the modest statistical evidence 
for association, because of their location close to known genes related to PD aetiology (Į-
synuclein and tau).
 The analysis with CLUMP yielded p-values  0.01 for 11 markers. The strongest 
evidence for association came from marker D10S1651 (p=0.001). Therefore we tested a 
larger control group (n=88) originating form the GRIP population in order to obtain a better 
estimate of the allele frequencies. Twelve additional markers on chromosome 10 around 
D10S1651 (D10S217, D10S1676, D10S1439, D10S1655, D10S1248, D10S169, D10S1770, 
D10S555, D10S1675, D10S590, D10S1711 and D10S1700) were tested. Attempts were made 
to construct haplotypes by using the originally associated marker as a starting point, but only 
by assuming early recombinations or mutations could any haplotype be extended beyond two 
markers. Moreover, the order of the markers in this region of chromosome 10q, especially for 
D10S1651 and the most telomeric markers, was unreliable (NCBI or Celera physical maps) as 
large parts of this region consist of draft and unfi nished sequence. 
Using CLUMP, one of the additional 13 markers (D10S1711, telomeric to D10S1651) 
showed evidence for association that was found with the 177-bp allele (p=0.006). For the 
original marker, D10S1651, two alleles (211 and 229-bp) were detected (p=0.049). All other 
markers had p-values > 0.30. 
Discussion
We here report the results of our genome scan performed in a group of 44 patients with 
typical PD from a genetically isolated population in The Netherlands. After performing the 
association analysis with DISLAMB, 4 markers were of interest (p 0.01): D2S2333, D4S405, 
D9S158, D13S153. 
D9S158 (LOD=1.37) was the only marker for which both analyses showed 
association. In addition, a neighbouring marker, D9S290, also showed association. Both 
markers are located in the long arm of chromosome 9, with 8 Mb in between according 
to the NCBI physical map. Even with the coarse marker grid used for this screening (10 
cM), a common haplotype extending up to fi ve markers was observed for several patients. 
The complete region extends around 21 Mb based on the NCBI physical map. A common 
haplotype extending at least 3 markers was observed for 10 patients (Fig. 1). In the control 
group this was observed in only one individual. 
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Patient D9S1776 D9S1682 D9S290 D9S1826 D9S158
1* 5 1 5 2 3
5* 5 1 5 2 3
16* 3 1 5 2 3
17* 6 1 5 2 3
2* 2 1 5 2 3
3* 5 2 5 2 3
7 5 1 5 2 3
8 6 1 5 2 3
4* 5 1 5 2 8
9* 5 1 5 4 3
12* 5 1 5 2 3
14* 5 1 5 2 3
6 5 2 5 2 3
10* 5 2 5 2 3
11 6 2 5 2 3
13* 7 1 5 2 3
15 5 1 5 6 6
18 3 1 5 2 4
Figure 1. Patients with PD showing a common haplotype in the chromosome 9 region. Dark grey boxes represent 
alleles which phase could be determined, light grey means phase unknown. The asterisks indicate all 12 patients 
that were related to a common ancestor.
This region overlaps with marker D9S1825 previously identifi ed during a sib-pairs 
analysis that found suggestive evidence of linkage with this marker 23. Marker D9S290, 
detected during this study is ~ 4 cM centromeric from D9S1825, suggesting that this interval 
might contain a gene involved in PD susceptibility. Moreover, evidence of linkage to PD age 
at onset was found at a region located  ~ 20 cM (telomeric, marker D9S930, maxLOD=2) 24.
Similarly, the PARK3 and PARK10 loci have been implicated in PD susceptibility and age at 
onset of the disease 24, 25. This line of evidence suggests that the same gene(s) could be involve 
in increasing susceptibility to PD and in modulating the age at onset of the disease.
Marker D2S2333 maps to the PARK3 locus and also showed association. Several 
studies have related this locus to PD susceptibility and age at onset of the disease 3, 24, and 
recently a haplotype harbouring the sepiapterin reductase gene, implicated in dopamine 
synthesis, was found associated to a younger onset of the disease 26.
Markers D4S1534 at 136 cM and D17S949 at 102 cM, close to the Į-synuclein and tau
gene, respectively, showed modest evidence of association.  Both genes have been implicated 
in PD. Three Į-synuclein  mutations are known to cause autosomal dominant PD. Moreover, 
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a polymorphism (Rep1) located within the gene promoter has been related to increased risk 
for late-onset PD in case-control studies of “sporadic” PD patients (mean onset age 64 and 66 
years in each study) 27, 28. Alpha-synuclein over-expression is believed to be a risk factor for 
PD and variation of the gene expression related to this polymorphism has been reported 29-31. In 
addition, a specifi c tau haplotype (H1) has been related to PD as well, in case-control studies 
with “sporadic” PD patients (mean age at onset 64 years, range 31 to 91 years) 32. We will next 
explore a possible association with Į-synuclein and tau gene variants in this sample set and 
investigate potential interactions with other detected regions such as the chromosome 9q.
Two markers showing association with PD in the CLUMP analysis are of special 
interest because of their genomic location. Marker D1S230 (Table 1, p=0.002) is located at 
the PARK10 region, which is the only locus mapped for typical late-onset PD. This region on 
chromosome 1p32 was found after a genome wide search in a group of 117 PD patients from 
Iceland 13. Marker D5S436 (147 cM, p=0.005) is also interesting because of its location close 
to an interval (~ 139 cM) detected during the analysis of 174 small families comprising 378 PD 
patients 33. Furthermore, excess of allele sharing between Icelandic PD patients was found for 
a marker in the same region (D5S666, 135 cM, LOD=1.6) 13. However, for marker D5S436, 
a total of 6 alleles were found associated with PD during this analysis. Because most of the 
patients are related to a common ancestor, such allelic heterogeneity is not expected. Several 
associated alleles were detected for markers on chromosome 7 and 11 as well (D7S684, 6 
alleles and D114175, 9 alleles) weakening the evidence of association.  
The lowest p-value obtained during our analysis corresponded to marker D10S1651 
(CLUMP, p=0.001). Upon saturating this region with a denser set of markers in an augmented 
sample, the control allele frequencies could be estimated more accurately. Besides marker 
D10S1651, marker D10S1711 yielded a p-value of 0.006. Haplotype analysis was not 
possible, fi rstly because the assumption of association of a single allele did not hold and 
secondly because of an unknown marker order. Although the association was maintained in 
the follow-up analysis, a marker order could not be determined with suffi cient certainty to 
construct haplotypes. This limits the interpretation of this last fi nding.
 Further fi ne mapping of the positive regions with subsequent haplotype analysis 
will be required to confi rm and eventually refi ne the detected regions. During this study we 
identifi ed candidate regions showing overlap with others previously described. This suggests 
that genes located within those regions might be involved in PD susceptibility in this isolated 
population.
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Abstract
A large, multiethnic series of patients with early-onset Parkinson’s disease (EOP) was studied 
in order to assess the frequency and nature of parkin/PARK2 gene mutations, and to investigate 
phenotype-genotype relationships. Forty-six EOP probands with onset age <45 years, and 14 
affected relatives were ascertained from Italy, Brazil, Cuba, and Turkey. The genetic screening 
included direct sequencing and exon dosage using a new real-time PCR method. Mutations 
were found in 33% of the index patients overall, and in 53% of those with a family history 
compatible with autosomal recessive inheritance. 
Fifteen parkin alterations were identifi ed, including 10 exon deletions and fi ve point mutations. Four 
of the mutations have not been described previously: Arg402Cys, Cys418Arg, IVS11-3C>G, and 
deletion of exon-8-9-10. Heterozygous genomic rearrangements represent 28% of the mutations 
found, confi rming the importance of testing exon dosage when screening parkin. The patients 
with parkin mutations showed signifi cantly earlier onset, longer disease duration, slower 
disease progression and more frequent symmetric onset than the patients without mutations, in 
agreement with previous studies. This study confi rms the frequent involvement of parkin and 
indicates the importance of genetic testing in the diagnostic work up of EOP. The novel, cost-
effective exon dosage method described here can also be applied to the study of other genes. 
Introduction
Previous studies suggest that genetic factors are more important in the aetiology of early-onset 
Parkinson’s disease (EOP) than in the common late-onset forms 1, and autosomal recessive 
forms are increasingly recognized among EOP cases 2. Mutations in two genes, parkin 3 and
DJ-1 4, have been identifi ed in autosomal recessive EOP, and a third locus, PARK6 5 bears a 
gene responsible for a further recessive form. So far, mutations in the parkin gene are the most 
frequent identifi able cause of EOP 6.
 Parkin mutations were fi rst identifi ed in Japanese patients with autosomal recessive 
juvenile parkinsonism 3. Since then, several mutations have been described in EOP cases, 
varying from point mutations to complex rearrangements including deletions and/or 
multiplications of complete exons 7-15. Some studies emphasized the importance of gene 
dosage assays as part of the mutational analysis of parkin, but the estimated frequency of exon 
rearrangements varies greatly (33 to 67%) 10, 11, 16.
 Most parkin mutations lead to the loss of the ubiquitin E3 ligase activity of the 
encoded protein, which normally tags specifi c substrates for degradation through the 
ubiquitin-proteasome pathway 17. However, the mechanisms by which parkin mutations cause 
neurodegeneration remain to be elucidated. Studies on parkin knock-out mice failed to fully 
reproduce the picture of the human disease, but did suggest a role for the parkin protein in the 
regulation of nigrostriatal dopaminergic neurotransmission 18, 19.
 Patients with parkin mutations are diffi cult to distinguish from other EOP patients on 
the basis of their clinical phenotypes 8, 20. Moreover, due to the complexity of the parkin gene
and the wide spectrum of mutations, the genotype-phenotype correlations have been diffi cult 
to establish. There is a wide variation (intra and inter-familial) in the clinical presentation 
and age at onset, even in patients with the same gene defects 20. Atypical clinical and genetic 
presentations, including pseudo-dominant inheritance have also been described 21, 22. Last, in 
a few patients, only one heterozygous mutation has been detected, suggesting that a second 
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mutation still escapes detection by current screening methods, or that some mutations in 
heterozygous form are suffi cient to cause this disease 11, 12, 14. It is clear that much work is 
still ahead to disentangle the complexity of the disease associated with parkin mutation (the 
“parkin disease”), and the analysis of large series of patients is therefore warranted. 
 Here we report on the nature and frequency of parkin mutations and on phenotype-
genotype relationships in a newly ascertained, multiethnic group of EOP patients. Genetic 
screening included direct sequencing of the parkin coding region and systematic exon dosage 
analysis. Previously developed methods for exon dosage use expensive fl uorescently labelled 
probes (i.e. LightCycler 10, TaqMan 21). Here we describe a novel and cost effective quantitative 
PCR method employing a fl uorescent intercalating agent and non-labelled oligonucleotides. 
Patients, Materials and Methods
Patients
We included in the study all the patients referred during the period 2000-2002, who fulfi lled 
the following criteria: clinical diagnosis of Parkinson’s disease (PD), and either: (a) positive 
family history compatible with autosomal recessive inheritance and age at onset ≤45 years 
in the index case; (b) isolated presentation with age at onset ≤40 years. According to these 
criteria, we collected a multiethnic group of 46 EOP index patients from Italy (n=39), Brazil 
(n=4), Cuba (n=2), and Turkey (n=1), plus 14 affected fi rst-degree relatives (total sample 
set n=60). Seventeen index cases were from families compatible with autosomal recessive 
inheritance, and 29 were isolated patients. Consanguinity was reported in eight families and 
two isolated cases.
 The clinical diagnosis of Parkinson’s disease was established according to the UK 
Parkinson’s Disease Society Brain Bank criteria 23, 24, when at least two of the three cardinal 
signs (resting tremor, rigidity and bradykinesia) and a positive response to dopaminergic 
therapy were present, in absence of atypical features or other causes of parkinsonism. 
Neurological examination of each patient was performed by neurologists with experience 
in movement disorders and included the Unifi ed Parkinson’s Disease Rating Scale (UPDRS, 
motor part) 25 and Hoehn Yahr scale 26 in “on” and (if possible) in “off” status. Clinical data 
were collected using a standard form. Informed consent was obtained from all patients. Venous 
whole blood was taken and DNA isolated according to standard procedures 27.
Molecular studies
Haplotype analysis
In the families compatible with autosomal recessive inheritance of EOP, we typed Short 
Tandem Repeats (STR) markers from the PARK2 (parkin) 3, PARK6 5 and PARK7 (DJ-1)
28 regions, by PCR using fl uorescently labelled primers and an ABI 3100 automatic DNA 
analyser, as described previously 29. Haplotypes were constructed based on the minimum 
number of recombinations.
Direct sequencing of parkin
Families showing no haplotype sharing for both alleles at the PARK2 locus were excluded 
from the mutational screening (n=3). For the remaining families and the isolated patients, 
direct sequencing of the parkin gene was performed using the BigDye terminator chemistry 
(Applied Biosystems). All 12 exons and exon-intron boundaries of the parkin gene were 
amplifi ed using intronic primers, as described 30. For exon 1, 6, and 10, we designed new 
Novel parkin mutations in a multiethnic series of cases with EOP
103
intronic primers (primers and PCR conditions available on request). PCR products were 
loaded on an ABI 3100 Automatic DNA sequencer and analysed with the SeqScape software 
version 1.1 (Applied Biosystems). 
The frequency of the novel detected variants was assessed in panels of at least 96 and up to 
500 chromosomes from ethnically matched control individuals by digestion with restriction 
enzymes or by the allele specifi c oligonucleotide hybridisation technique (ASO).
Splicing effect analysis
We used fi ve computer programs to predict the possible consequences on splicing of sequence 
changes in the proximity of the exon/intron boundaries 31-35.
Exon dosages studies
All index patients without mutations or with a single heterozygous mutation detected by 
sequencing were investigated further for exon rearrangements. Exon dosages studies were 
performed through quantitative PCR using an iCycler iQ™ Real-time PCR machine (Bio-Rad) 
and SYBR™ Green I as intercalation dye. 
 Exonic and intronic primers for the 12 exons of the parkin gene were designed 
(available on request), allowing amplifi cation of genomic fragments ranging from 81 to 139 
bp. Fifty nanograms of genomic DNA was used per 25µl of single PCR reactions (qPCR™ 
Core kit, Eurogentec) for parkin and the “control gene” (ȕ-globin, HBB). All samples were 
tested in triplicate and at least one positive and two negative controls were included in every 
plate (96 well plates). The thermal cycling parameters were: 95˚C - 10 minutes, 40 cycles of 
95˚C - 20 sec., 60˚C - 45 sec., 75˚C - 15 sec., allowing for real-time data collection. A melting 
curve was generated for each sample, enabling the detection of non-specifi c products during 
the amplifi cation. 
 The fl uorescence of the SYBR™ Green increases signifi cantly as it binds and 
intercalates into double-stranded DNA during the extension step of the amplifi cation cycle. 
During the PCR the accumulation of product results in a measurable change in fl uorescence 
of the reaction mixture, this point is called the Threshold cycle (CT). We used this value to 
perform our calculations, given that there is a linear relationship between the log of the starting 
amount of template and the corresponding CT during real-time PCR 36.
 The iCycler software (version 3.0a) calculates automatically the CT for every 
reaction. Since three different measurements are obtained per sample, the average CT and 
standard deviation (SD) are calculated for both parkin and ȕ-globin. The Average CT was used 
to calculate the ratio parkin/ȕ-globin (RP/ȕ) using the following formula: 
RP/ȕ= [(CCT Parkin - CCT ȕglobin) - (PCT Parkin - PCT ȕglobin)] 2
where CCT is the average threshold cycle for the negative (normal) control sample and PCT is 
the average threshold cycle for the patient sample. On the basis of the observed variability of 
the values of the ratios in normal individuals and positive controls with parkin heterozygous 
rearrangements, we considered as normal the ratios between 0.8 and 1.2. Values lower than 
0.7 or higher than 1.3 are interpreted as heterozygous deletion or duplication of the assessed 
exon, respectively. All positive results were confi rmed at least twice and an average ratio was 
calculated. Furthermore, all cases with homozygous or heterozygous exon deletions affecting 
only one exon were confi rmed with an independent set of primers to avoid false positive 
results due to primer mismatch caused by undetected polymorphisms. Segregation of detected 
rearrangements was investigated whenever DNA samples from relatives were available.
 Evaluation of the consequences of the exon deletion on the protein (in-frame or 
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frameshift) was predicted based on the parkin cDNA sequence published with accession no. 
AB009973.
Statistical analysis
All calculations were done using the SPSS package version 11 (SPSS, Inc., Chicago, IL). We 
used the nonparametric Mann-Whitney U test or the Student’s T test for comparison of means 
and the χ2 or Fisher’s exact test for comparison of proportions when appropriate. Differences of 
means (disease severity, UPDRS and Hoehn Yahr score in “off”) were tested using ANCOVA. 
P values for trend were obtained from simple linear regression models where type of mutation 
was included as a continuous term (0=No parkin mutation, 1= two parkin exon deletions, 
2=parkin heterozygous point mutation).
Results
Clinical studies
Patient characteristics are summarized in Table 1. The mean age at onset (AAO) was 33 
±11 years ranging from 14 to 65 years. Four of the 14 affected fi rst-degree relatives had a 
disease onset later than 50 years of age, while in the remaining cases the AAO was before 50. 
Resting tremor and bradykinesia at onset were found in around half of the patients (53 and 
54%). The onset of signs was asymmetric in most of them (79%). Bradykinesia was the most 
frequent sign found at clinical examination (96%) followed by rigidity, present in 91% of the 
examined patients. Other characteristics such as sleep benefi t and slow disease progression 
were occasionally noticed. 
 Some patients presented other features: severe depression, anxiety, panic attacks, 
dysphoria, and emotional liability were noted. In addition to EOP, one case presented 
a chromosomal abnormality (Robertsonian 13q-14q translocation), and another patient 
had mild mental retardation and facial dysmorphism. Eighty-eight percent of the patients 
received treatment with levodopa; the majority of these also presented with levodopa-induced 
dyskinesias (79%) and motor fl uctuations (73%).
Molecular studies
Haplotype analysis of the PARK2 region was performed in 8 families. In three of them the 
PARK2 locus was excluded since no haplotype sharing (on both chromosomes) was observed 
among the affected individuals. In the fi ve remaining families, haplotype analyses supported 
a causal role of parkin, and they were included in the mutational screening (three of them 
were consanguineous). Haplotype analysis could not be performed in 9 families because DNA 
samples from additional family members were not available. 
Parkin sequence analysis
Several intronic and exonic changes were identifi ed. Two novel intronic changes, IVS11-3C>G 
and IVS2-18T>A, were found close to acceptor splice sites. The coding variants included two 
novel point mutations in exon 11: 1305C>T predicted to cause the aminoacid change Arg402Cys, 
and 1353T>C leading to Cys418Arg. The previously described missense mutations Arg42Pro 
in exon 2, and Thr415Asn in exon 11 were also detected. We also found a novel synonymous 
change in exon 4, 620G>A (Thr173Thr). 
The known polymorphisms 7 1239G>C (Val380Leu), 1281C>A (Asp394Asn), IVS2+25T>C, 
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IVS3-20C>T, IVS7-35A>G were also repeatedly found (data not shown).
 The novel IVS11-3C>G change was identifi ed in a consanguineous Cuban family 
with three EOP patients. Haplotype analysis of the PARK2 region previously suggested the 
possibility of heterozygous mutations in the parkin gene, since all patients shared the same 
parental haplotypes without evidence of homozygosity (fi g. 1). The second mutation in this 
family was found by exon dosage analysis (see below). 
 The IVS11-3C>G change introduces a new cutting site for the restriction enzyme 
BseRI. We tested 96 chromosomes from unrelated Cuban controls and none was found to carry 
the base change, indicating this is not a common variant. All programs anticipated the abolition 
of the normal splicing acceptor site and the activation of the cryptic splice site ACAG/GAG to 
AG/AGGAG. Unfortunately, RNA from these individuals was unavailable. The PARK6 and 
PARK7 locus were both excluded by haplotype analysis (not shown).
 The remaining intronic change IVS2-18T>A, found in an Italian patient, was located 
further away from the splicing site. The same computer programs predicted no affectation of 
the normal splicing, and therefore the pathogenicity of this sequence change remains doubtful. 
No other changes were found.
 The novel sequence alterations 1305C>T (Arg402Cys) and 1353T>C (Cys418Arg) 
were found in heterozygous state (Table 2), they are located close to and within the second 
RING fi nger motif of the parkin protein and both affected highly conserved amino acids, 
suggesting they are pathogenic changes. However, in the patient carrying the 1305C>T 
(Arg402Cys) change, a second mutation was not found by the methods used in this study. This 
base change was found in 1 out of 500 control chromosomes  (320 and 180 chromosomes of 
Italian and Dutch origin, respectively). 
 The Arg42Pro mutation, located within the ubiquitin-like domain of the protein, and 
the Thr415Asn mutation were both detected previously in homozygous state in families of 
Italian origin with EOP 7, 37. Nucleotide changes were not found in the remaining patients by 
sequencing of the 12 parkin exons. 
Exon dosages analysis 
Homozygous deletions spanning up to 3 consecutive exons were found in eight probands (Table 
2). One patient carried a novel deletion involving exons 8, 9 and 10.Using a quantitative, real-
time PCR method, six index cases were found to carry heterozygous exon rearrangements. 
These include four out of the fi ve probands carrying heterozygous point mutations, and two 
probands carrying two different heterozygous exon rearrangements (Table 2). 
 In three families, co-segregation and phase of the heterozygous deletions could be 
resolved. In an Italian family (Ver-01) the proband carried a heterozygous point mutation 
(C418R) and a heterozygous deletion of exon 3. We confi rmed the presence of the C418R 
mutation in the mother and the deletion of exon 3 in the father, delineating the patient as a 
compound heterozygote (C418R/ex3del) of parkin mutations. 
 In the aforementioned Cuban family (Cu03), all patients carried the IVS11-3C>G 
change and a heterozygous deletion of exons 3-4 (fi g. 1). The IVS11-3C>G change was 
then found in the unaffected mother, whereas the unaffected father carried the heterozygous 
deletion of exons 3-4.
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Figure 1. The pedigrees from a Turkish, Ayd01 (A) and a Cuban family, Cu03 (B) are shown. Filled black symbols represent the 
patients with EOP. Haplotypes for the PARK2 region are displayed; alleles between brackets correspond to inferred genotypes. In
pedigree A, for marker D6S1599, hemizygosity was observed; the missing allele is represented with “X”. The bar graphs below the
pedigrees are showing the results from the exon dosage assay for the corresponding individuals.
 Finally, in a Turkish family, haplotype analysis previously showed parental non-
transmission of alleles suggesting hemizygosity for one intragenic marker (D6S1599), raising 
the possibility of a deletional event within the parkin gene. Subsequently, by means of real-
time PCR, the three patients were characterized as compound heterozygous for two different 
exon deletions involving exon 2 and exons 3-4, respectively. The phase of the alleles was 
distinguished by exon dosages assessment in other family members and by haplotype analysis 
(fi g.1). This revealed the possibility that the deceased mother (from whom no clinical data or 
DNA material was available) carried a homozygous exon 2 deletion. 
Frequency of parkin mutations 
We found parkin mutations in 15 out of 46 index cases (Table 2). In our series, parkin
mutations are therefore responsible for 33% of EOP. When we look at the form of presentation 
(familial or isolated cases), mutations were detected in 53% (9 out of 17) of the families with 
EOP, and in 21% (6 out of 29) of the isolated cases. 
 Among the 15 patients with parkin mutations, eight carried homozygous exon 
deletions, two were compound heterozygote for two different exon deletions and four were 
heterozygote for an exon deletion plus a point mutation. Homozygous and heterozygous exon 
deletions represented 55% (16 out of 29) and 28% (8 out of 29) of the observed mutant alleles, 
respectively. Exon 3 deletions were found repeatedly in both homozygous and heterozygous 
states in Italian patients. Deletions encompassing exon 3 to 4 were found in heterozygous state 
in three families from Cuba, Turkey and Italy. Point mutations represented 17% (5 out of 29 
alleles) of all parkin mutations; in each case the patient was heterozygote.
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Table 1.       Phenotype description of the complete sample set, and according to parkin genotype
Characteristics Total sample set n
Patients with 
Parkin mutations
n
Patients without 
Parkin mutations
n
Gender Male (%) 34  (57) 60 11 (48) 23 23 (61) 37
Age at onset, years (range) 33 ± 11 (14-65) 60 28 ± 9 (15-44) * 23 39 ±10 (14-65) 37
Disease duration, years (range) 15 ± 9 (1-36) 59 20 ±9 (6-36) ** 22 13 ±8 (1-30) 37
Age at examination, years (range) 49 ± 10 (19-71) 59 49 ±10 (32-70) 22 49 ±10 (19-71) 37
Symptoms and signs at onset
Bradykinesia (%) 31 (54) 57 10 (48) 21 21 (58) 36
Resting tremor (%) 30 (53) 57 10 (48) 21 20 (56) 36
Asymmetry (%) 46 (79) 58 13 (62) * 21 32 (89) 37
Dystonia (%) 7 (12) 57 3 (14) 21 4 (11) 36
Clinical signs at examination
Bradykinesia (%) 55 (96) 57 21 (100) 21 34 (94) 36
Resting tremor (%) 37 (66) 56 14 (67) 21 23 (66) 35
Rigidity (%) 52 (91) 57 19 (90) 21 33 (92) 36
UPDRS off (range) 49 ± 21.2 (6-90) 24 41± 20.5 (6-70) ¥ 8 53 ± 22 (18-90) 16
UPDRS on (range) 20 ± 11.0 (2-45) 42 20 ± 12.8 (2-43) 14 21 ± 10.1 (2-45) 28
Hoehn&Yahr off (range) 3.3 ± 0.9 (1-5) 30 2.9 ± 0.9   (1-4) ¥¥ 10 3.4 ± 0.9 (2-5) 20
Hoehn&Yahr on (range) 1.8 ± 0.7 (0-4) 48 1.9 ± 0.9 (0-4) 17 1.7 ± 0.6 (1-2.5) 31
Treatment
Treatment with L-dopa (%) 46 (88) 52 17 (81) 21 29 (93) 31
Daily dose of L-dopa in mg 
(range)
556 ± 304 (100-
1250)
44
497 ±337  (150-
1250)
15
587 ±288 (100-
1200)
29
Duration of treatment in months 
(range)
123 ± 92 (3-336) 36 139 ±102 (8-290) 13 115 ± 87 (3-336) 23
Other features (%)
L-dopa induced dyskinesias 34 (79) 45 12 (75) 16 21 (72) 29
L-dopa induced motor 
fl uctuations
33 (73) 43 10 (63) 16 24 (89) 27
* p=0.02, ** p=0.005, ¥ p=0.06, ¥¥ p=0.006 (the last two after adjustment for disease duration)
Genotype-Phenotype correlations
Signifi cant differences between the patients with and without parkin mutations were observed 
for AAO and disease duration (Table 1). The patients carrying parkin mutations have an 
earlier onset (28 ±9 vs. 39 ±10 years, p=0.02) and longer disease duration (20 ±9 vs. 13 ±8
years, p=0.005) than those where no mutations have been identifi ed. When the groups were 
compared according to the type of mutation (point mutation or exon deletion) the difference 
came mainly from the group of patients with heterozygous point mutations. In the patients 
carrying a point mutation (missense or splicing) we observed a mean AAO of 23 ±8 years 
(n=7) vs. 31 ±9 years (n=16) in the group with two exon deletions and 39 ±10 years (n=37) in 
the patients without parkin mutations (p for trend=0.002). A similar effect was observed for 
the disease duration; patients with point mutations have the longest disease duration, 22 ±10
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years, vs. 19 ±9 and 13 ±8 years for the group with exon deletions or no parkin mutations, 
respectively (p for trend=0.002). Although these results are statistically signifi cant, they are 
based on small numbers and therefore should be interpreted with caution. However, the data 
suggest an infl uence of the nature of mutation on the AAO.  
 Regarding the clinical features, both groups of patients were comparable, except 
for the asymmetry of signs at onset, which was found in 89% (32 out of 37) of the patients 
without parkin mutations and in only 62% (13 out of 21) of the patients with parkin mutations 
(p=0.02).
 After adjusting for disease duration, we observed a slower disease progression in 
the patients with parkin mutations according to the UPDRS motor scale (41±20.5 vs. 53±22,
p=0.057) and Hoehn-Yahr scale measured in “off” status (2.9±0.9 vs. 3.4±0.9, p=0.006).
Levodopa-induced motor fl uctuations were more frequent in the group without parkin
mutations that also have higher doses of levodopa (587 vs. 497 mg), but these differences 
were not signifi cant. 
Discussion
We have characterized clinically and genetically a series of 46 EOP index cases plus 14 
affected relatives, identifying 15 different parkin mutations in 15 index cases, including the 
fi rst Cuban family with EOP due to parkin mutations.
 From the fi ve identifi ed point mutations, three are novel changes: Arg402Cys, 
Cys418Arg and the splicing mutation IVS11-3C>G. Recent functional studies suggest that the 
Cys418Arg mutation is pathogenic because it decreases parkin solubility in cells, and leads to 
the formation of cytoplasmic aggregates 38. On the contrary, if the Arg402Cys variant is a rare 
polymorphism or a pathogenic mutation remains unclear, and further, functional studies are 
required to clarify this issue.
 To our knowledge, only three splicing mutations 12, 14 have been reported in the parkin
gene. It is known that the effi ciency of splicing is dependent not only on the GT and AG 
dinucleotides present at the 5’ and 3’ exon/intron junctions respectively, but also by consensus 
sequences spanning both 5’ and 3’ sides. For the splicing mutation reported here, fi ve different 
computer programs that predict splice sites in human genes, consistently showed a predicted 
abolition of the natural acceptor splicing site and the activation of a cryptic site that competes 
with the authentic one. As a consequence a 2 bp frameshift in the sequence of exon 12 (coding 
part of the second RING fi nger motif of the parkin protein) is introduced. 
 In the same family (Cuban origin) we also found a heterozygous exon 3-4 deletion 
in trans with the IVS11-3C>G change. The presence of compound heterozygous parkin
mutations in a consanguineous family illustrate that the absence of homozygous haplotypes 
is not enough to rule out the involvement of the gene/locus under study, and the possibility of 
compound heterozygous mutations should be considered also in consanguineous pedigrees.
 Up to now, semi-quantitative and quantitative methods have been used for 
determination of exon dosages in the parkin gene. The fi rst is based on the peak heights 
corresponding to each of the exons amplifi ed in a given reaction, compared to the peak heights 
of the control gene exon, obtained after assuming the log-linear phase of the multiplex PCR 
reactions 8.
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Quantitative methods, i.e. LightCycler, TaqMan, offer a precise (real-time) measurement of 
the threshold cycle. All methods used until now employ expensive fl uorescent primers or 
probes in multiplex reactions 8, 10, 15, 21.
 Here we described a novel method to assess exon dosages in the parkin gene. The 
method uses an intercalating dye, in this case SYBR® Green I, which function as a fl uorescent 
reporter, and non-labelled primers. The amplifi cation reaction was performed independently 
for both sets of primers (parkin and β-globin) using the same master mix and the same starting 
amount of DNA. The β-globin gene has been used by several groups that currently perform 
exon dosages assessments, and has been proved to be a reliable “control gene” 8, 10.
 Our method facilitates a rapid and accurate detection of exon rearrangements using a 
simple and cost effective technique. However, since this method employs only one fl uorescent 
reporter, multiplex reaction cannot be performed. The advantage of the lower starting costs 
needs therefore to be balanced toward the throughput of a given study design, and this assay is 
predicted to be especially convenient for low- or moderate throughput screenings.
Positive controls (i.e. parents and offspring of patients with homozygous deletions) were used 
in the respective experiments to confi rm the results and validate the method. Segregation 
analysis in available family members allowed the identifi cation of the allele phases and 
at the same time served as “quality controls”. We also confi rmed all exon rearrangements 
compromising only one exon with an independent set of primers, to avoid false positive results 
due to primer mismatch. 
 Heterozygous exon rearrangements were detected in 28% of the parkin patients in 
our study. The detected exon rearrangements were all deletions, confi rming that they are more 
frequent than duplications 8, 14. Without the exon dosage assay, either both or one mutation 
would have been missed in 11% of the index cases. 
 In one family (Ge-01) where a homozygous exon 3 deletion was initially found, 
the gene dosage assay also detected a heterozygous exon 4 deletion, delineating the affected 
siblings as compound heterozygote (exon 3del/exon 3-4del, Table 2). 
 In this newly ascertained EOP sample set, we detected parkin mutations in 53% of 
the familial cases, and in 21% of the isolated patients. These frequencies are consistent with 
previous studies that applied similar inclusion criteria but a different method for exon dosage: 
49% for familial and 15% for isolated EOP patients 8, 15. Our results suggest a contribution 
of parkin to one-third of the EOP cases overall, although referral bias can still be an issue to 
consider. Other studies have detected a lower frequency of parkin mutations (18% of all EOP 
patients), however, exon dosage assays were not performed 12.
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Table 2. Mutational screening of the parkin gene
Index case
(no. of aff, no. of tested siblings) Presentation Age at onset Disease duration Parkin Mutation 1 Parkin Mutation 2
Hom exon deletions
TOR-34 (3, 1) F 41, 42, 43 12, 14, 18 Exon 2-3 del Exon 2-3 del
PK-09-01 (2, 2) F C 20, 20 17, na Exon 3 del Exon 3 del
TOR-18 (3, 2) F 38, 42, na 14, 28, na Exon 5 del Exon 5 del
IVR-1 (3, 1) F C 20, 22, 29 23, na, na Exon 5-6 del Exon 5-6 del
PG-001 (3, 1) F 23, 25, 25 36, 50, na Exon 6 del Exon 6 del
PAL-1 S C 18 16 Exon 6-7 del Exon 6-7 del
ME-03 (2, 2) F 29, 40 19, 10 Exon 8 del Exon 8 del
PV-24 S 20 19 Exon 8-9-10 del Exon 8-9-10 del
Het exon deletions
Ayd01 (3, 3) F 34, 40, 44 6, 10, 10 Exon 2 del Exon 3-4 del
GE-01 (2, 2) F 31, 30 33, 28 Exon 3 del Exon 3-4 del
Het exon del / het  point mut. 
RM-417 S 16 30 Exon 3 del 1345C>A (Thr415Asn)
VER-1 S 15 21 Exon 3 del 1353T>C (Cys418Arg)
Cu03 (3, 3) F C 17, 23, 30 30, 16, 6 Exon 3-4 del IVS11-3C>G (Splicing)
MI-006-01 S 28 34 Exon 6 del 226G>C (Arg42Pro)
Het point mutation
RV-3 S 35 18 - 1305C>T (Arg402Cys)
Aff=affected F=Familial form S=Sporadic C=Consanguinity del=deletion Het=heterozygous Hom=homozygous na=not available
Phenotype-genotype correlations
Patients with parkin disease showed a signifi cantly earlier onset, longer disease duration, 
slower disease progression and more frequent symmetric onset than patients without parkin
mutations, confi rming previous fi ndings 8, 20, 39. Among the isolated patients with EOP, parkin
mutations were found in 67% of the patients with a disease onset ≤ 20 years old, in 14% and 
6% of the patients with AAO between 21-30 years and ≥ 31 years, respectively, showing that 
the earlier the AAO, the higher the probability of fi nding parkin mutations. 
 Recently, a more severe disease status was found in carriers of one missense mutation 
compared to carriers of two truncating mutations 20. No relationship with AAO was observed. 
However, we observed a signifi cantly lower AAO in patients with point mutations (missense 
and splicing) compared to patients with exon deletions or those without parkin mutations, 
suggesting a relationship between the nature of the mutation (point mutation vs. exon deletion) 
and the AAO.
 It has also been reported that missense mutations within the functional domains of 
the parkin protein might lead to earlier AAO 20. It is diffi cult to disentangle the effect of the 
localization from those of the nature of the mutation. For example, missense mutations located 
within the RING1 fi nger domain of parkin might lead to an abnormal distribution of the 
protein within large cytoplasmic and nuclear inclusions in cellular models 40.
 On the other hand, exon deletions can lead to in-frame or frameshift mutations. The 
stability of the shorter proteins or protein carrying missense changes is diffi cult to predict. 
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When the patients carrying at least one in-frame deletion (exon 2-3, 3-4, and 5) were removed 
from the analysis, the difference in AAO between the groups with point mutation (n=7) or 
exon deletions (not in frame, n=8) disappeared. However, due to the small number of patients 
it is diffi cult to establish conclusions. Exploring this potential relationship in larger and 
independent sample sets will shed more light on the topic.
 Previous studies have suggested that a single parkin mutation might sometimes cause 
EOP or represent a risk factor for late-onset PD 11, 12, 14, 20, 21, 39. However, whether a single parkin
mutation is suffi cient to cause EOP or whether the available methods are unable to detect a 
second parkin mutation, is not clear.
Final considerations
The analysis of this newly ascertained series of cases confi rms that parkin mutations are a 
relevant cause of EOP. An early age at onset and a slower disease course differentiate the group 
of patients with parkin mutations from the rest of the EOP cases. Among the parkin mutations, 
heterozygous exon rearrangements represent 28% of the mutations, confi rming the importance 
of exon dosage analysis when studying the parkin gene. We implemented a novel method to 
investigate gene dosage, which can be applied to the study of other genes where a dosage effect 
matters, including alpha-synuclein/PARK1 and DJ-1/PARK7. 
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The modern era of genetics started 135 years ago when Gregor Mendel described the 
“limpid” segregation of characters or traits trough generations based on his observations and 
experiments on the garden pea. Today, fi ve “Mendelian” patterns of inheritance are recognized 
in humans, when transmission of the defective gene (although mutations not always localize 
in a gene) is followed in a particular pedigree.
Resembling Mendel whose success describing the modes of gene segregation was 
based on the appropriate selection of the trait to study 1, the success of gene mapping in human 
diseases has been determined by the genetic component underlying the targeted phenotype. 
In that way, genes involved in disorders following a recognizable (Mendelian) pattern of 
inheritance has been fi rstly identifi ed, generating a wave of gene discoveries in the past 20 
years.
  However, fi nding and characterizing families with a suffi cient number of available 
patients distributed through several generations implies a great effort. Moreover, in the case 
of late-onset neurodegenerative disorders such as Parkinson’s (PD) and Alzheimer’s disease 
(AD), the scenario is more complicated: patients from previous generations are usually 
deceased, there is age-related penetrance and an enormous phenotypic complexity. Here the 
fi rst diffi culties emerge, large families powerful enough for linkage studies are diffi cult to 
obtain.
In Chapter 2 and 4 of this thesis, we presented genetic linkage studies in two large 
families of Cuban origin with AD and PD, respectively. In both cases, extensive clinical 
investigations were performed. Both families exhibited a clinical picture compatible with the 
common forms of these disorders; additionally, the segregation of the disease in the families 
suggested an autosomal dominant pattern of inheritance with high penetrance. 
Furthermore, the early onset of dementia in the AD family (59 years, 48-76) 
suggested the involvement of one of the known AD genes, especially PSEN1 or APP. Clinical 
investigation showed progressive deterioration of cognitive functions, and evidence of a 
vascular component in the phenotype, some patients presented transient ischemic cerebral 
attacks, motor defi cits, presence of hypodense regions at brain CT scan examinations, which 
is indicative of vascular lesions, or cerebral amyloid angiopathy at the neuropathological 
examination. Haplotype and linkage results (LOD=3.79) were compatible with PSEN1
involvement (chromosome 14q24.3). Indeed, direct sequence analysis revealed a novel 
missense mutation (a single base substitution that results in an aminoacid change) located 
within exon 6 of the PSEN1 gene. The mutation co-segregated with the identifi ed haplotype 
and was not found in ethnically matched controls. One patient of the family presented late-
onset AD (76 years of age) and did not carry the identifi ed disease-associated haplotype 
suggesting that this patient had dementia due to other causes.
 The second study was performed in a family where several members presented PD, 
with a mean age at onset of 61 years (45-76). The clinical study revealed the presence of not 
only typical PD (10 patients, from whom 6 were alive) but also essential tremor and atypical 
parkinsonism in 3 and 2 patients, respectively. Two more patients presented signs compatible 
with a prodromal clinical phase (possible PD). Evidence suggesting the presence of a novel 
PD locus on chromosome 19 was found. In the 19p13.3-q12 region, a common haplotype was 
identifi ed in 6 out of 7 PD patients. 
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In addition, the patients with atypical parkinsonism or essential tremor were not sharing the 
same haplotype.
 During both studies we encountered problems such as complex phenotypes, wide 
variation in the age at onset, coexistence of phenocopies and diffi culties related to age 
dependant penetrance. How do we solve such complications? 
The clinical diagnosis
For the clinical diagnosis a careful approach is recommended. Close collaboration between 
clinicians and researchers is essential, as well as the cooperation between different clinical 
specialties, that will enable a better assessment of the phenotype of the patients.  Clinical 
follow-up with repeated evaluations of the patients and at risk family members over a longer 
period of time is often the only method to establish a defi nite diagnosis.   To this end, the 
application of modern neuroimaging technologies provides data complementary to the 
clinical evaluation and allows temporal assessment of neuronal changes. Recent advances 
in functional imaging using single photon emission computerized tomography (SPECT) 
and positron emission tomography (PET) as well as structural imaging using magnetic 
resonance imaging (MRI) have provided useful clinical-research tools 2. The recent design 
of radiopharmaceuticals that target the dopamine system in PD 3-5 or amyloid in AD 6, 7, has 
allowed preclinical detection of the diseases as well as monitoring the disease progression. 
One disadvantage is that they are not available in all countries and the costs are usually very 
high, limiting their general application.
For a clinician the ultimate task is to establish the patient’s diagnosis with the 
consequent etiological search and corresponding treatment. However, from the genetic 
perspective the diagnosis has a different meaning that goes beyond the patient extending to the 
family. For a geneticist (who is hunting for genes) a “question mark” on the pedigree drawing 
is always better than an erroneous diagnosis. The consequences of having one patient less in 
the analysis are far preferable than the consequences of a misdiagnosis, which can ruin the 
complete research. 
A conservative approach that consider as affected only the individuals that beyond 
doubt fulfi l the criteria established for the diagnosis is therefore recommended. Individuals 
with unclear or incomplete phenotypes must be considered as “status unknown”. In this way 
one should start the analysis with the narrowest phenotype to ensure the fi nding of the true 
genomic location and subsequently proceed to expand the boundaries of the disease defi nition, 
once a genomic region has been identifi ed. 
As example, we can refer to the fi nding of essential tremor in families with PD, which 
is not an infrequent scenario. Essential tremor (ET) is a nosographic entity characterized by 
postural or action tremor that frequently behaves as an autosomal dominant trait. An increased 
prevalence of ET among fi rst-degree relatives of PD patients has been reported 8, 9, supporting 
a relationship between PD and ET. In a large pedigree (the Iowa kindred) with parkinsonism, 
several family members suffered also from essential tremor. Initially, suggestive linkage to 
chromosome 4p15 (PARK4) was reported, and a common haplotype in PD and ET patients 
was described 10. The cause of parkinsonism in this family was recently identifi ed, a triplication 
of the α-synuclein gene (PARK1, 4q21) with consequent protein over-expression 11. It turned 
out that the essential tremor phenotype is due to a different aetiology. 
In the Cuban family described in Chapter 3, the chromosome 19 haplotype was only 
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segregating with the PD phenotype. The coexistence of related phenotypes in a single family 
is intriguing and is diffi cult to explain on the bases of a monogenic model of inheritance. 
After many years of extensive gene search, only one PD gene (and 3 mutations) acting in an 
autosomal dominant manner has been found (PARK1/α-synuclein) 12, 13. One might wonder 
whether a monogenic model fi ts the familial PD cases with suggestive autosomal dominant 
inheritance or whether a digenic or trigenic inheritance would explain better the phenotypic 
variability observed in most of the PD families.
The recent identifi cation of a novel PD locus, PARK8, in a large Japanese family 14, and 
further independent confi rmation in two families (German-Canadian and western Nebraska) 
with large neuropathological variability15,  and eventually the identifi cation of the PARK8 
gene may help to clarify the issue.
The study design 
Family sampling should be preceded by evaluation of the pedigree and simulation studies 
performed to assess the statistical power of the family under study. In this way, the contribution 
of different patients (depending on the position they have in the pedigree structure) can be 
assessed. Threshold values can be then defi ned according the specifi c family structure and 
the number of available patients. In that way, when a LOD score of 2 is obtained in a family 
where only a small percentage of the replicates exceed such a value, then the result is probably 
corresponding to true linkage even when the value is not strictly signifi cant.  
When large number of families are available, segregation studies may allow us 
to explore the best fi tting genetic model helping to its specifi cation. In the case of a single 
extended pedigree the situation is more complicated and designing a genetic model is often 
based on the single family characteristics and the existing published data (gene frequencies, 
age dependant penetrances, phenocopies). Simulation calculations will also help investigating 
the loss of statistical power due to the specifi cation of a wrong model 16.
Finding genes involved in complex disorders has shown to be complicated and 
diffi cult to accomplish. Several approaches have been applied in AD and PD: (1) linkage-based 
studies that mostly involve a collection of small families with two or more patients, affected 
sib-pairs (ASP) and affected relative pairs (ARP) or multiplex families; (2) association-based 
studies that attempt a candidate gene approach in samples of patients and controls. The 
appropriate selection of both the choice of sample to collect (extended pedigrees, ASP, ARP) 
and the method of analysis is also a crucial step. In addition, the number of subjects included 
in the study and the origin of those individuals (population isolate, admixed population, ethnic 
group) are essential factors. 
Sibling pairs are expected to share 0, 1 or 2 parental haplotypes with a frequency 
of ¼, ½ and ¼, respectively. When ASPs are genotyped, it is expected to identify regions 
where the sharing of alleles exceeds the random probabilities. ARPs are expected to share 
less DNA fragments, according to the position they occupy in the pedigree structure. 
However, a large number of patient pairs  is required to fi nd the disease loci. The existence 
of genetic heterogeneity and the observed clinical variability complicate the task of obtaining 
a homogeneous sample set. Studies aimed to fi nd genetic factors involved in AD 17-20 and PD 
21-23 have identifi ed candidate genomic regions, some of them showing overlap among studies. 
However, methodological problems as multiple testing and poor study design are challenging 
the identifi cation of the already evasive genes (Chapter 1).
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Inaccuracy in genotyping can also generate false results in linkage studies. These types 
of errors can lower or infl ate the LOD scores, mostly introducing false recombinants. Extreme 
care and precision is needed when genotypes are determined. The use of adequate controls 
(samples with known genotypes such as the CEPH controls) and negative controls, in addition 
to the verifi cation of the segregation of alleles through the family, are strongly recommended. 
They allow the detection of incompatibilities and also of rare double recombinants or infrequent 
haplotypes; programs such as PEDCHECK and MERLIN are useful tools, especially when a 
large group of families or extended complex pedigrees are assessed. 
It is not a rare practice in linkage studies to assume equal allele frequencies for 
the marker loci. The explanation is that true allele frequencies are often not available, 
either because of poor characterization of the marker or absence of assessment in a specifi c 
population. However, assuming equal allele frequencies for the marker locus can lead to false 
positive evidence of linkage 24. In the case of large families it is sometimes possible to estimate 
the allele frequencies based on founder individuals. For smaller pedigrees a solution would 
be to test a group of unrelated controls originating form the same population. If actual allele 
frequencies are diffi cult to obtain for all markers used in a genome scan, estimating those 
frequencies for the “positive regions” may help. 
Genetic heterogeneity, variability of the clinical phenotype and the lack of reliable 
disease markers are affecting the success of gene mapping in complex disorders. Strategies 
such as stratifi cation of the sample set based on covariates such as age at onset, exclusion by 
linkage and sequencing analyses of known genes, and study of more homogeneous populations 
have been applied with promising results 25-27.
 In recently founded population isolates, extensive linkage disequilibrium might be 
expected. Using the last approach, we performed a genome-wide search in a genetic isolated 
population in The Netherlands (Chapter 5). Forty-four apparently unrelated patients displayed 
late-onset PD resembling the “sporadic” form of the disease; genealogical research linked 40 
of them to a common ancestor 16 generations ago.
Several STR markers were identifi ed for which one allele showed higher frequency 
in PD cases compared to controls originating from the same population (p<0.01). Some of 
these markers (on chromosomes 9q, 5q, 1p) overlap with regions detected during previous 
genome screenings 22, 25, 28, suggesting that some of them may indeed bear genes infl uencing 
the susceptibility to PD. Specifi cally for the chromosome 9q region, a common haplotype 
was observed in 23% of the patients and only 4% of the controls. In addition, two markers 
were located close to the α-synuclein and tau gene. For each gene  “risk haplotypes” has 
been previously reported as associated with PD 29-31. It will be interesting to elucidate whether 
these risk haplotypes are also present in these PD patients and whether they have a joined 
or independent effect. Fine mapping of the identifi ed regions will enable further haplotype 
analyses and eventually the identifi cation of a genomic region(s) commonly inherited from an 
ancestor bearing a PD susceptibility factor.
Genetic testing: PARK2 and PSEN1
We carried out a multi-centre based study of early-onset PD and developed a novel method for 
gene doses quantifi cation for parkin (PARK2). A multiethnic group of 46 index patients with 
early-onset PD were clinically and genetically characterized. Fifteen different mutations were 
identifi ed, four of which are described for fi st time. 
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The study confi rmed the worldwide distribution of parkin mutations, its high 
frequency among early-onset cases (33%) and the importance of exon dosage assessments that 
represent 28% of the mutations found. We also assessed phenotype-genotype relationships 
and confi rmed the earlier age at onset, symmetric onset, slower disease progression and longer 
disease duration that characterize the “parkin disease”. 
Our results (Chapter 6) confi rm previous reports on parkin mutation frequencies 
in early-onset cases with sporadic (15 to 18%; 21%, this thesis), or familial compatible 
with autosomal recessive inheritance (49%; 53% this thesis) 32, 33. Due to its high frequency 
especially among early-onset cases, testing for parkin mutations can be recommended for the 
diagnosis workup of the early-onset cases and for prognosis evaluation.
An overview of the reported parkin sequence alterations (n=71) is presented in Table 
1. Yet the pathogenicity of several of these changes has not been investigated, making diffi cult 
their interpretation, especially concerning the penetrance of the mutations.
Although the contribution of parkin mutations to PD (overall) seems to be rather 
small (0.4 to 0.7%) 34, only a few studies have conducted sequencing and exon dosage assays 
in late-onset PD cases 35  or in population-based series of patients. In a recent study, parkin
mutations (mainly in heterozygous state), were found in patients with late-onset familial PD 
suggesting that parkin could act as a susceptibility factor for late-onset PD 35.
The contribution of other “early-onset genes” seems to be smaller than parkin 36: initial 
estimates of around 1% for PARK7 (DJ-1) 36, 37 and 15% for PARK6 34 have been reported. 
Since the last is based on linkage reports, the contribution of PARK6 may be actually smaller. 
While genetic testing of PARK7 and PARK6 for research purposes is certainly fruitful, their 
application to the diagnosis workup of PD is expected to be limited. 
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Table 1. Sequence variations reported in the parkin (PARK2) gene. Nucleotides are numbered according to 
GeneBank accession number AB009973 (ATG is at position 102)
Exon
DNA change/
position Type of mutation AA change 
Frequency 
 in controls References 
1 102A>T Missense/Frameshift Met1Leu 0% Rawal et al. 2003 38
2 144A>G Missense Val15Met 0% Munoz et al. 2002 39
2 198C>T Nonsense Arg33Stop  Maruyama et al. 2000 40
2 199G>A Missense Arg33Gln 0% Oliveira et al. 2003 35
41
2 202-203delAG Frameshift/Nonsense Gln34Stop37 0% Abbas et al. 1999 42
2 211C>T Missense Pro37Leu  Kann et al. 2002 43
2 226G>C Missense Arg42Pro 0% Terreni et al. 2001 44
2 Missense/Nonsense Asn52Stop81 0% Abbas et al. 1999 42
2 237G>C Missense Ala46Pro 0% Xu, Liu et al. 2002 45
2 268T>A Missense Val56Glu 0% Hoenicka et al. 2002 46
3 Missense/Nonsense Trp74Stop81 0% Abbas et al. 1999 42
3 336G>T Nonsense Glu79Stop  Foroud et al. 2003 47
3 346C>A  Missense Ala82Glu  Hedrich et al. 2001 48
3 401G>C Polymorphism Gln100His 45% Chen et al. 2003 49
Leu112Stop 0% Farrer et al. 2001 50
3 474C>T Polymorphism His124His 50% Chen et al. 2003 49
4 584A>T Missense Lys161Asn 0% Abbas et al. 1999 42
4 601G>A Polymorphism Ser167Asn 1% Hattori et al. 1998 51
4 620G>A Silent Thr173Thr  Bertoli et al. (this thesis) 
5 636delG Frameshift/Nonsense Gln178/Stop187  Hattori et al. 1998 51
5 675A>G Missense Met192Val  Foroud et al. 2003 47
6 734A>T Missense Lys211Asn 0% Lucking et al. 2000 32
6 733A>G Missense Lys211Arg  Periquet et al. 2001 52
6 Missense Cys212Tyr 0% Pineda et al. 2001 53
6 820C>T Missense Thr240Met 0% Foroud et al. 2003 47
6 820C>G Missense Thr240Arg  Hattori et al. 1998 54
7 859G>A Missense Cys253Tyr 0% Oliveira et al. 2003 35
7 867C>T Missense Arg256Cys 0% Abbas et al. 1999 42
7 884G>A Silent Leu261Leu  Oliveira et al. 2003 35
7 905T>A  Nonsense Cys268Stop  Lucking et al. 2000 32
7 914A>T Polymorphism Arg271Ser 14% Chen et al. 2003 49
7 924C>T Missense Arg275Trp 0% Abbas et al. 1999 42
7 939G>A Missense Asp280Asn 0% Lucking et al. 2000 32
7 951G>C Missense Gly284Arg  Wang et al. 2003 55
7 966T>G Missense Cys289Gly  Lucking et al. 2000 32
7 972delG Frameshift/Nonsense Ala291/Stop297  Munoz et al. 2000 56
2 202 del A Frameshift/Nonsense Gln34Stop43 Nisipeanu et al. 2001 
255del A  
321 -322 insGT 
3 438-477 del(-40bp)  Frameshift/Nonsense
736G>A 
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Exon
DNA change/
position Type of mutation AA change 
Frequency 
 in controls References 
8 1032C>T Nonsense Gln311Stop  Hattori et al. 1998 
9 Frameshift/stop Val324/Stop434  Klein et al. 200057
9 1084G>A Missense Gly328Glu  Lucking et al. 2000 32
9 1101C>T Missense Arg334Cys  Lucking et al. 2000 32
9 1116G>T Polymorphism Ala339Ser 29% Chen et al. 2003 49
9 Frameshift/Nonsense Gln347/Stop368  Lucking et al. 2000 32
9 Frameshift Lys349/Stop368 0% Hedrich et al. 2001 48
9 1152A>C Missense Thr351Pro  Kann et al. 2002 43
10 1197C>T Polymorphism Arg366Trp 4% Wang et al. 1999 58
10 1239G>C Polymorphism Val380Leu 16% Abbas et al. 1999 42
Arg392/Stop394 0% Alvarez et al. 2001 59
11 1281C>A Polymorphism Asp394Asn 7% Abbas et al. 1999 42
11 1293G>A Missense Ala398Thr 0% Periquet et al. 2003 33
11 1305C>T Missense Arg402Cys 0.2% Bertoli et al. (this thesis) 
11 1326G>T Nonsense Glu409Stop  West et al. 2002 60
11 1345C>A Missense Thr415Asn 0% Abbas et al. 1999 42
11 1353T>C Missense Cys418Arg  Bertoli et al. (this thesis) 
11 1385insA Frameshift/Nonsense Asn428/Stop568 0% Rawal et al. 2003 38
12 1390G>A Missense Gly430Asp  Lucking et al. 2000 32
12 1393G>T Missense Cys431Phe 0% Maruyama et al. 2000 40
12 1411C>T Missense Pro437Leu 0% Nichols et al. 2002 61
12 1422T>C Missense Cys441Arg  West et al. 2002 60
12 1436G>A Nonsense Trp445Stop 0% Rawal et al. 2003 38
12 1459G>A Nonsense Trp453Stop 0% Abbas et al. 1999 42
IVS2 Polymorphism - 19% Abbas et al. 1999 42
IVS3 Polymorphism - 10% Abbas et al. 1999 42
IVS3 Polymorphism -  Oliveira et al. 2003 35
IVS5 IVS5+2T>A Splicing Splicing/Stop  West et al. 2002 60
IVS7 IVS7-1G>C Splicing Splicing/Frameshift 0% West et al. 2002 60
IVS7 Polymorphism - 27% Abbas et al. 1999 42
IVS8 IVS8 +35A>G Polymorphism -  Oliveira et al. 2003 35
IVS8 IVS8 -21 to -17del ? ?  Lucking et a. 2000 32
IVS9 IVS9 +4G>T Splicing Splicing 0% Oliveira et al. 2003 35
IVS11 IVS11-3C>G Splicing Splicing/Frameshift 0% Bertoli et al. (this thesis) 
1072 del T 
1142-1143delGA  
1147-1148 delAA  
11 1276-1277 delGA  Frameshift/stop
IVS2+25 T>C 
IVS3-20 C>T 
IVS3-21 T>C 
IVS7-35 A>G 
Table 1 continued
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From the perspective of the families the situation might be different. In Chapter 3, we 
investigated the genetic knowledge and attitudes towards the presymptomatic diagnosis 
of presenile AD in 56 relatives of AD patients from a large Cuban family, in which a 
novel PSEN1 mutation was identifi ed afterwards (Chapter 2).  All participants would use 
presymptomatic testing to know their own risk of developing the disease, a controversial issue 
for diseases where no prevention or effective treatments are available, being their main reason 
to be prepared for the disease. The study showed a clear need for genetic counselling for those 
individuals at high risk of developing the disease. 
The frequency of PSEN1 mutations in presenile AD has been estimated in 5 to 8%, but 
it rises to 18% in the cases with a positive family history (suggestive of autosomal dominant 
inheritance) 62-64. Thus, in familial cases investigating for PSEN1 mutations could be helpful 
for diagnostic considerations. A diffi culty here is that most of the 133 reported mutations  (AD 
mutation database, http://molgen-www.uia.ac.be/admutations/) are restricted to single families 
(“private mutations”). When two or more patients are available, haplotype analysis can help in 
the decision whether to proceed or not with further sequence analysis. 
Concerning other known AD genes, mutations in APP (n=16) and PSEN2 (n=9) 
are very rare, only a limited number of families have been described. However, testing and 
exclusion of the known genes is useful for further genetic research. Remarkably, the majority 
of the AD families do not have mutations in any of the known genes indicating the involvement 
of yet unidentifi ed genes. 
Where to move?
Early disease detection-diagnosis confi rmation: Biomarkers
A major goal for clinical research is to improve the early detection of neurodegenerative 
disorders by developing tools to move diagnosis in the neurodegeneration temporal course 
2. For genetic research, early disease detection will provide means to corroborate clinical 
diagnosis, occasionally before this is actually made, helping researchers in obtaining a large 
and homogeneous group of patients.
Diffi culties concerning the clinical diagnosis are a well-known problem not only 
in clinical practice but for genetic research as well, because clinical phenotypes frequently 
overlap, i.e. clinical distinction is often diffi cult to achieve between AD, Lewy body disease, 
frontotemporal dementia, vascular dementia, and others. The lack of adequate tools or reliable 
biomarkers that facilitate precise disease recognition is largely obstructing the identifi cation 
of genes, whose variants predispose to neurodegenerative disorders. Functional neuroimaging 
is one of the emerging strategies orientated to obtain a better disease evaluation. They might 
offer further phenotype delineation and enable the confi rmation of the clinical observations, 
providing additional power for genetic mapping. 
Quantitative outcomes of disease biomarkers could also be used for quantitative trait 
locus mapping (QTL), a promising approach that is beginning to give insights about complex 
phenotypes.  Due to the high number of susceptibility loci involved in determining complex 
disorders, looking at intermediate endpoint phenotypes might help the identifi cation of some 
of the genes and pathways 65. Finally, QTL mapping in animal models may predict gene 
localization in the human genome 66.
Accurate phenotype defi nition seems more than ever to be a necessary prerequisite to 
establish reliable genotype-phenotype relationships in the study of complex disorders 67.
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Genomic expression profi les 
Genomics, a recently introduced term, is the study not just of genes but also of their functions 
and interactions 68. Gene expression profi ling measures the expression levels of many genes 
at once 69. The combination of gene mapping methods with gene expression assays might 
assist the “gene discovery” in complex disorders. Gene expression data can point towards 
specifi c positional candidates identifi ed by linkage and association analysis, facilitating the 
identifi cation of the causative genes variants. 
Once mutations in a gene are identifi ed as causing a certain disease, investigating the 
genes or proteins involved in the same pathway might identify novel functional candidates. 
Looking back to the genes/proteins already identifi ed for AD, an earlier recognition of the APP 
processing, would probably have led to the easier identifi cation of the presenilins.
Grouping related genes into functional categories increases the explanatory and 
statistical power of gene expression. Furthermore, identifying analogies among biological 
processes in diverse organisms by comparative analysis of gene expression patterns 70 can be 
used to recognize genes that are important in processes such as aging. Genes whose functions 
are conserved among orthologous might be targeted as candidates related to the phenotype 
under study. 
Final remarks
The identifi cation of genes involved in the monogenic forms of PD and AD has orientated the 
research on the pathological pathways. Because of the identifi ed genes are mainly responsible 
for the rare monogenic forms, genetic testing is rarely used as disease predictor, although it can 
be useful as a diagnostic tool and to evaluate prognosis.
The genes involved in the common forms of the diseases are not yet recognized: 
a poorly understood interplay of genes with minor effects and the presence of genetic 
heterogeneity seem to be the main diffi culties.  The causal genes identifi ed until now represent 
the peak of a mountain seen from the distance, as we get closer we start to realize its immense 
magnitude.
126
Chapter 7
References
1. Risch NJ. Searching for genetic determinants in the new millennium. Nature. 2000;405:847-856.
2. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative 
disorders. Science. 2003;302:830-834.
3. Piccini P, Burn DJ, Ceravolo R et al. The role of inheritance in sporadic Parkinson’s disease: evidence from 
a longitudinal study of dopaminergic function in twins. Ann Neurol. 1999;45:577-582.
4. Dekker M, Bonifati V, van Swieten J et al. Clinical features and neuroimaging of PARK7-linked 
parkinsonism. Mov Disord. 2003;18:751-757.
5. Khan NL, Brooks DJ, Pavese N et al. Progression of nigrostriatal dysfunction in a parkin kindred: an 
[18F]dopa PET and clinical study. Brain. 2002;125:2248-2256.
6. Shoghi-Jadid K, Small GW, Agdeppa ED et al. Localization of neurofi brillary tangles and beta-amyloid 
plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24-35.
7. Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh 
Compound-B. Ann Neurol. 2004;55:306-319.
8. Jankovic J, Beach J, Schwartz K, Contant C. Tremor and longevity in relatives of patients with Parkinson’s 
disease, essential tremor, and control subjects. Neurology. 1995;45:645-648.
9. Bonifati V, Fabrizio E, Vanacore N et al. Familial Parkinson’s disease: a clinical genetic analysis. Can J 
Neurol Sci. 1995;22:272-279.
10. Farrer M, Gwinn-Hardy K, Muenter M et al. A chromosome 4p haplotype segregating with Parkinson’s 
disease and postural tremor. Hum Mol Genet. 1999;8:81-85.
11. Singleton AB, Farrer M, Johnson J et al. alpha-Synuclein locus triplication causes Parkinson’s disease. 
Science. 2003;302:841.
12. Polymeropoulos MH, Higgins JJ, Golbe LI et al. Mapping of a gene for Parkinson’s disease to chromosome 
4q21-q23. Science. 1996;274:1197-1199.
13. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identifi ed in families 
with Parkinson’s disease. Science. 1997;276:2045-2047.
14. Funayama M, Hasegawa K, Kowa H et al. A new locus for Parkinson’s disease (PARK8) maps to 
chromosome 12p11.2-q13.1. Ann Neurol. 2002;51:296-301.
15. Zimprich A, Muller-Myhsok B, Farrer M et al. The PARK8 Locus in Autosomal Dominant Parkinsonism: 
Confi rmation of Linkage and Further Delineation of the Disease-Containing Interval. Am J Hum Genet. 
2004;74:11-19.
16. Heutink P, van de Wetering BJ, Pakstis AJ et al. Linkage studies on Gilles de la Tourette syndrome: what 
is the strategy of choice? Am J Hum Genet. 1995;57:465-473.
17. Blacker D, Bertram L, Saunders AJ et al. Results of a high-resolution genome screen of 437 Alzheimer’s 
Disease families. Hum. Mol. Genet. 2003;12:23-32.
18. Pericak-Vance MA, Bass MP, Yamaoka LH et al. Complete genomic screen in late-onset familial 
Alzheimer disease. Evidence for a new locus on chromosome 12. Jama. 1997;278:1237-1241.
19. Kehoe P, Wavrant-De Vrieze F, Crook R et al. A full genome scan for late onset Alzheimer’s disease. Hum 
Mol Genet. 1999;8:237-245.
20. Myers A, Wavrant De-Vrieze F, Holmans P et al. Full genome screen for Alzheimer disease: stage II 
analysis. Am J Med Genet. 2002;114:235-244.
21. Pankratz N, Nichols WC, Uniacke SK et al. Signifi cant linkage of Parkinson disease to chromosome 2q36-
37. Am J Hum Genet. 2003;72:1053-1057.
22. DeStefano AL, Golbe LI, Mark MH et al. Genome-wide scan for Parkinson’s disease: the GenePD Study. 
Neurology. 2001;57:1124-1126.
23. Scott WK, Nance MA, Watts RL et al. Complete genomic screen in Parkinson disease: evidence for 
multiple genes. Jama. 2001;286:2239-2244.
24. Ott J. Strategies for characterizing highly polymorphic markers in human gene mapping. Am J Hum Genet. 
1992;51:283-290.
25. Hicks AA, Petursson H, Jonsson T et al. A susceptibility gene for late-onset idiopathic Parkinson’s disease. 
Ann Neurol. 2002;52:549-555.
26. Olson JM, Goddard KA, Dudek DM. A second locus for very-late-onset Alzheimer disease: a genome scan 
reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am J Hum 
Genet. 2002;71:154-161.
127
General discussion
27. Pankratz N, Nichols WC, Uniacke SK et al. Genome Screen to Identify Susceptibility Genes for Parkinson 
Disease in a Sample without parkin Mutations. Am J Hum Genet. 2002;71:124-135.
28. DeStefano AL, Lew MF, Golbe LI et al. PARK3 infl uences age at onset in Parkinson disease: a genome 
scan in the GenePD study. Am J Hum Genet. 2002;70:1089-1095.
29. Farrer M, Maraganore DM, Lockhart P et al. alpha-Synuclein gene haplotypes are associated with 
Parkinson’s disease. Hum Mol Genet. 2001;10:1847-1851.
30. Chiba-Falek O, Touchman JW, Nussbaum RL. Functional analysis of intra-allelic variation at NACP-Rep1 
in the alpha-synuclein gene. Hum Genet. 2003;113:426-431.
31. Maraganore DM, Hernandez DG, Singleton AB et al. Case-Control study of the extended tau gene 
haplotype in Parkinson’s disease. Ann Neurol. 2001;50:658-661.
32. Lucking CB, Durr A, Bonifati V et al. Association between Early-Onset Parkinson’s Disease and Mutations 
in the Parkin Gene. N Engl J Med. 2000;342:1560-1567.
33. Periquet M, Latouche M, Lohmann E et al. Parkin mutations are frequent in patients with isolated early-
onset parkinsonism. Brain. 2003;126:1271-1278.
34. Dekker MC, Bonifati V, van Duijn CM. Parkinson’s disease: piecing together a genetic jigsaw. Brain. 
2003;126:1722-1733.
35. Oliveira SA, Scott WK, Martin ER et al. Parkin mutations and susceptibility alleles in late-onset 
Parkinson’s disease. Ann Neurol. 2003;53:624-629.
36. Hedrich K, Djarmati A, Schafer N et al. DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) 
mutations in early-onset Parkinson disease. Neurology. 2004;62:389-394.
37. Abou-Sleiman PM, Healy DG, Quinn N et al. The role of pathogenic DJ-1 mutations in Parkinson’s 
disease. Ann Neurol. 2003;54:283-286.
38. Rawal N, Periquet M, Lohmann E et al. New parkin mutations and atypical phenotypes in families with 
autosomal recessive parkinsonism. Neurology. 2003;60:1378-1381.
39. Munoz E, Tolosa E, Pastor P et al. Relative high frequency of the c.255delA parkin gene mutation in 
Spanish patients with autosomal recessive parkinsonism. J Neurol Neurosurg Psychiatry. 2002;73:582-
584.
40. Maruyama M, Ikeuchi T, Saito M et al. Novel mutations, pseudo-dominant inheritance, and possible 
familial affects in patients with autosomal recessive juvenile parkinsonism. Ann Neurol. 2000;48:245-
250.
41. Nisipeanu P, Inzelberg R, Abo Mouch S et al. Parkin gene causing benign autosomal recessive juvenile 
parkinsonism. Neurology. 2001;56:1573-1575.
42. Abbas N, Lucking C, Ricard S et al. A wide variety of mutations in the parkin gene are responsible for 
autosomal recessive parkinsonism in Europe. French Parkinson’s Disease Genetics Study Group and the 
European Consortium on Genetic Susceptibility in Parkinson’s Disease. Hum. Mol. Genet. 1999;8:567-
574.
43. Kann M, Jacobs H, Mohrmann K et al. Role of parkin mutations in 111 community-based patients with 
early-onset parkinsonism. Ann Neurol. 2002;51:621-625.
44. Terreni L, Calabrese E, Calella AM et al. New mutation (R42P) of the parkin gene in the ubiquitinlike 
domain associated with parkinsonism. Neurology. 2001;56:463-466.
45. Xu Y, Liu Z, Wang Y et al. [A new point mutation on exon 2 of parkin gene in Parkinson’s disease]. 
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2002;19:409-411.
46. Hoenicka J, Vidal L, Morales B et al. Molecular fi ndings in familial Parkinson disease in Spain. Arch 
Neurol. 2002;59:966-970.
47. Foroud T, Uniacke SK, Liu L et al. Heterozygosity for a mutation in the parkin gene leads to later onset 
Parkinson disease. Neurology. 2003;60:796-801.
48. Hedrich K, Kann M, Lanthaler AJ et al. The importance of gene dosage studies: mutational analysis of the 
parkin gene in early-onset parkinsonism. Hum Mol Genet. 2001;10:1649-1656.
49. Chen R, Gosavi NS, Langston JW, Chan P. Parkin mutations are rare in patients with young-onset 
parkinsonism in a US population. Parkinsonism Relat Disord. 2003;9:309-312.
50. Farrer M, Chan P, Chen R et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann 
Neurol. 2001;50:293-300.
51. Hattori N, Kitada T, Matsumine H et al. Molecular genetic analysis of a novel Parkin gene in Japanese 
families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in 
the Parkin gene in affected individuals. Ann Neurol. 1998;44:935-941.
128
Chapter 7
52. Periquet M, Lucking C, Vaughan J et al. Origin of the mutations in the parkin gene in Europe: exon 
rearrangements are independent recurrent events, whereas point mutations may result from Founder 
effects. Am J Hum Genet. 2001;68:617-626.
53. Pineda N, Carvajal LG, Buritica O et al. A novel Cys212Tyr founder mutation in parkin and allelic 
heterogeneity of juvenile Parkinsonism in a population from North West Colombia. Neurosci Lett. 
2001;298:87-90.
54. Hattori N, Matsumine H, Asakawa S et al. Point mutations (Thr240Arg and Gln311Stop) [correction of 
Thr240Arg and Ala311Stop] in the Parkin gene. Biochem Biophys Res Commun. 1998;249:754-758.
55. Wang T, Liang Z, Sun S et al. Point mutation in the parkin gene on patients with Parkinson’s disease. J 
Huazhong Univ Sci Technolog Med Sci. 2003;23:145-147.
56. Munoz E, Pastor P, Marti MJ et al. A new mutation in the parkin gene in a patient with atypical autosomal 
recessive juvenile parkinsonism. Neurosci Lett. 2000;289:66-68.
57. Klein C, Pramstaller PP, Kis B et al. Parkin deletions in a family with adult-onset, tremor-dominant 
parkinsonism: expanding the phenotype. Ann Neurol. 2000;48:65-71.
58. Wang M, Hattori N, Matsumine H et al. Polymorphism in the parkin gene in sporadic Parkinson’s disease. 
Ann Neurol. 1999;45:655-658.
59. Alvarez V, Guisasola LM, Moreira VG et al. Early-onset Parkinson’s disease associated with a new parkin 
mutation in a Spanish family. Neurosci Lett. 2001;313:108-110.
60. West A, Periquet M, Lincoln S et al. Complex relationship between Parkin mutations and Parkinson 
disease. Am J Med Genet. 2002;114:584-591.
61. Nichols WC, Pankratz N, Uniacke SK et al. Linkage stratifi cation and mutation analysis at the Parkin locus 
identifi es mutation positive Parkinson’s disease families. J Med Genet. 2002;39:489-492.
62. Cruts M, van Duijn CM, Backhovens H et al. Estimation of the genetic contribution of presenilin-1 and -2 
mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet. 1998;7:43-51.
63. Finckh U, Muller-Thomsen T, Mann U et al. High prevalence of pathogenic mutations in patients with early-
onset dementia detected by sequence analyses of four different genes. Am J Hum Genet. 2000;66:110-117.
64. Arango D, Cruts M, Torres O et al. Systematic genetic study of Alzheimer disease in Latin America: 
mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia. Am J Med 
Genet. 2001;103:138-143.
65. Wright AF, Carothers AD, Pirastu M. Population choice in mapping genes for complex diseases. Nat 
Genet. 1999;23:397-404.
66. Korstanje R, Paigen B. From QTL to gene: the harvest begins. Nat Genet. 2002;31:235-236
67. Funalot B, Varenne O, Mas JL. A call for accurate phenotype defi nition in the study of complex disorders. 
Nat Genet. 2004;36:3; author reply 3-4.
68. Guttmacher AE, Collins FS. Genomic medicine--a primer. N Engl J Med. 2002;347:1512-1520.
69. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nat 
Genet. 1999;21:20-24.
70. McCarroll SA, Murphy CT, Zou S et al. Comparing genomic expression patterns across species identifi es 
shared transcriptional profi le in aging. Nat Genet. 2004;36:197-204.
Summary
Samenvatting
Resumen

131
Summary
In Chapter 1, the genetic aspects of Alzheimer’s and Parkinson’s disease are reviewed. The 
efforts and progress made in the mapping of genes involved in the genetic forms of Alzheimer’s 
and Parkinson’s disease and the ways in which “gene hunting” strategies have evolved are 
described. The signifi cance of the identifi cation of genes such as the presenilins (PSEN1 and
2), α-synuclein (PARK1), parkin (PARK2) and DJ-1 (PARK7) are discussed.  In addition, 
possible links between these two neurodegenerative disorders are reviewed. The clinical, 
pathological and genetic presentation of Alzheimer’s and Parkinson’s disease suggests the 
involvement of limited number of overlapping, interrelated pathways. Their features point to 
a spectrum of neurodegeneration (tauopathies, synucleinopathies, amyloidopathies) that will 
need further intense investigation to fi nd the missing links. 
The fi rst part of the experimental work described in this thesis concerns family 
studies on Alzheimer’s disease. In Chapter 2, the study of a Cuban family with autosomal 
dominant presenile dementia consisting of 281 members within six generations is described. 
Neuropathological studies confi rmed the clinical diagnosis of Alzheimer’s disease. Moreover, 
a signifi cant LOD score was obtained for marker D14S43, located in a 9 cM interval in which 
all patients shared the same haplotype. Sequencing of the PSEN1 gene revealed a novel 
heterozygous base substitution (C520A) that is predicted to cause an amino acid change 
from Leucine to Methionine in the transmembrane domain III of the presenilin 1 protein. The 
C520A change was not found in ethnically matched controls. The Leucine at position 174 of 
the presenilin 1 protein is highly conserved among different species and homologous proteins 
suggesting that it is important for the normal protein function. This is the fi rst genetic study on 
Alzheimer’s disease that identifi ed the involvement of the PSEN1 gene in Cuba. 
Yet genetic testing in Alzheimer’s disease remains controversial. In Chapter 3, the 
clinical and genetic knowledge about Alzheimer’s disease and attitudes toward the possible 
use of presymptomatic genetic testing in the previously described family are explored. 
Fifty-six fi rst-degree relatives of familial cases with Alzheimer’s disease were interviewed. 
The individuals had only limited knowledge about their personal risk of developing the 
disorder. All 56 family members would use presymptomatic testing to know their own risk 
of Alzheimer’s disease. Confronted with a hypothetical reproductive choice, 50% would 
choose not to have children if they themselves had the mutation. The decision to undergo 
genetic testing for diseases such as early-onset Alzheimer’s disease, where no cure or adequate 
treatment is available, is very complex. The present study suggests a need for education and 
genetic counselling of family members at high risk of the disease. 
The second part of the thesis is focused on Parkinson’s disease. In Chapter 4, a large 
Cuban family with typical, late-onset Parkinson’s disease and autosomal dominant inheritance 
is studied. The mean age at onset was 61.2 years (±12.53, 45-76). Other phenotypes such 
as essential tremor and atypical parkinsonism were observed in the family. We performed a 
genome-wide scan and linkage analyses. Multipoint analyses yielded a maximum LOD of 
2.26 between markers D19S221 and D19S840. Furthermore, haplotype analysis showed a 
region on chromosome 19 shared by six out of seven patients with Parkinson’s disease. The 
essential tremor phenotype and the atypical parkinsonism do not segregate with this haplotype, 
suggesting a different aetiology. These fi ndings suggest the presence of a novel locus for 
Parkinson’s disease on chromosome 19p13.3-q12. 
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 Chapter 5 focused on a population-based approach. The study of genetically 
isolated populations, which are thought to be more genetically homogeneous than the general 
population, has proven to be a successful strategy for disease gene mapping, including the 
monogenic variants of complex disorders such as Parkinson’s disease. In order to identify 
genomic regions containing genes that infl uence the susceptibility to the disease, 44 patients 
from an isolated community in the Netherlands with the diagnosis of idiopathic Parkinson’s 
disease were studied. Forty patients could be connected to a common ancestor. 
We performed a genome wide scan and single-marker association analysis. Four 
markers showed evidence of association (p 0.01): D2S2333, D4S405, D9S158, D13S153. 
Furthermore, for D9S158 (p=0.006) a neighbouring marker, D9S290, also showed evidence 
of association. A common haplotype was observed in this 9q region for 10 patients (23%), 
and only one control individual (4%). This region overlaps with a previously identifi ed 
interval that showed evidence of linkage with Parkinson’s disease. In addition, marker 
D2S2333 (p=0.009) maps to the same location of a PD locus, PARK3, implicated in disease 
susceptibility and age at onset. The results of the study of this genetic isolate are consistent 
with previous studies suggesting the presence of genes contributing to Parkinson’s disease 
susceptibility on chromosomes 2p and 9q. Further investigation of the identifi ed regions will 
allow the confi rmation and refi nement of these candidate PD loci.
In Chapter 6, a large, multiethnic series of patients with early-onset Parkinson’s 
disease were studied in order to assess the frequency and nature of parkin gene mutations, 
and to investigate phenotype-genotype relationships. Forty-six probands with early-onset 
Parkinson’s disease and 14 affected relatives were ascertained from Italy, Brazil, Cuba, and 
Turkey. The genetic screening included direct sequencing and exon dosage analyses using a 
new real-time PCR method. Mutations were found in 33% of the index patients overall, and 
in 53% of those with family history compatible with autosomal recessive inheritance. Fifteen 
parkin alterations were identifi ed, including 10 exon deletions and fi ve point mutations. 
Four of the mutations are novel: Arg402Cys, Cys418Arg, IVS11-3C>G, and exon 8-9-10 
deletion. Heterozygous genomic rearrangements represented 28% of the mutations found, 
confi rming the importance of exon dosage analyses when screening parkin. The patients with 
parkin mutations showed signifi cantly earlier onset, longer disease duration, slower disease 
progression and more frequent symmetric onset than the patients without mutations. This 
study confi rms the frequent involvement of parkin and indicates the importance of genetic 
testing in the diagnostic work up of the early-onset forms of Parkinson’s disease. The novel, 
cost-effective exon dosage method developed here can also be applied to the study of other 
genes.
Finally, in Chapter 7, the different methodologies and associated pitfalls that 
are encountered in the search for genes involved in neurodegenerative disorders such as 
Alzheimer’s and Parkinson’s disease are discussed.
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In Hoofdstuk 1 (Introduction) wordt een overzicht gegeven van de genetische aspecten 
van de ziekte van Alzheimer en de ziekte van Parkinson. We beschrijven de pogingen tot 
en de vorderingen van het in kaart brengen van genen die betrokken zijn bij de ziekte van 
Alzheimer en de ziekte van Parkinson. In dit overzicht beschrijven we op welke manier 
“de jacht op genen” zich gedurende de laatste jaren heeft ontwikkeld en  de relevantie van 
de genen die gevonden zijn, zoals presenilins, Į-synuclein, parkin en DJ-1. Bovendien 
bespreken we hier ook de mogelijke relatie tussen de twee neurodegeneratieve aandoeningen. 
De klinische, pathologische en genetische presentatie van de ziekte van Alzheimer en de 
ziekte van Parkinson suggereert mede de aanwezigheid van een aantal elkaar overlappende 
en gerelateerde oorzaken. De kenmerken van deze ziekten wijzen op een spectrum van 
neurodegeneratieve aandoeningen (tauopathieën, synucleinopathieën, amyloidopathieën), 
waarvoor verder intensief onderzoek noodzakelijk is om gemeenschappelijke oorzaken te 
kunnen vinden.
Het eerste deel van het experimentele werk uit dit proefschrift heeft betrekking 
op de ziekte van Alzheimer. Hoofdstuk 2 beschrijft de studie van een Cubaanse familie, 
bestaande uit 281 leden uit zes generaties, met autosomaal dominante preseniele dementie. 
Neuropathologische studies bevestigden de klinische diagnose van de ziekte van Alzheimer. 
Bovendien werd een signifi cante LOD score verkregen voor marker D14S43, welke is 
gelokaliseerd in een 9 cM interval, waar bij alle patiënten hetzelfde haplotype werd gevonden. 
Het analyseren van het PSEN1 gen liet een nieuwe heterozygote base substitutie zien die een 
aminozuur verandering tot gevolg heeft, waarbij in het TMIII van het presenilin 1 eiwit Leucine 
wordt vervangen door Methionine. Wij denken dat de nieuwe mutatie L174M zal leiden tot 
een abnormale N-terminus en waarschijnlijk ook tot abnormale C-terminal fragmenten en tot 
het slecht functioneren van het eiwitcomplex. Dit is de eerste genetische studie naar de ziekte 
van Alzheimer in Cuba, waarbij kan worden aangetoond dat het PSEN1 gen betrokken is. 
In Hoofdstuk 3 onderzochten we de klinische en genetische kennis met betrekking 
tot de ziekte van Alzheimer en de standpunten ten opzichte van de mogelijkheid van het 
presymptomatisch genetisch testen van de ziekte in de hierboven beschreven familie. We 
interviewden 56 eerstegraads bloedverwanten van familiaire gevallen met de ziekte van 
Alzheimer, waarbij bleek dat de individuen een beperkte kennis hadden over hun eigen risico 
voor het ontwikkelen van de ziekte van Alzheimer. Alle 56 personen gaven aan dat zij gebruik 
zouden maken van de mogelijkheid van presymptomatisch testen om te weten te komen wat 
hun eigen risico is op het krijgen van de ziekte van Alzheimer. Wanneer ze geconfronteerd 
worden met de hypothetische keuze van reproductie, zou 50% van deze groep ervoor kiezen 
geen kinderen te krijgen in het geval ze zelf de mutatie zouden hebben. Het presymptomatisch 
genetisch testen bij de ziekte van Alzheimer blijft echter controversieel. 
Het tweede deel van het proefschrift betreft de ziekte van Parkinson. In Hoofdstuk
4 wordt het onderzoek beschreven binnen een grote Cubaanse familie met de typische 
laatbeginnende vorm van de ziekte van Parkinson en autosomaal dominante overerving. 
De gemiddelde leeftijd waarop de ziekte begon was 61.2 jaar (± 12.53, 45-76). Verder 
werden binnen de familie nog andere phenotypes gezien, zoals essentiële tremor en atypisch 
parkinsonisme. We verrichtten een scan van het genoom en koppelingsonderzoek. Analyse 
van verschillende locaties liet een maximum LOD score zien van 2.26 tussen de markers 
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D19S221 en D19S840. Verder zagen we bij haplotype-analyse een gebied op chromosoom 19 
dat bij zes van de zeven Parkinson patiënten overeenkomt. De essentiële tremor en de atypisch 
parkinsonisme phenotypes komen niet overeen met dit haplotype, hetgeen suggereert dat 
hieraan een andere etiologie ten grondslag ligt. Onze bevindingen suggereren de aanwezigheid 
van een nieuw locus voor de ziekte van Parkinson op chromosoom 19p13.3-q12. Wij 
veronderstellen dat een oligogenetisch model met een gematigde betrokkenheid van twee of 
drie genen, in plaats van een “puur” monogenetisch model, de oorzaak zou kunnen zijn van het 
grote verschil van leeftijd waarop de ziekte zich manifesteert,  het gereduceerd voorkomen en 
de phenotypische gevarieerdheid in de Parkinson families.
Hoofdstuk 5 is gericht op populatieonderzoek. Uit de studie van genetisch geïsoleerde 
populaties, waarvan wordt gedacht dat ze genetisch meer homogeen zijn dan de gemiddelde 
populatie, is gebleken dat dit een succesvolle strategie is voor het in kaart brengen van 
genen welke betrokken zijn bij ziekten, inclusief de monogenetische varianten of complexe 
aandoeningen zoals de ziekte van Parkinson. Om het genomisch gebied te identifi ceren 
waarbinnen zich genen bevinden die de aanleg voor de ziekte van Parkinson beïnvloeden, 
bestudeerden we 44 patiënten met de  idiopathische vorm van de ziekte van Parkinson, 
waarvan 40 patiënten konden worden teruggekoppeld naar een gezamenlijke voorouder uit een 
geïsoleerde populatie in Nederland. We verrichtten een scan van het genoom en single-marker 
associatie analyse. Bij vier markers werd bewijs gevonden voor associatie (p  0.01): D2S2333, 
D4S405, D9S158, D13S153. Verder was D9S290, (p=0.006) een nabijgelegen marker van 
D9S158, ook geassocieerd. Bovendien werd bij 10 patiënten (23%) een gemeenschappelijk 
haplotype gezien in dit 9q gebied die maar bij 1 controlepersoon (4%) voorkwam. De overlap 
van deze regio met een eerder geïdentifi ceerd gebied laat bewijs zien van koppeling met de 
ziekte van Parkinson. Tevens bevindt marker D2S2333 zich op dezelfde locatie als een tot 
nu toe niet geïdentifi ceerd gen, PARK3, dat wordt geassocieerd met de aanleg voor de ziekte 
van Parkinson en de leeftijd waarop de ziekte zich manifesteert, hetgeen suggereert dat zich 
in deze gebieden genen bevinden die bijdragen aan de aanleg voor de ziekte van Parkinson. 
Nader onderzoek van de ontdekte gebieden met andere, dicht bij elkaar gelegen markers zal 
het mogelijk maken de bevindingen te bevestigen en de genomische gebieden te verfi jnen.
Hoofdstuk 6 presenteert een grote groep multi-ethnische patiënten met de 
vroegbeginnende vorm van de ziekte van Parkinson  die werden bestudeerd om vast stellen 
wat de frequentie en de aard van parkin-gen mutaties zijn.  Tevens werd de phenotype-
genotype relatie bestudeerd. Hierbij werden 46 patiënten met de vroegbeginnende vorm 
van de ziekte van Parkinson en 14 aangedane verwanten uit Italië, Brazilië, Cuba en Turkije 
onderzocht. De genetische screening bestond uit een directe volgordebepaling en uit een exon-
dosage bepaling, waarbij gebruik werd gemaakt van een real-time PCR methode. Globaal 
werden in 33% van de indexpatiënten mutaties gevonden, en in 53% van de personen met een 
familiegeschiedenis overeenkomend met een autosomaal recessieve overerving. We hebben 
15 parkin veranderingen geïdentifi ceerd, inclusief 10 exon deleties en 5 puntmutaties. Vier van 
deze mutaties zijn nieuw: Arg402Cys, Cys418Arg, IVS11-3C>G, en de exon 8-9-10 deletie. 
Van de gevonden mutaties bestaat 28% uit  heterozygote exon deleties, waarbij het belang van 
exon-dosage bij het screenen van het parkin-gen wordt bevestigd. 
Bij patiënten met parkin-gen mutaties werd een aanzienlijk vroegere aanvang van 
de ziekte van Parkinson gezien met een langere duur van de aandoening, een meer frequente 
symmetrische aanvang, en een langzamere progressie van de ziekte dan van de patiënten 
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zonder de mutatie. Deze studie bevestigt het frequente voorkomen van mutaties in het parkin-
gen en laat het belang zien van genetisch testen bij de diagnostiek van de vroegbeginnende 
vorm van de ziekte van Parkinson. De nieuwe kostenbesparende exon-dosage methode die hier 
is ontwikkeld kan ook worden toegepast bij het onderzoek naar andere genen.
Tenslotte, in Hoofdstuk 7 (General discussion), bediscussiëren we verschillende 
methoden en valkuilen die zowel wij, als andere onderzoekers tegen zijn gekomen bij het 
zoeken naar genen betrokken bij neurodegeneratieve aandoeningen zoals de ziekten van 
Alzheimer en Parkinson. 

137
Resumen
En el capítulo 1, dedicado a la introducción, se presenta una revisión completa de los aspectos 
genéticos conocidos en la enfermedad de Alzheimer y en la enfermedad de Parkinson. 
También se describen desde una perspectiva histórica los esfuerzos y progresos alcanzados en 
el mapeo y búsqueda de genes implicados en las formas hereditarias de estas dos enfermedades 
neurodegenerativas y como las estrategias y métodos usados han evolucionado en la última 
década, así como el signifi cado del hallazgo de genes como las presenilins (PSEN1 y PSEN2),
alfa-sinuclein (PARK1), parkin (PARK2) y DJ-1 (PARK7).  La presentación clínica, genética 
y patológica de estas enfermedades sugiere la intervención de mecanismos comunes o 
interrelacionados, sin embargo queda aún mucho por investigar para encontrar la manera y los 
mecanismos por los cuales estas enfermedades estan relacionadas.
La primera parte del trabajo experimental de esta tesis está dedicada a estudios 
familiares en la enfermedad de Alzheimer. En el capítulo 2 se describe el estudio de una extensa 
familia cubana (281 miembros en 6 generaciones) con demencia presenil y una herencia 
autosómica dominante. El estudio anatomopatológico en un paciente permitió confi rmar el 
diagnóstico clínico de enfermedad de Alzheimer. A través del análisis de ligamiento genético 
se obtuvieron resultados signifi cativos en la región genómica correspondiente al gen presenilin 
1, y la posterior secuenciación de este gen llevó a la identifi cación de una nueva mutación, 
localizada en el exon 6. Esta mutación tiene como consecuencia un cambio de aminoácido 
(Leucina por Metionina) en la secuencia de la proteína. Como resultado los fragmentos N-
terminal y C-terminal de la proteína podrían estar alterados y esto determinaría una función 
defectuosa del complejo proteínico. Por primera vez mutaciones en este gen son identifi cadas 
en pacientes cubanos.
En el capítulo 3 se presentan los resultados de una investigación que evaluó los 
conocimientos  y actitudes de los familiares de pacientes con enfermedad de Alzheimer hacia 
el diagnóstico presintomático de la enfermedad. En total se entrevistaron 56 miembros de la 
familia estudiada en el capítulo anterior. En general todas las personas entrevistadas tenían un 
conocimiento limitado sobre su riesgo personal de desarrollar enfermedad de Alzheimer. A la 
vez, todos los participantes en el estudio aceptaban realizar los estudios genéticos, una vez que 
estuvieran disponibles, orientados a obtener un diagnóstico presintomático. 
La segunda parte de esta tesis está dedicada a la enfermedad de Parkinson. En el 
capítulo 4 se describe el estudio de una extensa familia cubana, con enfermedad de Parkinson 
y herencia autosómica dominante. El promedio de edad de comienzo de la enfermedad en 
la familia fue similar al de la forma “idiopática” de esta patología (61 años). La completa 
caracterización clínica de pacientes y familiares permitió hacer el diagnóstico de temblor 
esencial y parkinsonismo atípico en otros miembros de esta familia. Con el objetivo de 
localizar la alteración genética responsable de la enfermedad de Parkinson, se realizó una 
búsqueda genómica completa y análisis de ligamiento genético. Con el análisis de  ligamiento 
de múltiples puntos se obtuvo un resultado de LOD máximo de 2.26, entre los marcadores 
D19S221 y D19S840. Además el análisis de haplotipos permitió detectar un haplotipo 
común en el cromosoma 19 que estaba presente en 6 de  los 7 pacientes con enfermedad de 
Parkinson. A su vez este haplotipo no se encontró en los pacientes con tremblor esencial o 
con parkinsonismo atípico o en personas no afectadas. Estos hallazgos sugieren la presencia 
de un nuevo locus para enfermedad de Parkinson en el cromosoma 19p13.3-q12. Un modelo 
oligogénico con moderada contribución de dos o tres genes podría explicar mejor la gran 
variación en edades de comienzo, penetrancia reducida y variabilidad fenotípica observada en 
familias afectadas por la enfermedad de Parkinson.
138
Resumen
El capítulo 5 está basado en estudios poblacionales. El estudio de poblaciones 
aisladas genéticamente, las cuales se consideran más homogéneas que la población general, 
ha demostrado ser  una estrategia exitosa en el mapeo de genes, incluyendo las variantes 
monogénicas de enfermedades complejas como la enfermedad de Parkinson. Con el objetivo 
de identifi car regiones genómicas que contengan genes implicados en la etiología de la 
enfermedad de Parkinson, se estudiaron 44 pacientes que padecían esta enfermedad. La 
mayoría de estos pacientes (n=40) pudieron ser conectados a un ancestro común con origen 
en esta comunidad aislada, localizada en el sur de Holanda. Se hizo una búsqueda genómica 
completa y análisis de asociación con cada marcador. Para 4 marcadores se obtuvieron 
evidencias de asociación (p 0.01): D2S2333, D4S405, D9S158, D13S153. Además para 
D9S158 (p=0.006), otro marcador (D9S290) localizado muy cercano en el cromosoma, se 
encontró también asociado (p=0.006). En esta región del cromosoma 9q se identifi có un 
haplotipo común en 10 de los pacientes (23%) y el mismo haplotipo sólo se encontró en un 
control (4%). Además, el marcador D2S2333 (p=0.009), está situado muy cerca del locus 
PARK3, el cual ha sido relacionado con una mayor susceptibilidad y con la edad de comienzo 
de la enfermedad. Estos hallazgos indican que posiblemente genes localizados en esta región 
genómica determinan una mayor susceptibilidad a la enfermedad de Parkinson.
El capítulo 6 presenta una extensa serie de pacientes con enfermedad de Parkinson 
de comienzo temprano, que fueron estudiados clínica y genéticamente con el objetivo 
de determinar la frecuencia de mutaciones en el gen de parkin y para investigar posibles 
correlaciones fenotipo-genotipo. Se estudiaron 46 casos índices con edad de comienzo menor 
de 45 años, y 14 familiares de primer grado afectados; los pacientes provenían de diferentes 
países: Italia, Brasil, Cuba y Turquía. Los estudios genéticos incluyeron secuenciación 
directa del gen (parkin) y estudios de dosis de exones para lo cual se utilizó un nuevo método 
desarrollado durante esta investigación. En 33% de los pacientes en general y en 53% de los 
casos con historia familiar positiva se detectaron mutaciones en el gen de parkin. En total 
se encontraron 15 alteraciones diferentes en el gen, incluyendo 10 deleciones de exones y 5 
mutaciones puntuales.  Cuatro de las mutaciones se describen por primera vez en este trabajo, 
ellas son: Arg402Cys, Cys418Arg, IVS11-3C>G y la deleción consecutiva de los exones 8-
9-10. Las alteraciones heterocigotas de exones representaron el 28% de todas las alteraciones 
génicas encontradas, confi rmando la importancia de realizar estudios de dosis de exones 
además de la secuenciación directa del gen. 
Los pacientes con mutaciones en este gen mostraron de forma signifi cativa un 
comienzo más temprano de la enfermedad, el cual ocurrió más frecuentemente de forma 
simétrica, un curso clínico más prolongado, y  progresión lenta de la enfermedad comparado 
con los pacientes sin mutaciones en el gen parkin. El presente estudio confi rma hallazgos 
anteriores con respecto a la relación fenotipo-genotipo, y a la alta frecuencia de mutaciones en 
parkin, indicando la importancia de los estudios genéticos en el diagnóstico de la enfermedad 
de Parkinson de comienzo temprano. El método para determinación de dosis de exones 
desarrollado durante esta investigación puede ser aplicado al estudio de otros genes como 
alfa-sinuclein y DJ-1.
Finalmente, en el capítulo 7 dedidado a la discusión general, se consideran las 
diferentes metodologías aplicadas y problemas encontrados durante la búsqueda de genes 
implicados en la etiología de enfermedades neurodegenerativas como la enfermedad de 
Alzheimer y la enfermedad de Parkinson. 
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Nuestra hija mayor
Por Gilberto B. de Bertoli de Armas y Aida V. Avella Iglesias
10 de marzo de 1965. Recibimos este dia, llenos de alegría, a la primera de nuestras 3 hijas, a 
la que pusimos el nombre de su mamá y su abuela paterna: Aida María. 
Su primera infancia la recordamos como una niña alegre y muy saludable, de un notable 
desarrollo y viveza. Cuando tenía alrededor de 3 años, paseando un día cerca de un prado 
donde pastaba una vaca y con intención de enseñarle que no debía temer a los animales, 
nos acercamos a ella e intenté pasarle la mano por el lomo, en ese momento la vaca hizo un 
movimiento brusco de la cabeza y muuuu!!, yo di un pequeño salto hacia atrás, mi hija se 
quedó mirándome y admirada me dijo: “pipo, tú también le tienes miedo a la vaca”.
Disfrutaba mucho los juegos, sobre todo al aire libre. A los 5 años le regalamos su primera 
bicicleta que fue para ella muy especial. Su incorporación a la escuela primaria fue fácil, 
aprendía rápidamente, despertando la estimación y admiración de sus profesores. En esta 
época de su vida nos impresionaban sus cuidados con sus materiales escolares, la limpieza 
y pulcritud con sus libros y su vestuario, nos llamaba la atención que su uniforme escolar se 
mantenía limpio mucho tiempo, el orden y cuidado para con sus juguetes y libros de cuentos. 
Era apasionada de la literatura infantil adquiriendo desde esta temprana edad hábitos y 
habilidades que nos asombran, con sus hermanas organizó una biblioteca usando códigos y 
etiquetas con los que marcaba cada libro.
Terminó la escuela primaria con magnífi cos resultados e hizo la enseñanza secundaria y 
preuniversitaria en un internado especial para estudiantes destacados, por primera vez dejó 
nuestra casa y solo ella sabe lo que le costó adaptarse. Un día con los ojos llenos de lágrimas 
nos dijo “Yo los extraño mucho, pero de aquí no me voy”. Por su carácter abierto hace 
amistades fácilmente, le gustan las fi estas, el baile y la buena cocina, es una persona alegre y 
dócil, generosa y modesta, aparentemente frágil, sin embargo nada ni nadie logra apartarla de 
sus obligaciones y tareas, por lo que desarrolla una gran autodisciplina que ha perfeccionado 
a través de los años. Es muy fi rme en el momento de tomar decisiones y mantenerlas. Es 
desprendida y solidaria, cuida y quiere mucho a sus hermanas, de las cuales se ha sentido 
siempre responsable, disfruta regalando y ayudando a los demás.
Desde pequeña mostró su predilección por la Medicina. De sus primeros días de la Universidad 
recuerdo que estoy al tanto de sus estudios para ayudarla, como médico sabía que era una 
carrera difícil, y cuando observé que además de su libreta de notas y su libro de texto básico, 
busca otros autores para ampliar la información, comprendí que mi presencia no era tan 
necesaria, pues sabía que ya era de los que no se conformaban con una sola opinión.
El tiempo me daría la razón, terminó su carrera de Medicina con Título de Oro y fue la 
más destacada en investigación en su curso. Escoge la especialidad de Genética Clínica, y 
le gusta el trabajo de laboratorio e investigación. A los 23 años se fue a la Habana donde 
defi nitivamente aprendió a ser independiente, terminó la especialización y obtuvo su primer 
empleo en el Centro Nacional de Genética Médica. Ahora vive en un país lejano del que supo 
por primera vez cuando leyó un cuento infantil sobre un niño que salva a su país taponenado 
con su dedo un dique que los protegía del mar. 
Para su abuela materna nació con muy buena estrella, para nosotros brilla tanto como ellas.
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Our oldest daughter 
By Gilberto B. Bertoli and Aida V. Avella. English version by Fernando Rivadeneira  
March 10, 1965. There was the rejoicing day that the fi rst of our three daughters was born. We 
named her Aida Maria in remembrance of her mother and grandmother. 
We remember her early childhood as that of a happy healthy girl, smart and fi nely developed. 
Once, when she was about three years old, we were walking through a fi eld close to a herd of 
cows. I brought her close with the intention of teaching her not to fear the animals. While I was 
attempting to pet one of the cows, the animal made a sudden move and mooed. I jumped back 
while my daughter stared at me and exclaimed: “Pipo, you are also afraid of the cow!”
She always enjoyed playing, especially outdoors. When she was fi ve we gave her her fi rst 
bicycle, which would be very special for her.  Her fi rst days at school went smoothly; she was 
a fast learner and drew the sympathy and admiration of her teachers. In that time, we would 
be impressed by how cautious she was with her school materials, the neatness of her books 
and attire. Her school uniform was clean for unusually long times, and she was always very 
delicate with her toys and story books. She was passionate for children literature in a way that 
would amaze us: together with her sisters she organized her own library with labels and codes 
for all her books.
She fi nished her primary school successfully and went to an intern school for outstanding 
children. There she completed her high school and pre-college education. This was the fi rst 
time she was away from home and only she knows how diffi cult this was. One day, with her 
eyes full of tears she told us: “I miss you so much, but I am not leaving”. Under a fragile 
appearance lies a determined person who will achieve all her duties and enterprises and is fi rm 
about making and committing to her decisions. She is a happy person, always generous and 
humble. Being such an open person makes her easy to get to know; she enjoys parties, dancing 
and magnifi cent cooking. She is generous, careful and always willing to support others; she 
loves and cares for her sisters and has always felt responsible for them.
Very early she was attracted to medicine. Being a physician myself and knowing what a 
diffi cult career it was, during the fi rst days at Medical School I was always looking forward to 
help her. Soon I learned this was not necessary when I noticed that for her, the information in 
the textbook was never enough. She would always search the literature thoroughly for other 
author’s opinions. In time I was proved correct: she fi nished the medical school with honours 
and in research she was the most outstanding student. She chose to specialize in clinical 
genetics, where she showed enormous affi nity for research and lab work. This way, when 
she turned 23 years old she went to Havana where she defi nitely became independent.  After 
fi nishing her residency she was employed at the National Centre of Medical Genetics. 
Today, she lives in a country faraway that she fi rst learned from a children’s story: the tale of 
a boy who saved his country by placing his fi nger in the hole of a breaking dike that protected 
the land from the sea.
Her maternal grandmother use to state she was born under a good star, for us she shines just 
like one.
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